{"nbformat":4,"nbformat_minor":0,"metadata":{"colab":{"name":"compare_results.ipynb","provenance":[],"collapsed_sections":["P95DxvqWi_2Y","TuzhEI6n1p8z","GwV6fdnWfXpI","j8KD69IqLwpD","1eOUIQDw6Utu","O8TW307E4k6H","beq8quv33szi","3GwOyy5P_Uq4","UDtHCt-k_Urh","0o6NKTHP8efg","vgkTqondvLFa","b2LLUGIVYbzU","FqG_9YB_vN-k","nM7u_9u0-U1D","zufJSxeZvoxF","X29XKbHHvoxF","Pk6oYRBZvoxH","rup_5B24-oPx","JyMOjvJ7weXd","wWXn75l1weXe","-tytAdjNweXg","_KwlG-cw-rG5","wn8hnTWEp6Tl","IzORzb_nYb0E","ioM6TYCJhgQy","j9K2GIPifCZ6","_afGnaAA-wMk","MqlsNBG9u2HW","79qTAM8Pu2Hd","bJP_unAY_Iaf","4gTs9EFbwY17","3ztqP179wY1_","lpqFe6x6BFol","2zQEYGZlxNSn","SEh3RzxwxNSp","98BwPF2dBJLv","YLhN6dB4x477","ktRVvfCiyFy0","iy7CHqTRyu-D"],"authorship_tag":"ABX9TyMQtpDLMHEQyQ99nwP5o5Hk"},"kernelspec":{"name":"python3","display_name":"Python 3"}},"cells":[{"cell_type":"markdown","metadata":{"id":"P95DxvqWi_2Y"},"source":["#### For Colab"]},{"cell_type":"code","metadata":{"id":"GD_KFnI1H1ip","colab":{"base_uri":"https://localhost:8080/","height":55},"executionInfo":{"status":"ok","timestamp":1608648598830,"user_tz":-60,"elapsed":865,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"9019aa09-25d8-4e50-9e45-f404aa2a927f"},"source":["\"\"\"\n","function ClickConnect(){\n","    console.log(\"Working\");\n","    document.querySelector(\"colab-toolbar-button\").click() \n","}\n","var i = setInterval(ClickConnect, 900000)\n","clearInterval(i)\n","\"\"\""],"execution_count":1,"outputs":[{"output_type":"execute_result","data":{"application/vnd.google.colaboratory.intrinsic+json":{"type":"string"},"text/plain":["'\\nfunction ClickConnect(){\\n    console.log(\"Working\");\\n    document.querySelector(\"colab-toolbar-button\").click() \\n}\\nvar i = setInterval(ClickConnect, 900000)\\nclearInterval(i)\\n'"]},"metadata":{"tags":[]},"execution_count":1}]},{"cell_type":"code","metadata":{"id":"RR-OcN_Wy1jE","colab":{"base_uri":"https://localhost:8080/"},"executionInfo":{"status":"ok","timestamp":1608648618936,"user_tz":-60,"elapsed":20953,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"1ac15cae-5f68-43cf-ffc4-23be5c8f8423"},"source":["from google.colab import drive\n","drive.mount('/content/drive')"],"execution_count":2,"outputs":[{"output_type":"stream","text":["Mounted at /content/drive\n"],"name":"stdout"}]},{"cell_type":"code","metadata":{"id":"au5Z9XQAC7C-","executionInfo":{"status":"ok","timestamp":1608648618938,"user_tz":-60,"elapsed":20949,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["drive_dir = '/content/drive/My Drive/MAGMA: Summarization/'\n","data_dir = '/content/drive/My Drive/MAGMA: Summarization/corpora/karger_books/'"],"execution_count":3,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"TuzhEI6n1p8z"},"source":["#### Init"]},{"cell_type":"code","metadata":{"id":"7sb6-YdB1sc0","executionInfo":{"status":"ok","timestamp":1608648620422,"user_tz":-60,"elapsed":5632,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["import matplotlib.pyplot as plt\n","import numpy as np\n","import torch\n","import re\n","import pandas as pd\n","import textwrap\n","\n","import random"],"execution_count":4,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"GwV6fdnWfXpI"},"source":["## **Config**"]},{"cell_type":"code","metadata":{"id":"MhieltNmfVoJ","executionInfo":{"status":"ok","timestamp":1608648620423,"user_tz":-60,"elapsed":5135,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["MODEL = 'bart'\n","\n","SEED = 7\n","\n","# Output directory\n","OUTPUT_PATH = drive_dir+'summarization/compare_results/'\n","\n","# Types of Rouge measures\n","R_TYPES = ['precision', 'recall', 'fmeasure']"],"execution_count":5,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"j8KD69IqLwpD"},"source":["## **Function Definition**"]},{"cell_type":"code","metadata":{"id":"Oe-IuAH_LvHo","executionInfo":{"status":"ok","timestamp":1608648620425,"user_tz":-60,"elapsed":4325,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["def plot_rouge(df, method, rouge, submethod=None):\n","    if submethod is None : submethod = method\n","\n","    fig, ax = plt.subplots(figsize=(10, 6))\n","    plt.boxplot(\n","        [df[rouge+'_'+r].tolist() for r in R_TYPES],\n","        widths=0.4,\n","        patch_artist=False,\n","        meanline=True,\n","        showmeans=True)\n","    ax.grid(True, axis='y', alpha=0.7, linestyle='--')\n","    ax.set_title(method.title()+' '+rouge, fontsize='xx-large')\n","    ax.set_ylabel(rouge, fontsize='x-large')\n","    ax.set_xticklabels(R_TYPES, fontsize='x-large')\n","    plt.savefig(OUTPUT_PATH+method+'/'+submethod+'_'+MODEL+'_'+rouge+'.png')\n","    plt.show()"],"execution_count":6,"outputs":[]},{"cell_type":"code","metadata":{"id":"7NyaySHtMtUN","executionInfo":{"status":"ok","timestamp":1608648620427,"user_tz":-60,"elapsed":4313,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["def plot_compare_rouge(df_list, method_list, rouge, folder=None):\n","    num_df = len(df_list)\n","    \n","    from matplotlib.cm import get_cmap\n","    color = get_cmap('tab10')(range(num_df))\n","\n","    def set_box_color(b, c):\n","        for k in b.keys():\n","            plt.setp(b[k], color=c)\n","\n","    xticks = np.array(.7*num_df*np.arange(1, len(R_TYPES)+1))\n","\n","    fig, ax = plt.subplots(figsize=(12, 8))\n","    box_plt_list = [plt.boxplot(\n","        [df[rouge+'_'+r].tolist() for r in R_TYPES],\n","        positions= xticks+var,\n","        sym='+',\n","        widths=0.4,\n","        patch_artist=False,\n","        meanline=True,\n","        showmeans=True)\\\n","        for df, var in zip(df_list, np.linspace(-0.15*num_df, 0.15*num_df, num_df))]\n","\n","    for i, bp in enumerate(box_plt_list):\n","        set_box_color(bp, color[i])\n","        plt.plot([], c=color[i], label=method_list[i])\n","    plt.legend()\n","\n","    ax.grid(True, axis='y', alpha=0.7, linestyle='--')\n","    ax.set_title(' vs '.join(method_list).title()+' '+rouge, fontsize='xx-large')\n","    ax.set_ylabel(rouge, fontsize='x-large')\n","    plt.xticks(xticks, R_TYPES, fontsize='x-large')\n","    if folder is not None:\n","        plt.savefig(OUTPUT_PATH+folder+'/'+' vs '.join(method_list)+'_'+MODEL+'_'+rouge+'.png')\n","    else:\n","        plt.savefig(OUTPUT_PATH+' vs '.join(method_list)+'_'+MODEL+'_'+rouge+'.png')\n","    plt.show()"],"execution_count":7,"outputs":[]},{"cell_type":"code","metadata":{"id":"H9_9ySlHFk4K","executionInfo":{"status":"ok","timestamp":1608648620429,"user_tz":-60,"elapsed":4309,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["def chapter_avg(df):\n","    return df.groupby('bullets').mean()\n","\n","def chapter_best(df):\n","    return df.groupby('bullets').max()"],"execution_count":8,"outputs":[]},{"cell_type":"code","metadata":{"id":"4wATszz44yXP","executionInfo":{"status":"ok","timestamp":1608648620430,"user_tz":-60,"elapsed":4304,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["def print_text_bull_summ(t, b, s):\n","    print('\\nText:')\n","    print(textwrap.fill(t, 150))\n","    print('\\nBullets:')\n","    print(textwrap.fill(b, 150))\n","    print('\\nPredicted Summary:')\n","    print(textwrap.fill(s, 150))\n","    print()\n","    print(''.join(['#']*150))\n","    print(''.join(['#']*150))\n","    print('\\n')\n","\n","def print_random_summaries(df, ids, summary_col='summary'):\n","    df_sort = df.sort_index()\n","\n","    for id in ids:\n","        text = df_sort.loc[id].text\n","        bullets = df_sort.loc[id].bullets\n","        summary = df_sort.loc[id][summary_col]\n","        \n","        if isinstance(text, str):\n","            print(id)\n","            print_text_bull_summ(text, bullets, summary)\n","\n","        elif isinstance(text, list):\n","            n_bull = 1\n","            for c, b, s in zip(text, bullets, summary):\n","                print(id, 'bullet', n_bull)\n","                print_text_bull_summ(c, b, s)\n","\n","                n_bull += 1\n","            print(id)\n","            print('\\nAll Bullets:')\n","            print(textwrap.fill(' '.join(bullets), 150))\n","            print('\\nAll Predicted Summary:')\n","            print(textwrap.fill(' '.join(summary), 150))\n","            print()\n","            print(''.join(['#']*150))\n","            print(''.join(['#']*150))\n","            print('\\n')\n","\n","        else:\n","            # we are considering a chapter divided in chunks\n","            # for each chunk we have a different summary which\n","            # tries to resembles the bullets of the entire cpt\n","            text = text.tolist()\n","            bullets = bullets.tolist()[0]\n","            summary = summary.tolist()\n","\n","            n_chunk = 1\n","            for c, s in zip(text, summary):\n","                print(id, 'chunk', n_chunk)\n","                print_text_bull_summ(c, bullets, s)\n","                n_chunk += 1"],"execution_count":9,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"bkpYr_N8wThJ"},"source":["## **Chunk Chapter (Baseline)**"]},{"cell_type":"markdown","metadata":{"id":"1eOUIQDw6Utu"},"source":["#### Loading data"]},{"cell_type":"code","metadata":{"id":"8xEn_SDHwK-U","executionInfo":{"status":"ok","timestamp":1608648622152,"user_tz":-60,"elapsed":3430,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["input_path = drive_dir+'summarization/baseline_output/'\n","df_base = pd.read_csv(input_path+'df_summ_'+MODEL+'.csv')\n","df_base = df_base.set_index(['book', 'chapter'])"],"execution_count":10,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"O8TW307E4k6H"},"source":["#### Rouge"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/","height":0},"id":"PWwXIX8UikYT","executionInfo":{"status":"ok","timestamp":1608648623287,"user_tz":-60,"elapsed":4541,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"3f7afe9f-c6e6-4e23-de77-c9188e883b9a"},"source":["plot_rouge(df_base, 'baseline', 'rougeL')"],"execution_count":11,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 720x432 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"markdown","metadata":{"id":"beq8quv33szi"},"source":["#### Print Random Summaries"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"T9hYsK053szv","executionInfo":{"status":"ok","timestamp":1608648623290,"user_tz":-60,"elapsed":4524,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"88a8324a-58e6-499c-9bc1-f39ec143c632"},"source":["random.seed(SEED)\n","RANDOM_IDS = random.sample(df_base.index.tolist(), 3)\n","print(RANDOM_IDS)"],"execution_count":12,"outputs":[{"output_type":"stream","text":["[(9781908541994, 'ch05'), (9781908541437, 'ch_9'), (9781910797181, 'ch01')]\n"],"name":"stdout"}]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"ayIjJ4AN4oKY","executionInfo":{"status":"ok","timestamp":1608648623292,"user_tz":-60,"elapsed":4513,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"b27544be-6ef1-4f39-a924-68176d5744b8"},"source":["print_random_summaries(df_base, RANDOM_IDS)"],"execution_count":13,"outputs":[{"output_type":"stream","text":["(9781908541994, 'ch05') chunk 1\n","\n","Text:\n","Topical therapy . Topical therapy is useful in nearly all acne regimens . mild localized acne . moderate acne; in combination with, and following,\n","oral therapy . maintenance therapy; after stopping systemic agents for severe acne . Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics . The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance . Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-\n","dose combination product to enhance adherence . Topical agents differ in their efficacy against the various etiologic factors . Retinoids, azelaic\n","acid and BPO are effective for comedones and inflammatory acne . Topical antibiotics such as erythromycin and clindamycin are most effective for\n","inflammatory lesions . Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions . It is important to note\n","that topical antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P . acnes) strains . Patients often\n","seek medical attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels . Active\n","ingredients include BPO, salicylic acid and alpha-hydroxy acids . Topical therapy is generally applied after washing the face and allowing it to dry\n","for 10-15 minutes . It is important to cover the entire affected area with a thin film of product, avoiding the eyes . Benzoyl peroxide . BPO is the\n","most potent agent against P . acnes, an obligate anaerobe that will not grow in the presence of oxygen . Unlike antibiotics, BPO is bactericidal\n","against P . acnes through its release of free oxygen radicals in sebaceous follicles . BPO therefore reduces bacterial colonization of the follicle\n","and kills both sensitive and resistant strains of P . acnes, which translates into a reduction in new inflammatory lesions . acnes does not develop\n","resistance to BPO; for this reason, the drug is a valuable component of any acne treatment regimen . BPO is mostly available in over-the-counter and\n","prescription formulations, including bar soaps, washes, gels and lotions . It is chiefly available in concentrations of 2.5%, 4%, 5% and 10% .\n","However, there is no evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the\n","2.5-5% concentrations . BPO is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene\n","(see page 52) . Topical retinoids and retinoid-like molecules . Topical retinoids are effective agents in the treatment of acne . Although\n","dermatologists readily prescribe them, topical retinoids are underutilized by pediatricians and general practitioners . Tretinoin, or all-trans-\n","retinoic acid, is a vitamin A derivative that reverses the altered keratinization in follicles affected by acne . By inhibiting the formation of the\n","microcomedone, tretinoin prevents the development of comedones and early inflammatory lesions . Tretinoin is available as a cream, gel or solution in\n","a variety of concentrations of differing potencies, which vary between countries . % gel / 0.05% cream . % gel / 0.1% cream .\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical therapy should be selected to help achieve medical adherence. Realistic\n","expectations of therapy should be explained. Combining therapies or using fixed combination topical products improves efficacy by targeting more than\n","one pathogenic feature and enhancing treatment adherence. Topical antibiotics can lead to the development of antimicrobial resistance. Topical\n","antibiotics should not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Any regimen containing\n","an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent\n","the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. Topical\n","antibiotics such as erythromycin and clindamycin are most effective for inflammatory lesions. Tretinoin, or all-trans-retinoic acid, is a vitamin A\n","derivative that reverses the altered keratinization in follicles affected by acne. It is available as a cream, gel or solution in a variety of\n","concentrations of differing potencies, which vary between countries. It is generally applied after washing the face and allowing it to dry for 10-15\n","minutes. It is important to cover the entire affected area with a thin film of product, avoiding the eyes.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') chunk 2\n","\n","Text:\n","Tretinoin is usually applied once daily at bedtime after the face has had adequate time to dry . Night-time application is most effective as the\n","active molecule is light sensitive . Tretinoin is also available in formulations with novel delivery systems, such as microspheres . Choice of\n","formulation depends upon whether the patient has dry or oily skin . Patients with oily skin usually prefer gels and patients with dry skin usually\n","prefer creams . Adapalene is a synthetic acid derivative with retinoid-like activity but a distinctly different chemical structure . Adapalene is a\n","potent modulator of cellular differentiation, keratinization and inflammatory processes, and the mechanism of action is believed to be similar to that\n","of retinoids . Adapalene interacts with nuclear retinoic acid receptors (RARs) beta and gamma . It has been hypothesized that this receptor\n","selectivity may account for its better side-effect profile . Adapalene has been shown to possess anti-inflammatory activity in a number of in-vitro\n","and in-vivo animal models . Along with tretinoin, adapalene has been shown to decrease the expression of toll-like receptor-2 (TLR2) on inflammatory\n","cells . Adapalene is available in concentrations of 0.1% and 0.3% (in the USA), and also as a fixed combination of 0.1% adapalene with 2.5% BPO for\n","daily use . Tazarotene is a synthetic acetylenic retinoid that has been formulated into a topical gel and cream . Following topical application,\n","tazarotene is converted to its active metabolite tazarotenic acid . This compound then binds to nuclear RARs and can affect the expression of genes\n","involved in cell proliferation, cell differentiation and inflammation . At the cellular level this may result in the modification of several\n","pathogenic factors in acne, including corneocyte accumulation and cohesion . Tazarotene is specific for RARs, rather than retinoid X receptors (RXRs),\n","and selectively activates RAR-beta and RAR-gamma, as does adapalene . Tazarotene is very effective in comedonal and inflammatory acne . It may have\n","greater potential for irritation in some patients, more so with the gel formulation than the cream . Tazarotene is licensed for the treatment of acne\n","in the USA but only licensed for the treatment of psoriasis in the UK . Dapsone is a sulfone that targets neutrophil-mediated inflammation . Stability\n","issues with a topical formulation were overcome with the development of a novel topical gel . The gel has been shown to be effective against acne at\n","5% concentration; recent studies suggest topical dapsone 5% gel may be particularly beneficial in regimens for adult women with acne (see pages 26-9)\n",". Topical isotretinoin is an alternative preparation, available as a 0.05% gel in the UK and Italy, but it is not available in the USA . This retinoid\n","has been shown to be less irritating than older retinoid preparations such as tretinoin . Salicylic, alpha-hydroxy and azelaic acids . Salicylic acid,\n","a beta-hydroxy acid, is keratolytic and an irritant; it may promote the resolution of inflammatory lesions through its drying effect . Salicylic acid\n","has mild comedolytic activity . It is available in a maximum concentration of 2% in over-the-counter preparations such as soaps, cleansers and gels .\n","Some salicylic acid products are tinted to help camouflage acne lesions . Combination products containing salicylic acid and BPO or sulfur are also\n","available .\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical therapy should be selected to help achieve medical adherence. Realistic\n","expectations of therapy should be explained. Combining therapies or using fixed combination topical products improves efficacy by targeting more than\n","one pathogenic feature and enhancing treatment adherence. Topical antibiotics can lead to the development of antimicrobial resistance. Topical\n","antibiotics should not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Any regimen containing\n","an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent\n","the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n","Tretinoin is usually applied once daily at bedtime after the face has had adequate time to dry. Night-time application is most effective as the active\n","molecule is light sensitive. Adapalene is a potent modulator of cellular differentiation, keratinization and inflammatory processes. Tazarotene is a\n","synthetic acetylenic retinoid that has been formulated into a topical gel and cream. Dapsone is a sulfone that targets neutrophil-mediated\n","inflammation. The gel has been shown to be effective against acne at 5% concentration; recent studies suggest topical dapsone 5% gel may be\n","particularly beneficial in regimens for adult women with acne. Topical isotretinoin is an alternative preparation, available as a 0.05% gel in the UK\n","and Italy, but it is not available in the USA.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') chunk 3\n","\n","Text:\n","alpha -hydroxy acids such as lactic acid, glycolic acid and citric acid are available in a variety of cosmetic preparations, including cleansers,\n","toners, moisturizers and chemical peels . alpha-hydroxy acids are thought to reverse the altered keratinization of follicles affected by acne and\n","improve the appearance of the skin by promoting desquamation of the stratum corneum . The effectiveness of alpha-hydroxy acids in acne, however, has\n","not yet been demonstrated in controlled clinical trials . Azelaic acid is a naturally occurring dicarboxylic acid found in cereal grains . It is\n","available as a topical cream that has been shown to be effective in inflammatory and comedonal acne . By inhibiting the growth of P . acnes, azelaic\n","acid reduces inflammatory acne . It also reverses the altered keratinization of follicles seen in acne and thus demonstrates comedolytic activity .\n","Azelaic acid can affect melanosomes and has been used to treat postinflammatory hyperpigmentation . Azelaic acid is reported to have fewer local side\n","effects than topical retinoids . Topical antibiotics . Topical antibiotics such as erythromycin, clindamycin and sodium sulfacetamide inhibit the\n","growth of P . acnes and reduce inflammatory lesions . Products containing these antibiotics are often applied twice daily and are generally well\n","tolerated . Topical antibiotics such as erythromycin and clindamycin come in a variety of formulations and packaging: creams, lotions, ointments, gels\n","and solutions . Solutions are available in dab-on applicators and pads, which are packaged either individually or in bulk . The choice of formulation\n","or packaging depends on the patient's complexion and preference . Many teenagers enjoy the convenience of the pad preparations . Sodium sulfacetamide\n","is a sulfonamide, which is thought to inhibit the growth of P . acnes through competitive antagonism of para-aminobenzoic acid, an essential\n","requirement for bacterial growth . Sodium sulfacetamide (10%) is available in combination with sulfur (5%) in a prescription lotion, either with or\n","without tint . Topical tetracycline is available in Italy, but not the UK or USA . Antibiotic resistance . Since the 1970s, P . acnes has developed\n","resistance to both topical and oral antibiotics . It is important to bear this in mind when prescribing antibiotics . acnes resistance has been shown\n","to affect clinical outcomes of acne treatment . In addition, overuse of antibiotics can drive resistance in other commensal bacteria . For these\n","reasons, the use of topical antibiotics as single agents for acne is to be discouraged . Topical retinoids and BPO are useful as first-line agents .\n","Any regimen containing an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with BPO . Combination\n","products . Recent advances in topical acne therapy include the development of fixed combination products that target more than one pathogenic feature\n","of the disease and may also increase treatment adherence among patients . Combination products that include BPO offer excellent bactericidal effects\n","and, when combined with erythromycin or clindamycin, offset the emergence of antibiotic-resistant P . acnes (see pages 51 and) . A fixed combination\n","of BPO with adapalene targets three of the four pathogenic features of acne without the use of antibiotics . Other combinations include topical\n","tretinoin 0.025% with clindamycin 1%, tretinoin 0.025% with erythromycin 4% and topical isotretinoin 0.05% with erythromycin 2% (none of these are\n","available in the USA) .\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical therapy should be selected to help achieve medical adherence. Realistic\n","expectations of therapy should be explained. Combining therapies or using fixed combination topical products improves efficacy by targeting more than\n","one pathogenic feature and enhancing treatment adherence. Topical antibiotics can lead to the development of antimicrobial resistance. Topical\n","antibiotics should not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Any regimen containing\n","an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent\n","the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n","alpha-hydroxy acids are thought to reverse the altered keratinization of follicles affected by acne. The effectiveness of alpha-hydroxy acids in acne\n","has not yet been demonstrated in controlled clinical trials. Azelaic acid is a naturally occurring dicarboxylic acid found in cereal grains. Topical\n","antibiotics such as erythromycin, clindamycin and sodium sulfacetamide inhibit the growth of P. acnes and reduce inflammatory lesions. Topical\n","retinoids and BPO are useful as first-line agents. A fixed combination of BPO with adapalene targets three of the four pathogenic features of acne\n","without the use of antibiotics. Topical tetracycline is available in Italy, but not the UK or USA.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') chunk 4\n","\n","Text:\n","Side effects . Local irritation . Most topical acne treatments, including salicylic acid, BPO and topical retinoids will cause some degree of\n","erythema, dryness and scaling of the skin . Contact dermatitis due to BPO has rarely been reported but should be considered if treated areas develop\n","an eczematous dermatitis . Use of topical antibiotics may also be associated with local irritation, but this tends to occur less often than with other\n","topical agents . The local side effects of topical retinoids include erythema, scaling, desquamation, burning or stinging, pruritus and increased\n","susceptibility to sunburn . Most patients will develop tolerance to the local side effects of topical retinoids within 3-4 weeks . If patients are\n","unable to tolerate daily application of a topical retinoid, an alternate-day or every-third-day regimen can be followed until tolerance develops .\n","Topical retinoids are not recommended in pregnancy because of the theoretical risk of teratogenicity . Fortunately, studies have shown that the risk\n","of birth defects from topical tretinoin is unlikely . Pharmacokinetic studies have shown that serum retinoid levels may be influenced more by diet\n","than by facial application of topical tretinoin for acne . Epidemiological studies have failed to demonstrate an increased risk of birth defects in\n","infants whose mothers used topical retinoids on the face during the first trimester of pregnancy . There have, however, been isolated case reports of\n","birth defects in infants whose mothers used topical tretinoin during pregnancy . For this reason, it is recommended that pregnant women cease using\n","topical retinoids . Bleaching and staining . BPO can bleach clothing or bedding, particularly when it is applied to the chest or back . It is\n","therefore best to advise use of this medication at bedtime and to recommend covering the treated areas with an old shirt . Management of side effects\n",". Excessive dryness of the skin is one of the main reasons why patients discontinue topical treatment . Thus, recommendations regarding effective ways\n","of managing facial dryness should be an integral part of any acne treatment plan . Regular use of moisturizers is especially important, but the\n","clinician should be aware of the reluctance of many patients to use them because of concerns that moisturizers might worsen their acne . These\n","patients need reassurance that this is not the case: most moisturizers from reputable companies are tested for comedogenicity in clinical trials and\n","are labeled 'non-comedogenic' . Studies show that moisturizers applied before or after topical retinoids do not alter efficacy . Moisturizers are\n","available as creams and lotions; most patients prefer to use lotions as they are easy to apply and do not feel greasy . Lotions containing sunscreens\n","should be recommended, particularly in patients using topical retinoids . For recalcitrant dry areas, a heavier cream may be needed . Sunscreens are\n","important, as the sun can exacerbate facial irritation caused by topical acne medications . Some topical preparations make patients more\n","photosensitive . Thus, regular use of a sunscreen or a moisturizer containing a sunscreen is recommended to avoid sunburn as a side effect from\n","thinning of the stratum corneum by topical retinoids or phototoxicity from oral doxycycline . Alternative regimens . If irritation remains a problem\n","despite adequate use of moisturizers, the treatment regimen can be temporarily altered . For example, topical retinoids could be used every other day\n","or every third day until they are tolerated, or the duration of application could be gradually increased . The goal is to gradually increase the\n","frequency of application until the patient can tolerate daily application .\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical therapy should be selected to help achieve medical adherence. Realistic\n","expectations of therapy should be explained. Combining therapies or using fixed combination topical products improves efficacy by targeting more than\n","one pathogenic feature and enhancing treatment adherence. Topical antibiotics can lead to the development of antimicrobial resistance. Topical\n","antibiotics should not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Any regimen containing\n","an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent\n","the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n","Most topical acne treatments, including salicylic acid, BPO and topical retinoids, will cause some degree of erythema, dryness and scaling of the\n","skin. Topical retinoids are not recommended in pregnancy because of the theoretical risk of teratogenicity. Excessive dryness of the skin is one of\n","the main reasons why patients discontinue topical treatment. Regular use of moisturizers is especially important, but the clinician should be aware of\n","many patients' reluctance to use them because of concerns that moisturizers might worsen their acne. Sunscreens are important, as the sun can\n","exacerbate facial irritation caused by topical acne medications and can make patients more photosensitive. The goal is to gradually increase the\n","frequency of application until the patient can tolerate daily application.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9') chunk 1\n","\n","Text:\n","Atrial flutter . Typical atrial flutter is a macro-entrant atrial rhythm, rotating counterclockwise, occasionally clockwise, within the right atrium\n","(see Figure 2.7) . Most common is a circuit confined to the anterior portion of the right atrium with a 2:1 atrioventricular (AV) block - an atrial\n","rate of 300 bpm and a regular ventricular response of 150 bpm related directly to the atrial rate . A QRS rate of exactly 150 bpm should raise\n","suspicion of atrial flutter . Other than atrial fibrillation (AF), atrial flutter is the most common arrhythmia seen by cardiologists . Patients who\n","have had AF may present with atypical atrial flutter at a later stage; patients who have had congenital abnormalities corrected at an early age may\n","present with atypical atrial flutter up to 10-20 years later . In typical atrial flutter, the circuit is critically dependent on an area of slow\n","conduction known as the cavotricuspid isthmus (see Figure 2.7) . Other rarer atypical forms occur, particularly in patients with scarring in the\n","atrium (exempli gratia after radiofrequency ablation [RFA] or previous heart surgery) . Atrial flutter typically has a saw-tooth appearance of flutter\n","waves on the baseline in the 12-lead ECG (see Figure 2.7) . Clinical presentation . Atrial flutter can be aysmptomatic or may present with\n","breathlessness, tiredness or frank heart failure . Persistent palpitations may be a feature . Anticoagulation therapy is based on the same risk\n","factors as those for AF (see Chapter 8) . Pharmacological treatment . In acute cases, cardioversion can be performed with intravenous ibutilide, or,\n","if there is no structural heart disease, a class 1c antiarrhythmic agent, such as flecainide or propafenone, combined with a beta-blocker .\n","Intravenous flecainide alone is sometimes used in Europe (but not in the USA) to slow conduction in the flutter circuit more than in the AV node\n","itself . However, in some cases this may slow the atrial rate from 300 to 200 bpm and may allow the AV node to conduct in a 1:1 fashion, producing a\n","paradoxical increase in the ventricular rate to 200 bpm, which may be associated with hemodynamic compromise; flecainide is often combined with a\n","beta-blocker to prevent the flutter being conducted to the ventricle in this 1:1 manner . The same principle applies for both intravenous and oral\n","flecainide . Oral sotalol is often used in patients with atrial flutter, as it has the combined action of an antiarrhythmic and a beta-blocker, but QT\n","considerations and renal excretion limit its use in women and the elderly .\n","\n","Bullets:\n","Ablation for typical atrial flutter is highly successful and low risk, and should be considered first-line treatment. The risk of systemic\n","embolization in atrial flutter should be considered similar to that for atrial fibrillation (AF). Atypical atrial flutter usually includes right\n","atrial flutter circling around regions of scarring, or left atrial flutter following ablation of AF.\n","\n","Predicted Summary:\n","Atrial flutter is the most common arrhythmia seen by cardiologists. Patients who have had AF may present with atypical atrial flutter at a later\n","stage. Atrial flutter typically has a saw-tooth appearance of flutter waves on the baseline in the 12-lead ECG. Intravenous flecainide alone is\n","sometimes used in Europe (but not in the USA) to slow conduction in the flutter circuit. Oral sotalol is often used in patients with atrial flutter,\n","as it has the combined action of an antiarrhythmic and a beta-blocker, but QT considerations and renal excretion limit its use in women and the\n","elderly.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9') chunk 2\n","\n","Text:\n","In the chronic setting, atrial flutter often responds poorly to drug therapy . AV nodal-blocking drugs slow the ventricular response . Direct-current\n","(DC) cardioversion is highly effective for atrial flutter . However, persistent atrial flutter (lasting longer than 48 hours) is associated with\n","significant embolic risk, and management before cardioversion should be as for patients with AF - treatment with oral anticoagulant therapy (warfarin)\n","for 4 weeks before cardioversion and for at least 1 month afterwards (see Chapter 8) . Alternatively, a transesophageal echocardiogram can be\n","performed in patients who are not taking warfarin, or in whom serial measurements of the international normalized ratio (INR) over a month have not\n","been documented, to exclude left atrial thrombus and enable immediate cardioversion . Patients are then started, or continued, on warfarin, while\n","heparin or low-molecular-weight heparin is given until the INR is greater than 2, continuing warfarin for 1 month or more . In the acute setting,\n","flutter often converts with a low-energy shock of about 50 J, sometimes as low as 25 J . Radiofrequency (catheter) ablation is recommended for long-\n","term treatment . RFA restores sinus rhythm by creating a linear destructive lesion, across which the circulating depolarizing wavefront cannot pass .\n","This is known as a line of block and is usually created at the inferior wall of the right atrium (Figure 7.1) . This technique is in contrast to the\n","ablation of accessory or slow pathways, which require highly localized lesions . The procedure can be performed during constant atrial flutter or in\n","sinus rhythm with pacing from the atrium or coronary sinus . Success rates are greater than 90% in most centers . The cavotricuspid isthmus is not\n","smooth throughout its length and has regions of thick muscle bundles . Ablation of these areas is best achieved with technology capable of producing\n","deep lesions, such as large-tip or cooled radiofrequency energy . Newer techniques involving computerized mapping of the atria and catheter position\n","are improving overall success . Most centers are now performing ablation as first-line treatment . Apart from the usual complications associated with\n","instrumentation of the venous circulation, heart block or cardiac tamponade are rarely reported . After ablation, the prognosis for patients with\n","typical atrial flutter is excellent . In patients with atypical atrial flutter recurrences are more common because of scarring of the atria . Up to\n","30% of patients with either type of atrial flutter develop AF late after a successful flutter ablation and may require further treatment; atrial\n","flutter and AF often go together .\n","\n","Bullets:\n","Ablation for typical atrial flutter is highly successful and low risk, and should be considered first-line treatment. The risk of systemic\n","embolization in atrial flutter should be considered similar to that for atrial fibrillation (AF). Atypical atrial flutter usually includes right\n","atrial flutter circling around regions of scarring, or left atrial flutter following ablation of AF.\n","\n","Predicted Summary:\n"," direct-current (DC) cardioversion is highly effective for atrial flutter. persistent atrial flutter (lasting longer than 48 hours) is associated with\n","significant embolic risk. Radiofrequency (catheter) ablation is recommended for long-term treatment. Up to 30% of patients with either type of atrial\n","flutter develop AF late after a successful flutter ablation and may require further treatment. Atrial flutter and AF often go together; the prognosis\n","for patients with typical atrial flutter is excellent. In patients with atypical atrial flutter recurrences are more common because of scarring of the\n","atria. The procedure can be performed during constant atrial flutter or in sinus rhythm with pacing from the atrium or coronary sinus.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') chunk 1\n","\n","Text:\n","Cigarettes as a nicotine delivery system . The cigarette . There are many different varieties of cigarette tobacco, each with its own flavor and\n","characteristics, and tobacco can be prepared in different ways that affect its taste, smell and pharmacological properties . Additives are included in\n","cigarettes by the manufacturers to engineer an attractive and efficient nicotine delivery system . Table 1.1 lists some of the many thousands of\n","chemicals in tobacco smoke . One thing that all cigarettes have in common is that they deliver nicotine to the lungs . A puff on a cigarette results\n","in rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation\n","(Figure 1.1); this process is repeated with every puff . In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette .\n","This is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply . In societies in\n","which cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more\n","nicotine from each cigarette, confirming that nicotine is the sought-after substance in tobacco . Control of the nicotine dose . As a drug delivery\n","system, cigarettes are very flexible because smokers can control the intensity and frequency of puffing . This 'fingertip control' of the nicotine\n","dose allows smokers to meet their current need while avoiding the acute adverse effects of too much nicotine . Many smokers, particularly older\n","smokers and women, choose so-called 'light' or 'low-tar' brands, believing that these are safer . According to the reported analyses of their\n","deliveries, these brands deliver as little as one-tenth of the tar and carbon monoxide of other brands . In fact, such reports are misleading: the\n","data are based on artificial measurements by smoking machines and do not mirror the actual delivery to a smoker . It is possible to extract as much\n","tar and nicotine from these cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that\n","would otherwise dilute the smoke - and that is exactly what smokers usually do . Each smoker appears to have a preferred level of nicotine intake and\n","will adjust the way he or she smokes to achieve that level . Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette\n","packaging and marketing in the USA and EU . Smokers who reduce the number of cigarettes they smoke typically compensate for the change by increasing\n","the intensity of smoking such that smoke exposure remains unchanged . An exception is when they use another nicotine product at the same time, such as\n","a nicotine patch or gum (see Chapter 7) . It also appears that if cigarette consumption drops below a threshold (perhaps around 5 cigarettes per day),\n","or if the cigarettes are designed to limit the potential for compensation (exempli gratia novel cigarettes in which the tobacco actually contains less\n","nicotine), compensation is very limited . Nicotine and its elimination from the body . Nicotine is an alkaloid obtained from tobacco plants and has\n","wide-ranging effects on the central nervous system (CNS) (see pages 37-8) .\n","\n","Bullets:\n","Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff. Smokers absorb an average 1-2 mg of nicotine per cigarette (more\n","when cigarettes are smoked more intensively). Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide. Smokers' intake of tar\n","and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes. Nicotine is rapidly\n","metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a day of abstinence. The\n","nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva or\n","urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.\n","\n","Predicted Summary:\n","A puff on a cigarette results in rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the\n","brain by the arterial circulation. In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-\n","sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply. Many smokers, particularly older\n","smokers and women, choose so-called 'light' or 'low-tar' brands, believing that these are safer. It is possible to extract as much tar and nicotine\n","from these cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') chunk 2\n","\n","Text:\n","Its structure (Figure 1.2) resembles that of the major neurotransmitter acetylcholine, and it activates cholinergic receptors in the brain, which\n","accounts for many of the psychoactive effects . Once in the bloodstream, nicotine is distributed around the body, readily crossing cell membranes and\n","entering every tissue . It is eliminated quite rapidly, mainly through metabolism, but partly by excretion in urine . It is metabolized mostly to the\n","oxides cotinine and nicotine-1'-N-oxide . These appear to be largely inactive and are further metabolized and excreted in urine . The plasma\n","concentration of nicotine reduces by half every 90-120 minutes (its half-life; see Figure 1.1) . Duration of withdrawal symptoms . All nicotine is\n","cleared from the body within a day or two of abstinence . Some people think that this must therefore be the period when smokers experience withdrawal\n","symptoms (see Chapter 5) . However, the duration of withdrawal symptoms has nothing to do with this; it is related to how long it takes the body to\n","get used to not having nicotine in the system . The duration for most symptoms is 2-4 weeks . Estimating nicotine intake . Nicotine concentrations in\n","the blood could conceptually be a useful index of dependence, but its short half-life means that a single measure does not give a particularly\n","accurate picture of total intake over a day . Measurement of its metabolite, cotinine, is used instead . Cotinine has a half-life of 14-20 hours, so\n","its concentration in the blood is more stable than that of nicotine and it can be easily measured in saliva, urine or even hair . Saliva samples are\n","simple to obtain by means of a dental swab and are the method of choice for accurate estimation of daily nicotine intake . A daily nicotine intake of\n","16 mg (approximately 16 cigarettes/day, or one every hour) corresponds on average to a saliva cotinine concentration of 200 ng/mL; a daily nicotine\n","intake of 10 mg generates a saliva cotinine concentration of about 125 ng/mL . These estimations are not the same for urine or blood measurements .\n","Monoamine oxidase inhibitors in cigarette smoke . There is evidence that cigarette smoke contains other psychoactive compounds which some now believe\n","may contribute to its addictive properties . Most notably, there is at least one monoamine oxidase inhibitor (MAOI) . MAOIs reduce the rate at which\n","monoamine neurotransmitters such as dopamine are broken down and have been found to reduce depressive symptoms . In the case of smoking, they might\n","contribute to the rewarding effect of cigarette smoke or act synergistically with nicotine (which is primarily rewarding as it causes release of\n","dopamine in the nucleus accumbens - see Chapter 5) . This may help explain why people who suffer from depression are particularly likely to smoke .\n","Research is in its early days, but if MAOIs play a role in cigarette addiction, pure nicotine delivery systems may be less addictive, even if they\n","deliver nicotine as rapidly as cigarettes .\n","\n","Bullets:\n","Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff. Smokers absorb an average 1-2 mg of nicotine per cigarette (more\n","when cigarettes are smoked more intensively). Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide. Smokers' intake of tar\n","and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes. Nicotine is rapidly\n","metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a day of abstinence. The\n","nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva or\n","urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.\n","\n","Predicted Summary:\n"," nicotine is distributed around the body, readily crossing cell membranes and entering every tissue. It is eliminated quite rapidly, mainly through\n","metabolism, but partly by excretion in urine. The plasma concentration of nicotine reduces by half every 90-120 minutes (its half-life; see Figure\n","1.1) The duration of withdrawal symptoms has nothing to do with this; it is related to how long it takes the body to get used to not having nicotine\n","in the system. There is evidence that cigarette smoke contains other psychoactive compounds which some believe may contribute to its addictive\n","properties. Most notably, there is at least one monoamine oxidase inhibitor (MAOI) MAOIs reduce the rate at which monoamine neurotransmitters such as\n","dopamine are broken down and have been found to reduce depressive symptoms.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n"],"name":"stdout"}]},{"cell_type":"markdown","metadata":{"id":"kVxQ39Q0Ki7Z"},"source":["Summaries are accurate. A summary from one chunk may not cover all information present in the bullets, since the info is not present in the chunk a priori. And the generated summary can be more verbose than the bullets.\n","\n","However, merging summaries from all chunks can cover better the information of the bullets. This would result in a much longer summary, but all information would be accurate."]},{"cell_type":"markdown","metadata":{"id":"8Yh7_qjd_Uqn"},"source":["## **Only TextRank**"]},{"cell_type":"markdown","metadata":{"id":"3GwOyy5P_Uq4"},"source":["#### Loading data"]},{"cell_type":"code","metadata":{"id":"EOZPRdxe_UrE","executionInfo":{"status":"ok","timestamp":1608648624111,"user_tz":-60,"elapsed":4455,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["input_path = drive_dir+'summarization/textrank_output/'\n","df_tr = pd.read_csv(input_path+'df_textrank_summ.csv')\n","df_tr = df_tr.set_index(['book', 'chapter'])\n","\n","df_tr.bullets = df_tr.bullets.map(eval)\n","df_tr.bullets = df_tr.bullets.map(lambda b: ' '.join(b))\n","df_tr = df_tr.rename(columns={'textrank_summary': 'summary'})"],"execution_count":14,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"UDtHCt-k_Urh"},"source":["#### Rouge"]},{"cell_type":"code","metadata":{"id":"JaD9rrm2_Urq","colab":{"base_uri":"https://localhost:8080/","height":0},"executionInfo":{"status":"ok","timestamp":1608648625389,"user_tz":-60,"elapsed":5720,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"709126dd-5e40-4fd7-e73f-827ba1d1de67"},"source":["plot_rouge(df_tr, 'textrank', 'rougeL')"],"execution_count":15,"outputs":[{"output_type":"display_data","data":{"image/png":"iVBORw0KGgoAAAANSUhEUgAAAmUAAAF9CAYAAABF4h9MAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAADh0RVh0U29mdHdhcmUAbWF0cGxvdGxpYiB2ZXJzaW9uMy4yLjIsIGh0dHA6Ly9tYXRwbG90bGliLm9yZy+WH4yJAAAgAElEQVR4nO3de3hcV33o/e/Piozs+FJH2HEtXyJ8lRgOl7rhJLgFJ9AkhULOoeTELZwERNKT1Co0L1CI3oJJa0roaWkfc21wCm1BadKcF9ImhpZESasCPXFaWiuSb4rji4xjI7uyjS1bsdf7x4xVWZVtKZZmtqTv53n2I+211+z5zew9o5/WWnvtSCkhSZKk0ppQ6gAkSZJkUiZJkpQJJmWSJEkZYFImSZKUASZlkiRJGWBSJkmSlAEmZZLGvYi4NSJSRLy51LFIGr9MyqRxrpCMDGb56jA+54SIWBMRNw7XPnXxCsckRcSiUscijUeXlDoASSX3nn7r/x34b8CHgBf6lLcP43NOAD4BfA345jDuV5JGLZMyaZxLKf1F3/VCK8l/A76VUtpemqjOFhFlwCUppROljmWwIuLSlNJPSh2HpNHD7ktJgxIR1RHxZxGxLyJORMTWiPitiJjQp86jEfGTiFja77FfiIhTEfGmiLgC6ClsuqVP9+iThbpvKqzfFhEfioh24ARwVWH7XRHxVETsL8SxPSJ+JyIm9nvOM+PErit0y+2JiO6I+MeIePUgXm9ZRHwtIk5GxM0XqPtkYf9LI+KxiDgMPNpn+3si4p8j4nhEHIyIhyNi2TnivWKA/aeIWNOv7Kcj4oGIOBwRXRHxUETMPkfdSyLiIxHRWngPfhwR34iI+Rd6HyQVjy1lki6o0Hr2feAnwOeB/cCbgE8DrwB+rVC1DtgE/EVEXJ1S6omIXwTuAH4/pfRkRFwK3EK+6/IfgD8pPLZvVynAB4DywvbjwI8K5R8CHiPf7dkNrADuBhYA/3OA8NcCp4E/ACoKj/9mRCxOKb14jtf7MuAvgV8AbkwpPXaBtwhgMvBd4G8Lz3G6sK8PAb8P/F/gY8BlQD3w/Yj42ZfSGhkRFYXnWgp8EWgD3kL+felfN4CHgLcCXwX+GKgCVgM/HxGvTSkdGGoMkkZASsnFxcWldwHWAAlY1KfsMeA5YHq/uv+7ULemT9k7CmW/C8wE9gE/BCb2qXNJoc5XB3j+NxW27Qd+aoDtkwco+wRwCqjqU3ZrYT9Pk+/6PFN+Y6H8Fweo+2ZgCvA40AX83CDfsycLj7+7X3kl+YRyI/CyPuWvK8T7VwPEcMUA+0/Amj7r9YWy2/vV+/MB6t5UKHt7v7qvAV4EPn2+Y+/i4lK8xe5LSecVETOA64GHgfKIePmZBdhQqHbNmfoppW8B64GPku/Cmw78akrp5BCf+hsppX/vX5hSOlaIqywifqoQRxP54Rg/M8B+7ktnt4g9Vfi5cIC6leQTslcBK1NK/zDEmL/Qb/0t5Fvn/ij1GQ+XUvpn8i1dvxgRL6XH4q3AYeBP+5X/0QB1VwEdwPf6Hbs9wDbg2pfw/JJGgN2Xki5kMRDku+Q+dI46s/qtfxC4AfhZ4EMppWdfwvMOeLVnRFwPfBxYTr57s6+fGuAhO/uupJQO5Xv0uGyAuvcBk4DXppRahhjvwQGSyCsKP9sGqN9Kvnv0cvJJ01BcAexMKfX0K982QN2l5Lsrz9VFuWuIzy1phJiUSbqQKPz8EvnWsoHs6Lf+WmB24fcLDqo/h+P/KZCIq8i3vv0T+S68PeQvAqgiP15qoNb/U+fYfwxQ9jD5cWkNEfHulNK5HjuoeIcoDVRYuPL0YgT543P7ObZ3X+T+JQ0TkzJJF/IchYQhpfTdC1WOiGnAnxUe903gQxHxrZRS34RuwARkEG4CTgLXppR6k6CIuO4l7q+/r5O/+OArwIsRcUtK6fRF7O9MsloDPNNvWw1wjP+4wOFQ4ecM4Pk+9V4xwH6fB66KiPJ+rWVLBqi7HXgj8NQALWuSMsQxZZLOK+WvzPsu+ekrlvbfHhHTClcrnrEOmEd+UtqPkR9o/+WI+Ok++zxFvoVmxhDDOUU+oes7DUcZ8OEh7uecUkr3k79a9FeBrxSuXnypvkv+df5G3yk7ClNyvAXY0Ge825mux2vO3gUfHGC/jwHTgPf2K//AAHUbgankx/idJfJefqEXIak4bCmTNBh3AN8DnomIr5AfD/VTwCuBdwI54PmI+GXy3X/3pJR+ABAR7wb+Bbif/DizM54G3lyYMmIPsD+l9MQF4vgWcBfweET8OfnxX/+DYf4HM6X05YgoJ59gvhgRv5ZSGnLrXkqpMyJ+m/yUGH8fEY38x5QYh8knrWfqtkXEU8DvRkQl+ffkF4A5A+z6PvLH5AsRkQM2k0/yzsw71jfWRvKTAd8TEf+V/IUM3UA1+Stlv0H+qsu+7oyIgwM871+klJ4f3KuXNFQmZZIuKKXUHhGvA/5f8rdhupN8d9s24JPAvkJL2JfJz8f1O30eu7WQeH0hIu5MKZ25QvEO8lcrfpL8HF9PAedNylJK/xARq4AG8tNxHCQ/B9d9wFAH5p9XSulzhcTsD8lPdvvrL3E//zsi9gO/CdxLfuxZE/npM/oPzH8P+ffkA+S7af+a/NxvP+63z+MRcS35qy3fS35OtA3ku3e302ecWEopRcT/IP9+v4/8VCWnyCd9fwc8OEDYv3mOl/MDzu5alTSM4iX88ydJyqBC4vwM+SlIvlHqeCQNjWPKJGkUiohJAxSfuZPAUwNsk5Rxdl9K0uj0QET8O/mxeRPJTyh7DfC5lNJQ5z2TlAF2X0rSKBQRd5C/52g1+bsGPEd+rrbfv8hpPCSViEmZJElSBjimTJIkKQNG/Ziyl7/85emKK64odRiSJEkX9Mwzz/w4pTRzoG2jPim74oor2LhxY6nDkCRJuqCI2HmubXZfSpIkZYBJmSRJUgaYlEmSJGWASZkkSVIGmJRJkiRlgEmZJElSBpiUSZIkZYBJmSRJUgaYlEmSJGWASZkk9dHY2Egul6OsrIxcLkdjY2OpQ5I0ThT1NksRcT3wx0AZ8JWU0qf7bf8ssLKwOhmYlVL6qWLGKGn8amxspKGhgfXr17NixQqam5upq6sDYNWqVSWOTtJYFyml4jxRRBmwFXgLsAd4GliVUmo9R/164LUppfedb7/Lly9P3vtS0nDI5XKsW7eOlStX9pY1NTVRX19PS0tLCSOTNFZExDMppeUDbStm9+WVwPaU0nMppZPAA8A7zlN/FWC/gaSiaWtrY8WKFWeVrVixgra2thJFJGk8KWb3ZRWwu8/6HuD1A1WMiAVANfDEObbfDtwOMHfuXDZt2gTA7NmzmTRpEjt27ABg2rRpzJ8/v/c/3LKyMmpra2lvb+fYsWMALFq0iK6uLg4cOADAnDlzKC8vZ+fO/E3cp0+fTlVVFa2t+Qa98vJyli1bxrZt2+ju7gZgyZIldHZ20tnZmX+hVVVMmDCB3bvzL3fGjBlcfvnlbN68GYCJEyeydOlStmzZwsmTJwFYtmwZL7zwAocOHQJg3rx5nD59mo6ODgAqKyuprKxk69atAFRUVLB48WI2b95MT08PALW1tXR0dNDV1QXAggUL6OnpYe/evQDMnDmT6dOns337dgAmT57MwoULaW1t5dSpU0C+pWDXrl0cPnwYgOrqao4fP86+ffsAmDVrFlOnTqW9vR2AKVOmUF1dTUtLCyklIoJcLseOHTs4evQoAAsXLuTIkSPs37/f4+RxyvRxesUrXsGf/dmfceWVV/Yep7/7u7+jurqaw4cPe5wycpz8PHmcRvNxOp9idl/+MnB9Sun9hfX3AK9PKa0eoO5vAXNTSvUX2q/dl5KGy7nGlK1du9YxZZKGxfm6L4vZUtYBzOuzPrdQNpCbgV8f8YgkqY8ziVd9fT1tbW3U1NSYkEkqmmK2lF1CfqD/teSTsaeBX0kpPduv3jLg20B1GkRwtpRJkqTRIhMD/VNKLwKrge8AbcCDKaVnI+KeiHh7n6o3Aw8MJiGTJEkaK4o6T1lK6THgsX5lH++3vqaYMUmSJGWBM/pLkiRlgEmZJElSBpiUSZIkZYBJmSRJUgaYlEmSJGWASZkkSVIGmJRJkiRlgEmZJElSBpiUSZIkZYBJmST10djYSC6Xo6ysjFwuR2NjY6lDkjROFPU2S5KUZY2NjTQ0NLB+/XpWrFhBc3MzdXV1AKxatarE0Uka62K03/d7+fLlaePGjaUOQ9IYkMvlWLduHStXruwta2pqor6+npaWlhJGJmmsiIhnUkrLB9xmUiZJeWVlZXR3d1NeXt5b1tPTQ0VFBadOnSphZJLGivMlZY4pk6SCmpoampubzyprbm6mpqamRBFJGk9MyiSpoKGhgbq6Opqamujp6aGpqYm6ujoaGhpKHZqkccCB/pJUcGYwf319PW1tbdTU1LB27VoH+UsqCseUSZIkFYljyiRJkjLOpEySJCkDTMokSZIywKRMkiQpA0zKJEmSMsCkTJIkKQNMyiRJkjLApEySJCkDTMokSZIywKRMkiQpA0zKJEmSMsCkTJIkKQNMyiRJkjLApEySJCkDTMokSZIywKRMkiQpA0zKJEmSMsCkTJIkKQOKmpRFxPURsSUitkfER89R56aIaI2IZyPiG8WMT5IkqVQuKdYTRUQZ8HngLcAe4OmIeCSl1NqnzmLgY8AbUkqHImJWseKTJEkqpWK2lF0JbE8pPZdSOgk8ALyjX53bgM+nlA4BpJT2FzE+SZKkkilmUlYF7O6zvqdQ1tcSYElE/GNE/CAiri9adJIkSSVUtO7LQboEWAy8CZgL/H1EvCql9O99K0XE7cDtAHPnzmXTpk0AzJ49m0mTJrFjxw4Apk2bxvz582lpaQGgrKyM2tpa2tvbOXbsGACLFi2iq6uLAwcOADBnzhzKy8vZuXMnANOnT6eqqorW1nwva3l5OcuWLWPbtm10d3cDsGTJEjo7O+ns7ASgqqqKCRMmsHt3PgedMWMGl19+OZs3bwZg4sSJLF26lC1btnDy5EkAli1bxgsvvMChQ4cAmDdvHqdPn6ajowOAyspKKisr2bp1KwAVFRUsXryYzZs309PTA0BtbS0dHR10dXUBsGDBAnp6eti7dy8AM2fOZPr06Wzfvh2AyZMns3DhQlpbWzl16hQAuVyOXbt2cfjwYQCqq6s5fvw4+/btA2DWrFlMnTqV9vZ2AKZMmUJ1dTUtLS2klIgIcrkcO3bs4OjRowAsXLiQI0eOsH//fo+Tx8nj5HHyOHmcxvVxOp9IKV2w0nCIiKuANSml6wrrHwNIKf1enzpfAv4ppfSnhfXHgY+mlJ4+136XL1+eNm7cOKKxS5IkDYeIeCaltHygbcXsvnwaWBwR1RExEbgZeKRfnW+SbyUjIl5OvjvzuSLGKGmca2xsJJfLUVZWRi6Xo7GxsdQhSRonitZ9mVJ6MSJWA98ByoD7U0rPRsQ9wMaU0iOFbb8QEa3AKeDDKaXOYsUoaXxrbGykoaGB9evXs2LFCpqbm6mrqwNg1apVJY5O0lhXtO7LkWL3paThksvlWLduHStXruwta2pqor6+vndMiSRdjPN1X5qUSVJBWVkZ3d3dlJeX95b19PRQUVHRO9hYki5GVsaUSVKm1dTU0NzcfFZZc3MzNTU1JYpI0nhiUiZJBQ0NDdTV1dHU1ERPTw9NTU3U1dXR0NBQ6tAkjQNZm6dMkkpm1apVfO973+OGG27gxIkTvOxlL+O2225zkL+korClTJIKGhsbefTRR9mwYQMnT55kw4YNPProo06LIakoHOgvSQVefSlppHn1pSQNgldfShppXn0pSYPg1ZeSSsmkTJIKvPpSUil59aUkFZy5yrK+vp62tjZqampYu3atV19KKgrHlEmSJBWJY8okSZIyzqRMkiQpA0zKJEmSMsCkTJIkKQNMyiRJkjLApEyS+mhsbCSXy1FWVkYul/O+l5KKxnnKJKmgsbGRhoYG1q9fz4oVK2hubqaurg7AucokjTjnKZOkAm9ILmmkeUNySRoEb0guaaQ5eawkDYI3JJdUSiZlklTgDckllZID/SWpwBuSSyolx5RJkiQViWPKJEmSMs6kTJIkKQNMyiRJkjLApEySJCkDTMokSZIywKRMkiQpA0zKJEmSMsCkTJIkKQNMyiRJkjLApEySJCkDTMokSZIywKRMkiQpA4qalEXE9RGxJSK2R8RHB9h+a0QciIgfFpb3FzM+SZKkUilaUhYRZcDngRuAWmBVRNQOUPUvU0qvKSxfKVZ8kgRQX19PRUUFEUFFRQX19fWlDknSOFHMlrIrge0ppedSSieBB4B3FPH5Jem86uvr+dKXvsSnPvUpfvKTn/CpT32KL33pSyZmkoqimElZFbC7z/qeQll/74yIf4uIv4qIecUJTZLgvvvu49577+Wuu+5i8uTJ3HXXXdx7773cd999pQ5N0jhwSakD6OevgcaU0omI+DXga8A1/StFxO3A7QBz585l06ZNAMyePZtJkyaxY8cOAKZNm8b8+fNpaWkBoKysjNraWtrb2zl27BgAixYtoquriwMHDgAwZ84cysvL2blzJwDTp0+nqqqK1tZWAMrLy1m2bBnbtm2ju7sbgCVLltDZ2UlnZycAVVVVTJgwgd278znojBkzuPzyy9m8eTMAEydOZOnSpWzZsoWTJ08CsGzZMl544QUOHToEwLx58zh9+jQdHR0AVFZWUllZydatWwGoqKhg8eLFbN68mZ6eHgBqa2vp6Oigq6sLgAULFtDT08PevXsBmDlzJtOnT2f79u0ATJ48mYULF9La2sqpU6cAyOVy7Nq1i8OHDwNQXV3N8ePH2bdvHwCzZs1i6tSptLe3AzBlyhSqq6tpaWkhpUREkMvl2LFjB0ePHgVg4cKFHDlyhP3793ucPE6ZPk4nTpzgDW94A5s2beo9Tm94wxs4ceIEhw8f9jhl5Dj5efI4jebjdD6RUrpgpeEQEVcBa1JK1xXWPwaQUvq9c9QvAw6mlKafb7/Lly9PGzduHO5wJY1DFRUVfOpTn+Kuu+7qLfvDP/xD7r777t4/cpJ0MSLimZTS8oG2FbP78mlgcURUR8RE4Gbgkb4VIuKn+6y+HWgrYnySxrnbbruND3/4w8yePZuIYPbs2Xz4wx/mtttuK3VoksaBoiVlKaUXgdXAd8gnWw+mlJ6NiHsi4u2Far8REc9GxL8CvwHcWqz4JOnqq6/m0ksv5eDBgwAcPHiQSy+9lKuvvrrEkUkaD4rWfTlS7L6UNFxyuRzr1q1j5cqVvWVNTU3U19f3jimRpItxvu5LkzJJKigrK6O7u5vy8vLesp6eHioqKnoHG0vSxcjKmDJJyrSamhqam5vPKmtubqampqZEEUkaT0zKJKmgoaGBuro6mpqa6Onpoampibq6OhoaGkodmqRxIGvzlElSyaxatQrIz+zf1tZGTU0Na9eu7S2XpJHkmDJJkqQicUyZJElSxpmUSZIkZYBJmSRJUgaYlEmSNM40NjaSy+UoKysjl8vR2NhY6pCEV19KkjSuNDY20tDQwPr161mxYgXNzc3U1dUBeKVxiXn1pSRJ44i3Eystb7MkSZIAbydWak6JIWlciIjMLlJWeDux7DIpkzRmpJSGbRmJ/UlZ4O3EssuB/pIkjSPeTiy7HFMmSQOICFu4JA07x5RJkiRlnEmZJElSBpiUSZIkZYBJmSRJUgaYlEmSJGWASZkkSVIGmJRJkiRlgEmZJElSBpiUSZIkZYBJmSRJUgaYlEmSJGWASZkkSeNMY2MjuVyOsrIycrkcjY2NpQ5JwCWlDkCSJBVPY2MjDQ0NrF+/nhUrVtDc3ExdXR0Aq1atKnF045stZZIkjSNr165l/fr1rFy5kvLyclauXMn69etZu3ZtqUMb9yKlVOoYLsry5cvTxo0bSx2GpDEmIhjt34/SQMrKyuju7qa8vLy3rKenh4qKCk6dOlXCyMaHiHgmpbR8oG0X3VIWEZMi4sqL3Y8kSRp5NTU1NDc3n1XW3NxMTU1NiSLSGcPRfbkE+P4w7EeSJI2whoYG6urqaGpqoqenh6amJurq6mhoaCh1aOOeA/0lSRpHzgzmr6+vp62tjZqaGtauXesg/wwwKZMkaZxZtWqVSVgGefWlJElSBlwwKYuIOedbgFmDfbKIuD4itkTE9oj46HnqvTMiUkQMeHWCJEnSWDOY7ss9wPmuC48LbM9XiigDPg+8pbDPpyPikZRSa796U4EPAP80iNgkSZLGhMEkZSuH6bmuBLanlJ4DiIgHgHcArf3q/Q5wL/DhYXpeSZKkzLtgUpZSemqYnqsK2N1nfQ/w+r4VIuJ1wLyU0qMRcc6kLCJuB24HmDt3Lps2bQJg9uzZTJo0iR07dgAwbdo05s+fT0tLC5CfMK+2tpb29naOHTsGwKJFi+jq6uLAgQMAzJkzh/Lycnbu3AnA9OnTqaqqorU1nzuWl5ezbNkytm3bRnd3NwBLliyhs7OTzs7O/AutqmLChAns3p1/uTNmzODyyy9n8+bNAEycOJGlS5eyZcsWTp48CcCyZct44YUXOHToEADz5s3j9OnTdHR0AFBZWUllZSVbt24FoKKigsWLF7N582Z6enoAqK2tpaOjg66uLgAWLFhAT08Pe/fuBWDmzJlMnz6d7du3AzB58mQWLlxIa2tr74SBuVyOXbt2cfjwYQCqq6s5fvw4+/btA2DWrFlMnTqV9vZ2AKZMmUJ1dTUtLS2klIgIcrkcO3bs4OjRowAsXLiQI0eOsH//fo+Tx2nUHCeAXbt2eZwyfpz8PHmcRttxOp8hzegfEZXArwKLgTUppc6I+K/Aj1JKOy/w2F8Grk8pvb+w/h7g9Sml1YX1CcATwK0ppecj4kngQyml807X74z+kkaCM/pLGgnnm9F/0FNiREQOaAK6gAXAZ4FO4G3AfOB/XmAXHcC8PutzC2VnTAVywJMRATAbeCQi3n6hxEySJGm0G8qUGH8AfIN8K1l3n/JvAz83iMc/DSyOiOqImAjcDDxyZmNKqSul9PKU0hUppSuAHwAmZBnS2NhILpejrKyMXC5HY2NjqUOSJGnMGMrksT8LrE4ppUJL1hm7ybdqnVdK6cWIWA18BygD7k8pPRsR9wAbU0qPnH8PKqXGxkYaGhpYv349K1asoLm5mbq6OgAnIJQkaRgMekxZRBwC3pBSao2II8CrU0rPRcQK4OGU0uUjGei5OKasOHK5HOvWrWPlyv+4GLepqYn6+vreAZDSWOKYMkkj4XxjyobSffk4cGef9VTohvx/gb+9iPg0CrS1tbFixYqzylasWEFbW1uJIpIkaWwZSlL2W8A7I+J7wMvITwS7jfzg/LtHIDZlSE1NDc3NzWeVNTc3U1NTU6KIJEkaWwadlKWU2oFXk28VO9My9jXgdSml3ed8oMaEhoYG6urqaGpqoqenh6amJurq6mhoaCh1aJIkjQlDGehPSmk/sGZkQlGWnRnMX19fT1tbGzU1Naxdu9ZB/pIkDZOhDPS/+hybEvkpMtpTSoeHK7DBcqC/pJHgQH9JI2G4Bvo3A/9QWJr7rDcDzwCdEfH1iKi4yHglSdIIct7JbBpKUvZLwHPkr8B8TWG5E9gO3ATUkb95+ZrhDVGSJA2XM/NOrlu3ju7ubtatW0dDQ4OJWQYMpfuyGfhM/0leI+LtwG+llN4QETcBv5tSWjL8oQ7M7ktJI8HuS41VzjtZWufrvhxKUnYc+C8ppW39yhcD/5ZSmhQRVwBtKaVJFxfy4JmUSRoJJmUaq8rKyuju7qa8vLy3rKenh4qKCk6dOlXCyMaH4RpT1gG8e4DydwN7Cr9fBhwcWngaLRyDIEmjn/NOZtdQpsT4beAvIuJN5G8WnoCrgDcAv1qosxL47nAGqGzw3peSNDacmXey//f52rVrSx3auDfo7kuAiPgZ4DeB2kJRK/CHKaV/HoHYBsXuy+JwDILGG7svNZbV19dz3333ceLECV72spdx2223sW7dulKHNS4MV/clKaVnUkrvTim9rrC8u5QJmYqnra2NPXv2nNV9uWfPHu99KUmjTGNjI48++igbNmzg5MmTbNiwgUcffdQhKRkwlIH+88+3PaW0a1giGiJbyopj3rx5vPjii3zjG9/obe7+lV/5FS655BJ27/YuWxp7bCnTWGXPR2mdr6VsKGPKnic/juxcyoYSlEafiDjvuiQp+9ra2lixYsVZZStWrLDnIwOGkpT9XL/1cuBnyE8g+7Fhi0iZtHfvXr761a+ede/Le++9l1tvvbXUoUmShqCmpoZPfvKTfPOb3+z9Pr/xxhu9+jIDBj2mLKX0j/2WJ1NKfwB8FLhl5EJUFtTU1DB37lxaWlo4deoULS0tzJ071w+xJI0yK1eu5N577+V973sfR44c4X3vex/33nvvWd2ZKo0hDfQ/h2eANw3DfpRhZy6hbmpqoqenh6amJurq6mhoaCh1aJKkIWhqauJtb3sbd999N5deeil33303b3vb22hqaip1aOPeULov/5PIDyp6H/Cj4QlHWXVmLrK+3Zdr1651jjJJGmVaW1s5duwYGzZsOGuesueff77UoY17g07KImIbZw/0D2AWMBm4bZjjUgatWrXKJEySRrmJEyeyevXq3u7KlStXsnr1au6+++4SR6ahTInxiX5Fp4H9QFNKaetwBzZYTokhaSQ4JYbGqgkTJlBZWcmUKVPYtWsX8+fP5+jRo3R2dnL69OlShzfmDcuUGCmlTw5fSJIkqRSqqqo4ePAgXV1dnD59mo6ODsrLy6mqqip1aOPekAf6R8SKiPi1wnL1SAQlSZJGxrFjxzhx4gSf/vSn+clPfsKnP/1pTpw4wbFjx0od2rg36KQsImZGxJPA3wOfLizNEdEUES8fofgkSdIwOnjwIB/5yEe4//77mTp1Kvfffz8f+chHOHjwYKlDG/eG0lL2R8AM4DUppRkppRnAa4HLgM+ORHCSJGn4rVy58qx5J52jLBuGkpTdANyRUvq3MwUppX8Ffh1463AHJkmSht/cuXO55ZZbzpp38pZbbmHu3LmlDm3cG0pSVgH8+wDlh4CXDU84kiRpJE2mlEoAABgrSURBVH3mM5/h6NGjXHfddUycOJHrrruOo0eP8pnPfKbUoY17Q0nKNgIfi4jeKzYLv38MeHq4A5MkSSOjoqKCqqoqJkyYQFVVFRUVFaUOSQxtRv8PA38LPBcRPyiU/VdgGvALwx2YJEkafmvXruUv//IvzxpH1tTURH19vROEl9igJo+NiHJgJ3ATcB1QW9j0LPC5lNL+EYvwApw8VtJIcPJYjVVlZWV0d3dTXl7eW9bT00NFRQWnTp0qYWTjw0VPHptS6snf5pIfp5R+eziDkyRJxVNTU0Nzc/NZLWXNzc3U1NSUMCrB0MaUfQX4jZEKRJIkjbyGhgbq6urOuvqyrq6OhoaGUoc27g0lKZsD/GpEbI6Ir0fEn/RdRipAZUdjYyO5XI6ysjJyuRyNjY2lDkmSNESrVq3irW99KzfccAMTJ07khhtu4K1vfavjyTJgKEnZQuCfgR+RT9AW91kWDX9oypLGxkYaGhpYt24d3d3drFu3joaGBhMzSRplGhsbefTRR9mwYQMnT55kw4YNPProo36fZ8CgBvpnmQP9iyOXy7Fu3boBr9ZpaWkpYWTSyHCgv8aqXC7HjTfeyDe/+U3a2tqoqanpXff7fOSdb6C/SZkGxat1NJIuu+wyDh06VOowMm/GjBnen1AXbcKECVxxxRWsX7+eFStW0NzcTF1dHc8//zynT58udXhj3vmSsqF0Xw5HINdHxJaI2B4RHx1g+/+KiE0R8cOIaI6I2oH2o+I7c7VOX16to+Fy6NAhUkouF1hMXDUcJk6cyOrVq1m5ciXl5eWsXLmS1atXM3HixFKHNu4VraUsIsqArcBbgD3k7wKwKqXU2qfOtJTS4cLvbwfuTCldf7792lJWHGfGlPX/z2rt2rUODtVFs6twcHyfBPnzIKs8Py/soucpGyZXAttTSs8VgnoAeAfQm5SdScgKLgU8uhlxJvGqr6/vHYNgQiZJxXexiU/fMWXPPvssr3zlKx1TlhHFTMqqgN191vcAr+9fKSJ+HbgLmAhcM9COIuJ24HbI3+1+06ZNAMyePZtJkyaxY8cOAKZNm8b8+fN7T7KysjJqa2tpb2/n2LFjACxatIiuri4OHDgAwJw5cygvL2fnzp0ATJ8+naqqKlpb87ljeXk5y5YtY9u2bXR3dwOwZMkSOjs76ezszL/Qwv3Edu/Ov9wZM2Zw+eWXs3nzZiDfdLx06VK2bNnCyZMnAVi2bBkvvPBCb/fEvHnzOH36NB0dHQBUVlZSWVnJ1q1bgfx9yxYvXszmzZvp6ekBoLa2lo6ODrq6ugBYsGABPT097N27F4CZM2cyffp0tm/fDsDkyZNZuHAhra2tvePCcrkcu3bt4vDhfH5cXV3N8ePH2bdvH7lcjscff5ypU6fS3t4OwI4dO6iurqalpYWUEhFBLpdjx44dHD16FICFCxdy5MgR9u/f73EqwnECmDVr1lnHacqUKZk+TkDv59jjdP7jdOzYMT9Po+A4Zfl774Mf/CBr1qzhk5/8JO9///v57Gc/y3vf+17q6+vZsmWLx2mEj9P5FLP78peB61NK7y+svwd4fUpp9Tnq/wpwXUrplvPt1+5LafSzW25wfJ80XBobG1m7dm1vS1lDQ4M9H0WSle7LDmBen/W5hbJzeQD44ohGJEnSOLRq1SpWrVpFRNhlmSHFvPryaWBxRFRHxETgZuCRvhUiYnGf1bcC24oYnyRJUskUraUspfRiRKwGvgOUAfenlJ6NiHuAjSmlR4DVEfFmoAc4BJy361KD59U6kiRlWzG7L0kpPQY81q/s431+/0Ax4xlPhjPxcVyLJEnDr6iTx0qSJGlgJmWSJEkZYFImSZKUASZlkiRJGWBSJkmSlAEmZZIkSRlgUiZJkpQBJmWSJEkZYFImSZKUASZlkiRJGVDU2yxJ0kBm3TiLV33tVb3rD7ztAQBu/pube8vuePUd3PmaO7nmwWs4cPwAADWX1fDgLz3Imu+t4eFtD/fWffxdj9Pa2Ur9E/W9ZR+/6uO8a8m7znqeN859I5+79nOsfnw1T+15qrd80y2beGjrQ9zz/Xt6y9Zds47aylqufeja3rJ3Ln4na65ew01/fRNtB9sAmDlpJk/c9ARf+OEX+OK/fnFYX5OksS1G+z0Mly9fnjZu3FjqMMYV732p4eY5NTi+TxpunlPFFxHPpJSWD7TN7ktJkqQMMCmTJEnKAJMySZKkDHCgv6SSS5+YBmumlzqMzEufmFbqECSNIJMySSUXnzzsYONBiAjSmlJHIWmk2H0pSZKUASZlkiRJGWBSJkmSlAEmZZIkSRlgUiZJkpQBJmWSJEkZYFImSZKUASZlkiRJGWBSJkmSlAEmZZIkSRlgUiZJkpQBJmWSJEkZYFImSZKUASZlkiRJGWBSJkmSlAEmZZIkSRlgUiZJkpQBJmWSJEkZUNSkLCKuj4gtEbE9Ij46wPa7IqI1Iv4tIh6PiAXFjE+SpJFy2WWXERGZWoCSx9B/ueyyy0p8pErnkmI9UUSUAZ8H3gLsAZ6OiEdSSq19qv0LsDyldCwi7gA+A/yPYsUoSdJIOXToECmlUoeReWeSxfGomC1lVwLbU0rPpZROAg8A7+hbIaXUlFI6Vlj9ATC3iPFJkiSVTDGTsipgd5/1PYWyc6kDNoxoRJIkSRlRtO7LoYiIdwPLgTeeY/vtwO0Ac+fOZdOmTQDMnj2bSZMmsWPHDgCmTZvG/PnzaWlpAaCsrIza2lra29s5dizfILdo0SK6uro4cOAAAHPmzKG8vJydO3cCMH36dKqqqmhtzfeylpeXs2zZMrZt20Z3dzcAS5YsobOzk87OTgCqqqqYMGECu3fnc9AZM2Zw+eWXs3nzZgAmTpzI0qVL2bJlCydPngRg2bJlvPDCCxw6dAiAefPmcfr0aTo6OgCorKyksrKSrVu3AlBRUcHixYvZvHkzPT09ANTW1tLR0UFXVxcACxYsoKenh7179wIwc+ZMpk+fzvbt2wGYPHkyCxcupLW1lVOnTgGQy+XYtWsXhw8fBqC6uprjx4+zb98+AGbNmgXQ+55PmTKF6upqWlpaSCkREeRyOXbs2MHRo0cBWLhwIUeOHGH//v0epyIep6lTp9Le3j4qjhOM7y6LwZo2bRrHjh3z8zRKP0/wH9+dHqfzH6f29vYx+713PlGs/u2IuApYk1K6rrD+MYCU0u/1q/dmYB3wxpTS/gvtd/ny5Wnjxo0jELHOJSIcF6Exz/Ncw81zanDG+vsUEc+klJYPtK2Y3ZdPA4sjojoiJgI3A4/0rRARrwW+DLx9MAmZJEnSWFG0pCyl9CKwGvgO0AY8mFJ6NiLuiYi3F6r9PjAFeCgifhgRj5xjd5IkSWNKUceUpZQeAx7rV/bxPr+/uZjxSJIkZYUz+kuSJGWASZkkSVIGmJRJkiRlQCbnKdN/uOyyy3rnhsmSrM0pNWPGDA4ePFjqMCRJeslMyjLOe6UNTtaSREnqb9aNs3jV117Vu/7A2x4A4Oa/ubm37I5X38Gdr7mTax68hgPH85OR1lxWw4O/9CBrvreGh7c93Fv38Xc9TmtnK/VP1PeWffyqj/OuJe8663neOPeNfO7az7H68dU8teep3vJNt2zioa0Pcc/37+ktW3fNOmora7n2oWt7y965+J2suXoNN/31TbQdbANg5qSZPHHTE3zhh1/gi//6xWF9TeNZ0SaPHSljffLYsT6J3nDxfdJw85zScPOcGpyx/j5lZfJYSZIknYPdl5IkFUH6xDRYM73UYWRe+sS0UodQMiZlkiQVQXzy8JjulhsuEUFaU+ooSsPuS0mSpAwwKZMkScoAkzJJkqQMMCmTJEnKAJMySZKkDDApkyRJygCTMkmSpAwwKZMkScoAkzJJkqQMcEb/jJt14yxe9bVX9a4/8LYHALj5b27uLbvj1Xdw52vu5JoHr+HA8QMA1FxWw4O/9CBrvreGh7c93Fv38Xc9TmtnK/VP1PeWffyqj/OuJe8663neOPeNfO7az7H68dU8teep3vJNt2zioa0Pcc/37+ktW3fNOmora7n2oWt7y965+J2suXoNN/31TbQdbANg5qSZPHHTE3zhh1/gi//6xWF9TZIkjXYx2m/5sHz58rRx48ZShzFiIsLbcgyC75OGm+eUhpvn1OCM9fcpIp5JKS0faJstZRnnDWwHZzzfwFbS6BERpQ4h82bMmFHqEErGpCzjvIHt4IznG9hKGh2y+F0+1lulRhsH+kuSJGWASZkkSVIGmJRJkiRlgEmZJElSBpiUSZIkZYBJmSRJUgaYlEmSJGWA85RJGjOGe2LO4dyfc0FJuhCTMkljhomPpNHM7ktJkqQMMCmTJEnKAJMySZKkDDApkyRJygCTMkmSpAwoalIWEddHxJaI2B4RHx1g+89HxD9HxIsR8cvFjE2SJKmUipaURUQZ8HngBqAWWBURtf2q7QJuBb5RrLgkSZKyoJjzlF0JbE8pPQcQEQ8A7wBaz1RIKT1f2Ha6iHFl3nBPiDkWzZgxo9QhSJJ0UYqZlFUBu/us7wFeX8TnH5WyOBlmRGQyLkmSRrNROaN/RNwO3A4wd+5cNm3aBMDs2bOZNGkSO3bsAGDatGnMnz+flpYWAMrKyqitraW9vZ1jx44BsGjRIrq6ujhw4AAAc+bMoby8nJ07dwIwffp0qqqqaG3NN+iVl5ezbNkytm3bRnd3NwBLliyhs7OTzs5OAKqqqpgwYQK7d+dz0BkzZnD55ZezefNmACZOnMjSpUvZsmULJ0+eBGDZsmW88MILHDp0CIB58+Zx+vRpOjo6AKisrKSyspKtW7cCUFFRweLFi9m8eTM9PT0A1NbW0tHRQVdXFwALFiygp6eHvXv3AjBz5kymT5/O9u3bAZg8eTILFy6ktbWVU6dOAZDL5di1axeHDx8GoLq6muPHj7Nv3z4AZs2aBdD7nk+ZMoXq6mpaWlpIKRER5HI5duzYwdGjRwFYuHAhR44cYf/+/R6nIh6nqVOn0t7e7nHyOHmcPE7nPE4APT09HqciHqfziWK1eETEVcCalNJ1hfWPAaSUfm+Aul8F/ial9FcX2u/y5cvTxo0bhzlanY8tZZI0Nvh9XnwR8UxKaflA24p59eXTwOKIqI6IicDNwCNFfH5JkqTMKlpSllJ6EVgNfAdoAx5MKT0bEfdExNsBIuJnI2IP8C7gyxHxbLHikyRJKqWijilLKT0GPNav7ON9fn8amFvMmCRJkrLAGf0lSZIywKRMkiQpA0zKJEmSMsCkTJIkKQNMyiRJkjLApEySJCkDTMokSZIywKRMkiQpA0zKJEmSMqCoM/pLkqSLExGZ3Z83N784JmWSJI0iJj5jl92XkiRJGWBSJkmSlAEmZZIkSRlgUiZJkpQBJmWSJEkZYFImSZKUASZlkiRJGWBSJkmSlAEmZZIkSRlgUiZJkpQBJmWSJEkZ4L0vxwlvYCtJUraZlI0TJj6SJGWb3ZeSJEkZYFImSZKUASZlkiRJGWBSJkmSlAEmZZIkSRlgUiZJkpQBJmWSJEkZYFImSZKUASZlkiRJGWBSJkmSlAEmZZIkSRlgUiZJkpQBJmWSJEkZECmlUsdwUSLiALCz1HGMMy8HflzqIKQR5nmu8cDzvPgWpJRmDrRh1CdlKr6I2JhSWl7qOKSR5Hmu8cDzPFvsvpQkScoAkzJJkqQMMCnTS/EnpQ5AKgLPc40HnucZ4pgySZKkDLClTJIkKQNMyjQkEXFrRLw4hPpfjYjvjmRMUhb0P9cjYk1EbC9lTBodIuL3IuKFiEgRcWup41HpXFLqADTq/CWwYQj1P4DJvyQNKCJeD3wUuBH4J6CrtBGplEzKxomImJhSOnmx+0kpHQeOD6G+XzAqqeE696URshg4nVL6VqkDGQkREcAlKaWeUscyGtiCMUpFxJMRcX9EfDoifhwRhyPiTyKios/29RHxOxHxI2BXoXxRRDwcEf8eEYci4m8j4lX99v0zEfHtwj6PRsT/Lfw395+6LyNiWkT8aUTsi4gTEbE7Iv6wz/b+XToRER+KiOci4mREtEfEB/s9//MRcU9E/HFEHCw06382IvwnQhc00Lk/DOd9dUT8n4jYGxHHImJTRLynJC9QY0ZEfBX4c2BCoesynfnOjIj6iNhTOBe/EhHlEfG/ImJn4Rz+k4iY2G9/9RGxOSK6I2JbRDT0/d6MiF+JiH+KiK7C341HI2JJv33cXfh+PhERByLiOxExqbDtP3XJR8SKQtxXFNZvjYgXI2JlRPwLcAJ4cyH+NRGxoxDfsxHxayPwto5q/pEb3X6ZfHfizwGLgPXAT4DfLGy/Cfg6cC1QFhGXA83A/1d4zElgNfBkRCxLKR2IiFcCfw88AlxDvil9OedO4H8XeB3wDuBHwFzgleeJ+U7gd8h3azYVYvujiDiSUlrfp149cC/weuC1hdfRUniN0oX0PfdncvHn/RTgCeCTwFHgF4E/jYg9KaWmor0qjTUfAP4F+APy350AnwauBDqAt5D/bn8IqAIOANcDrwD+qvDYL0I+YQLeC3wQ+CFQA3wJqAB+u7Dvl5H/zm4FppE/nx+NiFemlE5GxH8n35X6q8C/ApcBb3oJr2sC+e/vu8jfBvEIcB/5vxW/BmwrvMYvR8SL/b77x7eUkssoXIAngeeBsj5ltwPdwKWF7VuBCX22rwF+0G8/AbQDHyys/zn5D+OEczzvrcCLfda/BXz1PHF+Ffhun/XdwGf61fks8Fyf9eeBR/rV2QA0lvp9d8n+0v/cH47z/hzP8y3gvj7r/c/1NcD2Ur8fLtleBvhO/SqwH5jYp+xR8venfFmfsm8Bf1X4fTJwDLi+377/J/Dv53nuy4AEvKGw/puFz075Oer/p3MaWFHYxxV9Xk8Cfq5PnWrgNLCs32M/Dvyw1McgS4stZaPb/00pneqz/o/k/xNaWFh/JqV0us/2nwV+JiKO9tvPJPLjGgB+Bvh2v8edzxeAhyNiOfA48G3gOwM9PiKmkf9v8O/7bXoK+EBETE4pHSuU/bBfnb3kP9jSYPQ99y/6vI+IyeT/gPwS8NPARPKfNVvJNBLa0tnjIPcBW1JKJ/qV1RR+fyX58/nhiOg7+WgZUBERM1O+Rfg1wCeA15C/EXkU6i0g//fjQeA3gJ0R8bfkv9O/mVI68hJew9N9fl9eeK6NEdG3ziVA379h455J2dj2k37rE8h/yFYPUPclDchPKX0nIuYD15Fv5v4LYFNEXNsvYRyq/gOzE46B1OD1PfeH47z/ffJd9HcBWwr7/wNg+kXEKJ1L/0Hx6RxlZ74Tz/x8F/mWrv4OFv6x+FvyXfnvBV4obHuW/D8ZpJQ6ImIZsJJ8N/5vA/dGxOtTSrvJt3ZFv32XD/B8p1JK3X3Wz8R3NfkWvf6vQwUmZaPbz0ZEWZ/k52rygyrbz1F/I/mm5T39PjB9PQNcGxETBttallI6CDQCjRHxp8D3gVpgU796hyNiD/DzwN/02fRGYEefVjJpOA3Hef/zwNdTSg8CRMQEYAn/8YdNKqVnyQ9deUVK6bGBKkREDfnxlQ0ppbZC2dX0S7IKrXHfBr4dEb9N/hy/EVhHvlt1Vr+/O68bRHzPFH7OTyn9zXlrjnO2PIxulcDnI6ImIt5KfgD9l1NK/VvIzvgc+ebsb0XEz0XEFYUrZ9YWPpwAnyHfpfP1iFgeEQsj4l0RcdVAOyw89r9HxNKIWEx+gOhRCld7DuD3gPqIuC0iFheuvrkD+NRLeQOkQRiO834L8I6IuDIiasnfL3BO0V+JNICU0lHy36GfiohfL3wfvzIibo6IewvVdpL/p72+cH5fC/wxfVqqIqKu8N386ohYQP77fCr5CwMg310/GbjnzGcE+PVBxLcduB+4LyLeE/mroV8dEe+LiN8anndhbDApG93+ivxVLc3AA+Rbnz56rsoppReAq8gPGP0/5P/QfJ38eIIfFepsIt8NOZP8WK8fAv8P5+737wbuIf+f0EbgvwA3pHPPT/ZF8mNz7ib/Qf8t4KPJq280QobpvP9N8n/Umsh3hXaQ//xJmZBS+h3y3eu3kb9opZn8eft8YfuPgXeTv6LzWeB/Ax8i3yV5xiHyXZtPAm2F/d2eUnq8sI8thf2vIn81/PvIf5cPxu3kL+pqIP/d/zhwC/Dc0F/t2OUNyUepiHiS/FUw7y91LJIk6eLZUiZJkpQBJmWSJEkZYPelJElSBthSJkmSlAEmZZIkSRlgUiZJkpQBJmWSJEkZYFImSZKUASZlkiRJGfD/AzcOW9evg1K2AAAAAElFTkSuQmCC\n","text/plain":["<Figure size 720x432 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"markdown","metadata":{"id":"0o6NKTHP8efg"},"source":["#### Print Random Summaries"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"x_j6Z3Sx8efp","executionInfo":{"status":"ok","timestamp":1608648625392,"user_tz":-60,"elapsed":5702,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"c48a005c-b44d-416b-b557-dd5af3d2a148"},"source":["print_random_summaries(df_tr, RANDOM_IDS)"],"execution_count":16,"outputs":[{"output_type":"stream","text":["(9781908541994, 'ch05')\n","\n","Text:\n","Topical therapy . Topical therapy is useful in nearly all acne regimens . mild localized acne . moderate acne; in combination with, and following,\n","oral therapy . maintenance therapy; after stopping systemic agents for severe acne . Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics . The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance . Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-\n","dose combination product to enhance adherence . Topical agents differ in their efficacy against the various etiologic factors . Retinoids, azelaic\n","acid and BPO are effective for comedones and inflammatory acne . Topical antibiotics such as erythromycin and clindamycin are most effective for\n","inflammatory lesions . Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions . It is important to note\n","that topical antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P . acnes) strains . Patients often\n","seek medical attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels . Active\n","ingredients include BPO, salicylic acid and alpha-hydroxy acids . Topical therapy is generally applied after washing the face and allowing it to dry\n","for 10-15 minutes . It is important to cover the entire affected area with a thin film of product, avoiding the eyes . Benzoyl peroxide . BPO is the\n","most potent agent against P . acnes, an obligate anaerobe that will not grow in the presence of oxygen . Unlike antibiotics, BPO is bactericidal\n","against P . acnes through its release of free oxygen radicals in sebaceous follicles . BPO therefore reduces bacterial colonization of the follicle\n","and kills both sensitive and resistant strains of P . acnes, which translates into a reduction in new inflammatory lesions . acnes does not develop\n","resistance to BPO; for this reason, the drug is a valuable component of any acne treatment regimen . BPO is mostly available in over-the-counter and\n","prescription formulations, including bar soaps, washes, gels and lotions . It is chiefly available in concentrations of 2.5%, 4%, 5% and 10% .\n","However, there is no evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the\n","2.5-5% concentrations . BPO is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene\n","(see page 52) . Topical retinoids and retinoid-like molecules . Topical retinoids are effective agents in the treatment of acne . Although\n","dermatologists readily prescribe them, topical retinoids are underutilized by pediatricians and general practitioners . Tretinoin, or all-trans-\n","retinoic acid, is a vitamin A derivative that reverses the altered keratinization in follicles affected by acne . By inhibiting the formation of the\n","microcomedone, tretinoin prevents the development of comedones and early inflammatory lesions . Tretinoin is available as a cream, gel or solution in\n","a variety of concentrations of differing potencies, which vary between countries . % gel / 0.05% cream . % gel / 0.1% cream . Tretinoin is usually\n","applied once daily at bedtime after the face has had adequate time to dry . Night-time application is most effective as the active molecule is light\n","sensitive . Tretinoin is also available in formulations with novel delivery systems, such as microspheres . Choice of formulation depends upon whether\n","the patient has dry or oily skin . Patients with oily skin usually prefer gels and patients with dry skin usually prefer creams . Adapalene is a\n","synthetic acid derivative with retinoid-like activity but a distinctly different chemical structure . Adapalene is a potent modulator of cellular\n","differentiation, keratinization and inflammatory processes, and the mechanism of action is believed to be similar to that of retinoids . Adapalene\n","interacts with nuclear retinoic acid receptors (RARs) beta and gamma . It has been hypothesized that this receptor selectivity may account for its\n","better side-effect profile . Adapalene has been shown to possess anti-inflammatory activity in a number of in-vitro and in-vivo animal models . Along\n","with tretinoin, adapalene has been shown to decrease the expression of toll-like receptor-2 (TLR2) on inflammatory cells . Adapalene is available in\n","concentrations of 0.1% and 0.3% (in the USA), and also as a fixed combination of 0.1% adapalene with 2.5% BPO for daily use . Tazarotene is a\n","synthetic acetylenic retinoid that has been formulated into a topical gel and cream . Following topical application, tazarotene is converted to its\n","active metabolite tazarotenic acid . This compound then binds to nuclear RARs and can affect the expression of genes involved in cell proliferation,\n","cell differentiation and inflammation . At the cellular level this may result in the modification of several pathogenic factors in acne, including\n","corneocyte accumulation and cohesion . Tazarotene is specific for RARs, rather than retinoid X receptors (RXRs), and selectively activates RAR-beta\n","and RAR-gamma, as does adapalene . Tazarotene is very effective in comedonal and inflammatory acne . It may have greater potential for irritation in\n","some patients, more so with the gel formulation than the cream . Tazarotene is licensed for the treatment of acne in the USA but only licensed for the\n","treatment of psoriasis in the UK . Dapsone is a sulfone that targets neutrophil-mediated inflammation . Stability issues with a topical formulation\n","were overcome with the development of a novel topical gel . The gel has been shown to be effective against acne at 5% concentration; recent studies\n","suggest topical dapsone 5% gel may be particularly beneficial in regimens for adult women with acne (see pages 26-9) . Topical isotretinoin is an\n","alternative preparation, available as a 0.05% gel in the UK and Italy, but it is not available in the USA . This retinoid has been shown to be less\n","irritating than older retinoid preparations such as tretinoin . Salicylic, alpha-hydroxy and azelaic acids . Salicylic acid, a beta-hydroxy acid, is\n","keratolytic and an irritant; it may promote the resolution of inflammatory lesions through its drying effect . Salicylic acid has mild comedolytic\n","activity . It is available in a maximum concentration of 2% in over-the-counter preparations such as soaps, cleansers and gels . Some salicylic acid\n","products are tinted to help camouflage acne lesions . Combination products containing salicylic acid and BPO or sulfur are also available . alpha\n","-hydroxy acids such as lactic acid, glycolic acid and citric acid are available in a variety of cosmetic preparations, including cleansers, toners,\n","moisturizers and chemical peels . alpha-hydroxy acids are thought to reverse the altered keratinization of follicles affected by acne and improve the\n","appearance of the skin by promoting desquamation of the stratum corneum . The effectiveness of alpha-hydroxy acids in acne, however, has not yet been\n","demonstrated in controlled clinical trials . Azelaic acid is a naturally occurring dicarboxylic acid found in cereal grains . It is available as a\n","topical cream that has been shown to be effective in inflammatory and comedonal acne . By inhibiting the growth of P . acnes, azelaic acid reduces\n","inflammatory acne . It also reverses the altered keratinization of follicles seen in acne and thus demonstrates comedolytic activity . Azelaic acid\n","can affect melanosomes and has been used to treat postinflammatory hyperpigmentation . Azelaic acid is reported to have fewer local side effects than\n","topical retinoids . Topical antibiotics . Topical antibiotics such as erythromycin, clindamycin and sodium sulfacetamide inhibit the growth of P .\n","acnes and reduce inflammatory lesions . Products containing these antibiotics are often applied twice daily and are generally well tolerated . Topical\n","antibiotics such as erythromycin and clindamycin come in a variety of formulations and packaging: creams, lotions, ointments, gels and solutions .\n","Solutions are available in dab-on applicators and pads, which are packaged either individually or in bulk . The choice of formulation or packaging\n","depends on the patient's complexion and preference . Many teenagers enjoy the convenience of the pad preparations . Sodium sulfacetamide is a\n","sulfonamide, which is thought to inhibit the growth of P . acnes through competitive antagonism of para-aminobenzoic acid, an essential requirement\n","for bacterial growth . Sodium sulfacetamide (10%) is available in combination with sulfur (5%) in a prescription lotion, either with or without tint .\n","Topical tetracycline is available in Italy, but not the UK or USA . Antibiotic resistance . Since the 1970s, P . acnes has developed resistance to\n","both topical and oral antibiotics . It is important to bear this in mind when prescribing antibiotics . acnes resistance has been shown to affect\n","clinical outcomes of acne treatment . In addition, overuse of antibiotics can drive resistance in other commensal bacteria . For these reasons, the\n","use of topical antibiotics as single agents for acne is to be discouraged . Topical retinoids and BPO are useful as first-line agents . Any regimen\n","containing an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with BPO . Combination products .\n","Recent advances in topical acne therapy include the development of fixed combination products that target more than one pathogenic feature of the\n","disease and may also increase treatment adherence among patients . Combination products that include BPO offer excellent bactericidal effects and,\n","when combined with erythromycin or clindamycin, offset the emergence of antibiotic-resistant P . acnes (see pages 51 and) . A fixed combination of BPO\n","with adapalene targets three of the four pathogenic features of acne without the use of antibiotics . Other combinations include topical tretinoin\n","0.025% with clindamycin 1%, tretinoin 0.025% with erythromycin 4% and topical isotretinoin 0.05% with erythromycin 2% (none of these are available in\n","the USA) . Side effects . Local irritation . Most topical acne treatments, including salicylic acid, BPO and topical retinoids will cause some degree\n","of erythema, dryness and scaling of the skin . Contact dermatitis due to BPO has rarely been reported but should be considered if treated areas\n","develop an eczematous dermatitis . Use of topical antibiotics may also be associated with local irritation, but this tends to occur less often than\n","with other topical agents . The local side effects of topical retinoids include erythema, scaling, desquamation, burning or stinging, pruritus and\n","increased susceptibility to sunburn . Most patients will develop tolerance to the local side effects of topical retinoids within 3-4 weeks . If\n","patients are unable to tolerate daily application of a topical retinoid, an alternate-day or every-third-day regimen can be followed until tolerance\n","develops . Topical retinoids are not recommended in pregnancy because of the theoretical risk of teratogenicity . Fortunately, studies have shown that\n","the risk of birth defects from topical tretinoin is unlikely . Pharmacokinetic studies have shown that serum retinoid levels may be influenced more by\n","diet than by facial application of topical tretinoin for acne . Epidemiological studies have failed to demonstrate an increased risk of birth defects\n","in infants whose mothers used topical retinoids on the face during the first trimester of pregnancy . There have, however, been isolated case reports\n","of birth defects in infants whose mothers used topical tretinoin during pregnancy . For this reason, it is recommended that pregnant women cease using\n","topical retinoids . Bleaching and staining . BPO can bleach clothing or bedding, particularly when it is applied to the chest or back . It is\n","therefore best to advise use of this medication at bedtime and to recommend covering the treated areas with an old shirt . Management of side effects\n",". Excessive dryness of the skin is one of the main reasons why patients discontinue topical treatment . Thus, recommendations regarding effective ways\n","of managing facial dryness should be an integral part of any acne treatment plan . Regular use of moisturizers is especially important, but the\n","clinician should be aware of the reluctance of many patients to use them because of concerns that moisturizers might worsen their acne . These\n","patients need reassurance that this is not the case: most moisturizers from reputable companies are tested for comedogenicity in clinical trials and\n","are labeled 'non-comedogenic' . Studies show that moisturizers applied before or after topical retinoids do not alter efficacy . Moisturizers are\n","available as creams and lotions; most patients prefer to use lotions as they are easy to apply and do not feel greasy . Lotions containing sunscreens\n","should be recommended, particularly in patients using topical retinoids . For recalcitrant dry areas, a heavier cream may be needed . Sunscreens are\n","important, as the sun can exacerbate facial irritation caused by topical acne medications . Some topical preparations make patients more\n","photosensitive . Thus, regular use of a sunscreen or a moisturizer containing a sunscreen is recommended to avoid sunburn as a side effect from\n","thinning of the stratum corneum by topical retinoids or phototoxicity from oral doxycycline . Alternative regimens . If irritation remains a problem\n","despite adequate use of moisturizers, the treatment regimen can be temporarily altered . For example, topical retinoids could be used every other day\n","or every third day until they are tolerated, or the duration of application could be gradually increased . The goal is to gradually increase the\n","frequency of application until the patient can tolerate daily application .\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical therapy should be selected to help achieve medical adherence. Realistic\n","expectations of therapy should be explained. Combining therapies or using fixed combination topical products improves efficacy by targeting more than\n","one pathogenic feature and enhancing treatment adherence. Topical antibiotics can lead to the development of antimicrobial resistance. Topical\n","antibiotics should not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Any regimen containing\n","an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent\n","the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n","Mild acne that consists of open and closed comedones and/or few inflammatory lesions is amenable to topical therapy using agents such as salicylic\n","acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical antibiotics . The use of topical antibiotics as single agents for acne is\n","discouraged because of the potential for the development of bacterial resistance . Topical retinoids are useful as first-line agents and topical\n","antibiotics, when used, should be combined with BPO, ideally as a fixed-dose combination product to enhance adherence . Retinoids, azelaic acid and\n","BPO are effective for comedones and inflammatory acne . It is important to note that topical antibiotics should be combined with BPO to reduce the\n","emergence of resistant Propionibacterium acnes (P . BPO is generally used as a single agent and in combination products with topical antibiotics or\n","the topical retinoid adapalene (see page 52) . It is available as a topical cream that has been shown to be effective in inflammatory and comedonal\n","acne . Recent advances in topical acne therapy include the development of fixed combination products that target more than one pathogenic feature of\n","the disease and may also increase treatment adherence among patients .\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9')\n","\n","Text:\n","Atrial flutter . Typical atrial flutter is a macro-entrant atrial rhythm, rotating counterclockwise, occasionally clockwise, within the right atrium\n","(see Figure 2.7) . Most common is a circuit confined to the anterior portion of the right atrium with a 2:1 atrioventricular (AV) block - an atrial\n","rate of 300 bpm and a regular ventricular response of 150 bpm related directly to the atrial rate . A QRS rate of exactly 150 bpm should raise\n","suspicion of atrial flutter . Other than atrial fibrillation (AF), atrial flutter is the most common arrhythmia seen by cardiologists . Patients who\n","have had AF may present with atypical atrial flutter at a later stage; patients who have had congenital abnormalities corrected at an early age may\n","present with atypical atrial flutter up to 10-20 years later . In typical atrial flutter, the circuit is critically dependent on an area of slow\n","conduction known as the cavotricuspid isthmus (see Figure 2.7) . Other rarer atypical forms occur, particularly in patients with scarring in the\n","atrium (exempli gratia after radiofrequency ablation [RFA] or previous heart surgery) . Atrial flutter typically has a saw-tooth appearance of flutter\n","waves on the baseline in the 12-lead ECG (see Figure 2.7) . Clinical presentation . Atrial flutter can be aysmptomatic or may present with\n","breathlessness, tiredness or frank heart failure . Persistent palpitations may be a feature . Anticoagulation therapy is based on the same risk\n","factors as those for AF (see Chapter 8) . Pharmacological treatment . In acute cases, cardioversion can be performed with intravenous ibutilide, or,\n","if there is no structural heart disease, a class 1c antiarrhythmic agent, such as flecainide or propafenone, combined with a beta-blocker .\n","Intravenous flecainide alone is sometimes used in Europe (but not in the USA) to slow conduction in the flutter circuit more than in the AV node\n","itself . However, in some cases this may slow the atrial rate from 300 to 200 bpm and may allow the AV node to conduct in a 1:1 fashion, producing a\n","paradoxical increase in the ventricular rate to 200 bpm, which may be associated with hemodynamic compromise; flecainide is often combined with a\n","beta-blocker to prevent the flutter being conducted to the ventricle in this 1:1 manner . The same principle applies for both intravenous and oral\n","flecainide . Oral sotalol is often used in patients with atrial flutter, as it has the combined action of an antiarrhythmic and a beta-blocker, but QT\n","considerations and renal excretion limit its use in women and the elderly . In the chronic setting, atrial flutter often responds poorly to drug\n","therapy . AV nodal-blocking drugs slow the ventricular response . Direct-current (DC) cardioversion is highly effective for atrial flutter . However,\n","persistent atrial flutter (lasting longer than 48 hours) is associated with significant embolic risk, and management before cardioversion should be as\n","for patients with AF - treatment with oral anticoagulant therapy (warfarin) for 4 weeks before cardioversion and for at least 1 month afterwards (see\n","Chapter 8) . Alternatively, a transesophageal echocardiogram can be performed in patients who are not taking warfarin, or in whom serial measurements\n","of the international normalized ratio (INR) over a month have not been documented, to exclude left atrial thrombus and enable immediate cardioversion\n",". Patients are then started, or continued, on warfarin, while heparin or low-molecular-weight heparin is given until the INR is greater than 2,\n","continuing warfarin for 1 month or more . In the acute setting, flutter often converts with a low-energy shock of about 50 J, sometimes as low as 25 J\n",". Radiofrequency (catheter) ablation is recommended for long-term treatment . RFA restores sinus rhythm by creating a linear destructive lesion,\n","across which the circulating depolarizing wavefront cannot pass . This is known as a line of block and is usually created at the inferior wall of the\n","right atrium (Figure 7.1) . This technique is in contrast to the ablation of accessory or slow pathways, which require highly localized lesions . The\n","procedure can be performed during constant atrial flutter or in sinus rhythm with pacing from the atrium or coronary sinus . Success rates are greater\n","than 90% in most centers . The cavotricuspid isthmus is not smooth throughout its length and has regions of thick muscle bundles . Ablation of these\n","areas is best achieved with technology capable of producing deep lesions, such as large-tip or cooled radiofrequency energy . Newer techniques\n","involving computerized mapping of the atria and catheter position are improving overall success . Most centers are now performing ablation as first-\n","line treatment . Apart from the usual complications associated with instrumentation of the venous circulation, heart block or cardiac tamponade are\n","rarely reported . After ablation, the prognosis for patients with typical atrial flutter is excellent . In patients with atypical atrial flutter\n","recurrences are more common because of scarring of the atria . Up to 30% of patients with either type of atrial flutter develop AF late after a\n","successful flutter ablation and may require further treatment; atrial flutter and AF often go together .\n","\n","Bullets:\n","Ablation for typical atrial flutter is highly successful and low risk, and should be considered first-line treatment. The risk of systemic\n","embolization in atrial flutter should be considered similar to that for atrial fibrillation (AF). Atypical atrial flutter usually includes right\n","atrial flutter circling around regions of scarring, or left atrial flutter following ablation of AF.\n","\n","Predicted Summary:\n","Most common is a circuit confined to the anterior portion of the right atrium with a 2:1 atrioventricular (AV) block - an atrial rate of 300 bpm and a\n","regular ventricular response of 150 bpm related directly to the atrial rate . In typical atrial flutter, the circuit is critically dependent on an\n","area of slow conduction known as the cavotricuspid isthmus (see Figure 2.7) . However, in some cases this may slow the atrial rate from 300 to 200 bpm\n","and may allow the AV node to conduct in a 1:1 fashion, producing a paradoxical increase in the ventricular rate to 200 bpm, which may be associated\n","with hemodynamic compromise; flecainide is often combined with a beta-blocker to prevent the flutter being conducted to the ventricle in this 1:1\n","manner . However, persistent atrial flutter (lasting longer than 48 hours) is associated with significant embolic risk, and management before\n","cardioversion should be as for patients with AF - treatment with oral anticoagulant therapy (warfarin) for 4 weeks before cardioversion and for at\n","least 1 month afterwards (see Chapter 8) . After ablation, the prognosis for patients with typical atrial flutter is excellent .\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01')\n","\n","Text:\n","Cigarettes as a nicotine delivery system . The cigarette . There are many different varieties of cigarette tobacco, each with its own flavor and\n","characteristics, and tobacco can be prepared in different ways that affect its taste, smell and pharmacological properties . Additives are included in\n","cigarettes by the manufacturers to engineer an attractive and efficient nicotine delivery system . Table 1.1 lists some of the many thousands of\n","chemicals in tobacco smoke . One thing that all cigarettes have in common is that they deliver nicotine to the lungs . A puff on a cigarette results\n","in rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation\n","(Figure 1.1); this process is repeated with every puff . In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette .\n","This is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply . In societies in\n","which cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more\n","nicotine from each cigarette, confirming that nicotine is the sought-after substance in tobacco . Control of the nicotine dose . As a drug delivery\n","system, cigarettes are very flexible because smokers can control the intensity and frequency of puffing . This 'fingertip control' of the nicotine\n","dose allows smokers to meet their current need while avoiding the acute adverse effects of too much nicotine . Many smokers, particularly older\n","smokers and women, choose so-called 'light' or 'low-tar' brands, believing that these are safer . According to the reported analyses of their\n","deliveries, these brands deliver as little as one-tenth of the tar and carbon monoxide of other brands . In fact, such reports are misleading: the\n","data are based on artificial measurements by smoking machines and do not mirror the actual delivery to a smoker . It is possible to extract as much\n","tar and nicotine from these cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that\n","would otherwise dilute the smoke - and that is exactly what smokers usually do . Each smoker appears to have a preferred level of nicotine intake and\n","will adjust the way he or she smokes to achieve that level . Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette\n","packaging and marketing in the USA and EU . Smokers who reduce the number of cigarettes they smoke typically compensate for the change by increasing\n","the intensity of smoking such that smoke exposure remains unchanged . An exception is when they use another nicotine product at the same time, such as\n","a nicotine patch or gum (see Chapter 7) . It also appears that if cigarette consumption drops below a threshold (perhaps around 5 cigarettes per day),\n","or if the cigarettes are designed to limit the potential for compensation (exempli gratia novel cigarettes in which the tobacco actually contains less\n","nicotine), compensation is very limited . Nicotine and its elimination from the body . Nicotine is an alkaloid obtained from tobacco plants and has\n","wide-ranging effects on the central nervous system (CNS) (see pages 37-8) . Its structure (Figure 1.2) resembles that of the major neurotransmitter\n","acetylcholine, and it activates cholinergic receptors in the brain, which accounts for many of the psychoactive effects . Once in the bloodstream,\n","nicotine is distributed around the body, readily crossing cell membranes and entering every tissue . It is eliminated quite rapidly, mainly through\n","metabolism, but partly by excretion in urine . It is metabolized mostly to the oxides cotinine and nicotine-1'-N-oxide . These appear to be largely\n","inactive and are further metabolized and excreted in urine . The plasma concentration of nicotine reduces by half every 90-120 minutes (its half-life;\n","see Figure 1.1) . Duration of withdrawal symptoms . All nicotine is cleared from the body within a day or two of abstinence . Some people think that\n","this must therefore be the period when smokers experience withdrawal symptoms (see Chapter 5) . However, the duration of withdrawal symptoms has\n","nothing to do with this; it is related to how long it takes the body to get used to not having nicotine in the system . The duration for most symptoms\n","is 2-4 weeks . Estimating nicotine intake . Nicotine concentrations in the blood could conceptually be a useful index of dependence, but its short\n","half-life means that a single measure does not give a particularly accurate picture of total intake over a day . Measurement of its metabolite,\n","cotinine, is used instead . Cotinine has a half-life of 14-20 hours, so its concentration in the blood is more stable than that of nicotine and it can\n","be easily measured in saliva, urine or even hair . Saliva samples are simple to obtain by means of a dental swab and are the method of choice for\n","accurate estimation of daily nicotine intake . A daily nicotine intake of 16 mg (approximately 16 cigarettes/day, or one every hour) corresponds on\n","average to a saliva cotinine concentration of 200 ng/mL; a daily nicotine intake of 10 mg generates a saliva cotinine concentration of about 125 ng/mL\n",". These estimations are not the same for urine or blood measurements . Monoamine oxidase inhibitors in cigarette smoke . There is evidence that\n","cigarette smoke contains other psychoactive compounds which some now believe may contribute to its addictive properties . Most notably, there is at\n","least one monoamine oxidase inhibitor (MAOI) . MAOIs reduce the rate at which monoamine neurotransmitters such as dopamine are broken down and have\n","been found to reduce depressive symptoms . In the case of smoking, they might contribute to the rewarding effect of cigarette smoke or act\n","synergistically with nicotine (which is primarily rewarding as it causes release of dopamine in the nucleus accumbens - see Chapter 5) . This may help\n","explain why people who suffer from depression are particularly likely to smoke . Research is in its early days, but if MAOIs play a role in cigarette\n","addiction, pure nicotine delivery systems may be less addictive, even if they deliver nicotine as rapidly as cigarettes .\n","\n","Bullets:\n","Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff. Smokers absorb an average 1-2 mg of nicotine per cigarette (more\n","when cigarettes are smoked more intensively). Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide. Smokers' intake of tar\n","and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes. Nicotine is rapidly\n","metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a day of abstinence. The\n","nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva or\n","urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.\n","\n","Predicted Summary:\n","A puff on a cigarette results in rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the\n","brain by the arterial circulation (Figure 1.1); this process is repeated with every puff . As a drug delivery system, cigarettes are very flexible\n","because smokers can control the intensity and frequency of puffing . It is possible to extract as much tar and nicotine from these cigarettes as from\n","higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that would otherwise dilute the smoke - and that is\n","exactly what smokers usually do . Each smoker appears to have a preferred level of nicotine intake and will adjust the way he or she smokes to achieve\n","that level . Nicotine concentrations in the blood could conceptually be a useful index of dependence, but its short half-life means that a single\n","measure does not give a particularly accurate picture of total intake over a day . Cotinine has a half-life of 14-20 hours, so its concentration in\n","the blood is more stable than that of nicotine and it can be easily measured in saliva, urine or even hair .\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n"],"name":"stdout"}]},{"cell_type":"markdown","metadata":{"id":"uGWwCCuvLNJz"},"source":["In this case, since this method is extractive, generated summaries sometimes are not very coherent. Sometimes the summary are accurate, sometimes are about something totally different from the bullets."]},{"cell_type":"markdown","metadata":{"id":"6VwoVRk0YbzM"},"source":["## **Topic Modeling**"]},{"cell_type":"markdown","metadata":{"id":"vgkTqondvLFa"},"source":["### **LDA**"]},{"cell_type":"markdown","metadata":{"id":"b2LLUGIVYbzU"},"source":["#### Loading data"]},{"cell_type":"code","metadata":{"id":"3g7226MNYbzf","executionInfo":{"status":"ok","timestamp":1608648626690,"user_tz":-60,"elapsed":4996,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["input_path = drive_dir+'summarization/topic_modeling_output/'\n","df_lda_redu = pd.read_csv(input_path+'df_lda_redu.csv')\n","df_lda_redu = df_lda_redu.set_index(['book', 'chapter'])\n","\n","df_lda_summ = pd.read_csv(input_path+'df_lda_summ_'+MODEL+'.csv')\n","df_lda_summ = df_lda_summ.set_index(['book', 'chapter'])"],"execution_count":17,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"FqG_9YB_vN-k"},"source":["#### Rouge"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/","height":0},"id":"DT73IpCyvQSq","executionInfo":{"status":"ok","timestamp":1608648628758,"user_tz":-60,"elapsed":7047,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"e6438bdc-195f-4b98-d759-0c9a566a4f06"},"source":["plot_rouge(df_lda_summ, 'topic_modeling', 'rougeL', submethod='lda')"],"execution_count":18,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 720x432 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"markdown","metadata":{"id":"nM7u_9u0-U1D"},"source":["#### Print Random Summaries"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"UdKk_usB-U1J","executionInfo":{"status":"ok","timestamp":1608648628766,"user_tz":-60,"elapsed":7046,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"9dd52f05-7434-4c09-b960-158c1bad5a8b"},"source":["print_random_summaries(df_lda_summ, RANDOM_IDS, 'lda_summary')"],"execution_count":19,"outputs":[{"output_type":"stream","text":["(9781908541994, 'ch05')\n","\n","Text:\n","Topical therapy . Topical therapy is useful in nearly all acne regimens . mild localized acne . moderate acne; in combination with, and following,\n","oral therapy . maintenance therapy; after stopping systemic agents for severe acne . Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics . The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance . Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-\n","dose combination product to enhance adherence . Topical agents differ in their efficacy against the various etiologic factors . Retinoids, azelaic\n","acid and BPO are effective for comedones and inflammatory acne . Topical antibiotics such as erythromycin and clindamycin are most effective for\n","inflammatory lesions . Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions . It is important to note\n","that topical antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P . acnes) strains . Patients often\n","seek medical attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels . Active\n","ingredients include BPO, salicylic acid and alpha-hydroxy acids . Topical therapy is generally applied after washing the face and allowing it to dry\n","for 10-15 minutes . It is important to cover the entire affected area with a thin film of product, avoiding the eyes . Benzoyl peroxide . BPO is the\n","most potent agent against P . acnes, an obligate anaerobe that will not grow in the presence of oxygen . Unlike antibiotics, BPO is bactericidal\n","against P . acnes through its release of free oxygen radicals in sebaceous follicles . BPO therefore reduces bacterial colonization of the follicle\n","and kills both sensitive and resistant strains of P . acnes, which translates into a reduction in new inflammatory lesions . acnes does not develop\n","resistance to BPO; for this reason, the drug is a valuable component of any acne treatment regimen . BPO is mostly available in over-the-counter and\n","prescription formulations, including bar soaps, washes, gels and lotions . It is chiefly available in concentrations of 2.5%, 4%, 5% and 10% .\n","However, there is no evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the\n","2.5-5% concentrations . BPO is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene\n","(see page 52) . Topical retinoids and retinoid-like molecules . Topical retinoids are effective agents in the treatment of acne . Although\n","dermatologists readily prescribe them, topical retinoids are underutilized by pediatricians and general practitioners . Tretinoin, or all-trans-\n","retinoic acid, is a vitamin A derivative that reverses the altered keratinization in follicles affected by acne . By inhibiting the formation of the\n","microcomedone, tretinoin prevents the development of comedones and early inflammatory lesions . Tretinoin is available as a cream, gel or solution in\n","a variety of concentrations of differing potencies, which vary between countries . % gel / 0.05% cream . % gel / 0.1% cream . Tretinoin is usually\n","applied once daily at bedtime after the face has had adequate time to dry . Night-time application is most effective as the active molecule is light\n","sensitive . Tretinoin is also available in formulations with novel delivery systems, such as microspheres . Choice of formulation depends upon whether\n","the patient has dry or oily skin . Patients with oily skin usually prefer gels and patients with dry skin usually prefer creams . Adapalene is a\n","synthetic acid derivative with retinoid-like activity but a distinctly different chemical structure . Adapalene is a potent modulator of cellular\n","differentiation, keratinization and inflammatory processes, and the mechanism of action is believed to be similar to that of retinoids . Adapalene\n","interacts with nuclear retinoic acid receptors (RARs) beta and gamma . It has been hypothesized that this receptor selectivity may account for its\n","better side-effect profile . Adapalene has been shown to possess anti-inflammatory activity in a number of in-vitro and in-vivo animal models . Along\n","with tretinoin, adapalene has been shown to decrease the expression of toll-like receptor-2 (TLR2) on inflammatory cells . Adapalene is available in\n","concentrations of 0.1% and 0.3% (in the USA), and also as a fixed combination of 0.1% adapalene with 2.5% BPO for daily use . Tazarotene is a\n","synthetic acetylenic retinoid that has been formulated into a topical gel and cream . Following topical application, tazarotene is converted to its\n","active metabolite tazarotenic acid . This compound then binds to nuclear RARs and can affect the expression of genes involved in cell proliferation,\n","cell differentiation and inflammation . At the cellular level this may result in the modification of several pathogenic factors in acne, including\n","corneocyte accumulation and cohesion . Tazarotene is specific for RARs, rather than retinoid X receptors (RXRs), and selectively activates RAR-beta\n","and RAR-gamma, as does adapalene . Tazarotene is very effective in comedonal and inflammatory acne . It may have greater potential for irritation in\n","some patients, more so with the gel formulation than the cream . Tazarotene is licensed for the treatment of acne in the USA but only licensed for the\n","treatment of psoriasis in the UK . Dapsone is a sulfone that targets neutrophil-mediated inflammation . Stability issues with a topical formulation\n","were overcome with the development of a novel topical gel . The gel has been shown to be effective against acne at 5% concentration; recent studies\n","suggest topical dapsone 5% gel may be particularly beneficial in regimens for adult women with acne (see pages 26-9) . Topical isotretinoin is an\n","alternative preparation, available as a 0.05% gel in the UK and Italy, but it is not available in the USA . This retinoid has been shown to be less\n","irritating than older retinoid preparations such as tretinoin . Salicylic, alpha-hydroxy and azelaic acids . Salicylic acid, a beta-hydroxy acid, is\n","keratolytic and an irritant; it may promote the resolution of inflammatory lesions through its drying effect . Salicylic acid has mild comedolytic\n","activity . It is available in a maximum concentration of 2% in over-the-counter preparations such as soaps, cleansers and gels . Some salicylic acid\n","products are tinted to help camouflage acne lesions . Combination products containing salicylic acid and BPO or sulfur are also available . alpha\n","-hydroxy acids such as lactic acid, glycolic acid and citric acid are available in a variety of cosmetic preparations, including cleansers, toners,\n","moisturizers and chemical peels . alpha-hydroxy acids are thought to reverse the altered keratinization of follicles affected by acne and improve the\n","appearance of the skin by promoting desquamation of the stratum corneum . The effectiveness of alpha-hydroxy acids in acne, however, has not yet been\n","demonstrated in controlled clinical trials . Azelaic acid is a naturally occurring dicarboxylic acid found in cereal grains . It is available as a\n","topical cream that has been shown to be effective in inflammatory and comedonal acne . By inhibiting the growth of P . acnes, azelaic acid reduces\n","inflammatory acne . It also reverses the altered keratinization of follicles seen in acne and thus demonstrates comedolytic activity . Azelaic acid\n","can affect melanosomes and has been used to treat postinflammatory hyperpigmentation . Azelaic acid is reported to have fewer local side effects than\n","topical retinoids . Topical antibiotics . Topical antibiotics such as erythromycin, clindamycin and sodium sulfacetamide inhibit the growth of P .\n","acnes and reduce inflammatory lesions . Products containing these antibiotics are often applied twice daily and are generally well tolerated . Topical\n","antibiotics such as erythromycin and clindamycin come in a variety of formulations and packaging: creams, lotions, ointments, gels and solutions .\n","Solutions are available in dab-on applicators and pads, which are packaged either individually or in bulk . The choice of formulation or packaging\n","depends on the patient's complexion and preference . Many teenagers enjoy the convenience of the pad preparations . Sodium sulfacetamide is a\n","sulfonamide, which is thought to inhibit the growth of P . acnes through competitive antagonism of para-aminobenzoic acid, an essential requirement\n","for bacterial growth . Sodium sulfacetamide (10%) is available in combination with sulfur (5%) in a prescription lotion, either with or without tint .\n","Topical tetracycline is available in Italy, but not the UK or USA . Antibiotic resistance . Since the 1970s, P . acnes has developed resistance to\n","both topical and oral antibiotics . It is important to bear this in mind when prescribing antibiotics . acnes resistance has been shown to affect\n","clinical outcomes of acne treatment . In addition, overuse of antibiotics can drive resistance in other commensal bacteria . For these reasons, the\n","use of topical antibiotics as single agents for acne is to be discouraged . Topical retinoids and BPO are useful as first-line agents . Any regimen\n","containing an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with BPO . Combination products .\n","Recent advances in topical acne therapy include the development of fixed combination products that target more than one pathogenic feature of the\n","disease and may also increase treatment adherence among patients . Combination products that include BPO offer excellent bactericidal effects and,\n","when combined with erythromycin or clindamycin, offset the emergence of antibiotic-resistant P . acnes (see pages 51 and) . A fixed combination of BPO\n","with adapalene targets three of the four pathogenic features of acne without the use of antibiotics . Other combinations include topical tretinoin\n","0.025% with clindamycin 1%, tretinoin 0.025% with erythromycin 4% and topical isotretinoin 0.05% with erythromycin 2% (none of these are available in\n","the USA) . Side effects . Local irritation . Most topical acne treatments, including salicylic acid, BPO and topical retinoids will cause some degree\n","of erythema, dryness and scaling of the skin . Contact dermatitis due to BPO has rarely been reported but should be considered if treated areas\n","develop an eczematous dermatitis . Use of topical antibiotics may also be associated with local irritation, but this tends to occur less often than\n","with other topical agents . The local side effects of topical retinoids include erythema, scaling, desquamation, burning or stinging, pruritus and\n","increased susceptibility to sunburn . Most patients will develop tolerance to the local side effects of topical retinoids within 3-4 weeks . If\n","patients are unable to tolerate daily application of a topical retinoid, an alternate-day or every-third-day regimen can be followed until tolerance\n","develops . Topical retinoids are not recommended in pregnancy because of the theoretical risk of teratogenicity . Fortunately, studies have shown that\n","the risk of birth defects from topical tretinoin is unlikely . Pharmacokinetic studies have shown that serum retinoid levels may be influenced more by\n","diet than by facial application of topical tretinoin for acne . Epidemiological studies have failed to demonstrate an increased risk of birth defects\n","in infants whose mothers used topical retinoids on the face during the first trimester of pregnancy . There have, however, been isolated case reports\n","of birth defects in infants whose mothers used topical tretinoin during pregnancy . For this reason, it is recommended that pregnant women cease using\n","topical retinoids . Bleaching and staining . BPO can bleach clothing or bedding, particularly when it is applied to the chest or back . It is\n","therefore best to advise use of this medication at bedtime and to recommend covering the treated areas with an old shirt . Management of side effects\n",". Excessive dryness of the skin is one of the main reasons why patients discontinue topical treatment . Thus, recommendations regarding effective ways\n","of managing facial dryness should be an integral part of any acne treatment plan . Regular use of moisturizers is especially important, but the\n","clinician should be aware of the reluctance of many patients to use them because of concerns that moisturizers might worsen their acne . These\n","patients need reassurance that this is not the case: most moisturizers from reputable companies are tested for comedogenicity in clinical trials and\n","are labeled 'non-comedogenic' . Studies show that moisturizers applied before or after topical retinoids do not alter efficacy . Moisturizers are\n","available as creams and lotions; most patients prefer to use lotions as they are easy to apply and do not feel greasy . Lotions containing sunscreens\n","should be recommended, particularly in patients using topical retinoids . For recalcitrant dry areas, a heavier cream may be needed . Sunscreens are\n","important, as the sun can exacerbate facial irritation caused by topical acne medications . Some topical preparations make patients more\n","photosensitive . Thus, regular use of a sunscreen or a moisturizer containing a sunscreen is recommended to avoid sunburn as a side effect from\n","thinning of the stratum corneum by topical retinoids or phototoxicity from oral doxycycline . Alternative regimens . If irritation remains a problem\n","despite adequate use of moisturizers, the treatment regimen can be temporarily altered . For example, topical retinoids could be used every other day\n","or every third day until they are tolerated, or the duration of application could be gradually increased . The goal is to gradually increase the\n","frequency of application until the patient can tolerate daily application .\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical therapy should be selected to help achieve medical adherence. Realistic\n","expectations of therapy should be explained. Combining therapies or using fixed combination topical products improves efficacy by targeting more than\n","one pathogenic feature and enhancing treatment adherence. Topical antibiotics can lead to the development of antimicrobial resistance. Topical\n","antibiotics should not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Any regimen containing\n","an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent\n","the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. Topical\n","antibiotics such as erythromycin and clindamycin are most effective for inflammatory lesions. Tazarotene is licensed for the treatment of acne in the\n","USA but onlylicensed for the treatment of psoriasis in the UK. Topical dapsone 5% gel may be particularly beneficial in regimens for adult women with\n","acne (see pages 26-9) Topical retinoids and retinoid-like molecules are effective agents in the treatment of acne. Most topical acne treatments will\n","cause some degree of erythema, dryness and scaling of the skin.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9')\n","\n","Text:\n","Atrial flutter . Typical atrial flutter is a macro-entrant atrial rhythm, rotating counterclockwise, occasionally clockwise, within the right atrium\n","(see Figure 2.7) . Most common is a circuit confined to the anterior portion of the right atrium with a 2:1 atrioventricular (AV) block - an atrial\n","rate of 300 bpm and a regular ventricular response of 150 bpm related directly to the atrial rate . A QRS rate of exactly 150 bpm should raise\n","suspicion of atrial flutter . Other than atrial fibrillation (AF), atrial flutter is the most common arrhythmia seen by cardiologists . Patients who\n","have had AF may present with atypical atrial flutter at a later stage; patients who have had congenital abnormalities corrected at an early age may\n","present with atypical atrial flutter up to 10-20 years later . In typical atrial flutter, the circuit is critically dependent on an area of slow\n","conduction known as the cavotricuspid isthmus (see Figure 2.7) . Other rarer atypical forms occur, particularly in patients with scarring in the\n","atrium (exempli gratia after radiofrequency ablation [RFA] or previous heart surgery) . Atrial flutter typically has a saw-tooth appearance of flutter\n","waves on the baseline in the 12-lead ECG (see Figure 2.7) . Clinical presentation . Atrial flutter can be aysmptomatic or may present with\n","breathlessness, tiredness or frank heart failure . Persistent palpitations may be a feature . Anticoagulation therapy is based on the same risk\n","factors as those for AF (see Chapter 8) . Pharmacological treatment . In acute cases, cardioversion can be performed with intravenous ibutilide, or,\n","if there is no structural heart disease, a class 1c antiarrhythmic agent, such as flecainide or propafenone, combined with a beta-blocker .\n","Intravenous flecainide alone is sometimes used in Europe (but not in the USA) to slow conduction in the flutter circuit more than in the AV node\n","itself . However, in some cases this may slow the atrial rate from 300 to 200 bpm and may allow the AV node to conduct in a 1:1 fashion, producing a\n","paradoxical increase in the ventricular rate to 200 bpm, which may be associated with hemodynamic compromise; flecainide is often combined with a\n","beta-blocker to prevent the flutter being conducted to the ventricle in this 1:1 manner . The same principle applies for both intravenous and oral\n","flecainide . Oral sotalol is often used in patients with atrial flutter, as it has the combined action of an antiarrhythmic and a beta-blocker, but QT\n","considerations and renal excretion limit its use in women and the elderly . In the chronic setting, atrial flutter often responds poorly to drug\n","therapy . AV nodal-blocking drugs slow the ventricular response . Direct-current (DC) cardioversion is highly effective for atrial flutter . However,\n","persistent atrial flutter (lasting longer than 48 hours) is associated with significant embolic risk, and management before cardioversion should be as\n","for patients with AF - treatment with oral anticoagulant therapy (warfarin) for 4 weeks before cardioversion and for at least 1 month afterwards (see\n","Chapter 8) . Alternatively, a transesophageal echocardiogram can be performed in patients who are not taking warfarin, or in whom serial measurements\n","of the international normalized ratio (INR) over a month have not been documented, to exclude left atrial thrombus and enable immediate cardioversion\n",". Patients are then started, or continued, on warfarin, while heparin or low-molecular-weight heparin is given until the INR is greater than 2,\n","continuing warfarin for 1 month or more . In the acute setting, flutter often converts with a low-energy shock of about 50 J, sometimes as low as 25 J\n",". Radiofrequency (catheter) ablation is recommended for long-term treatment . RFA restores sinus rhythm by creating a linear destructive lesion,\n","across which the circulating depolarizing wavefront cannot pass . This is known as a line of block and is usually created at the inferior wall of the\n","right atrium (Figure 7.1) . This technique is in contrast to the ablation of accessory or slow pathways, which require highly localized lesions . The\n","procedure can be performed during constant atrial flutter or in sinus rhythm with pacing from the atrium or coronary sinus . Success rates are greater\n","than 90% in most centers . The cavotricuspid isthmus is not smooth throughout its length and has regions of thick muscle bundles . Ablation of these\n","areas is best achieved with technology capable of producing deep lesions, such as large-tip or cooled radiofrequency energy . Newer techniques\n","involving computerized mapping of the atria and catheter position are improving overall success . Most centers are now performing ablation as first-\n","line treatment . Apart from the usual complications associated with instrumentation of the venous circulation, heart block or cardiac tamponade are\n","rarely reported . After ablation, the prognosis for patients with typical atrial flutter is excellent . In patients with atypical atrial flutter\n","recurrences are more common because of scarring of the atria . Up to 30% of patients with either type of atrial flutter develop AF late after a\n","successful flutter ablation and may require further treatment; atrial flutter and AF often go together .\n","\n","Bullets:\n","Ablation for typical atrial flutter is highly successful and low risk, and should be considered first-line treatment. The risk of systemic\n","embolization in atrial flutter should be considered similar to that for atrial fibrillation (AF). Atypical atrial flutter usually includes right\n","atrial flutter circling around regions of scarring, or left atrial flutter following ablation of AF.\n","\n","Predicted Summary:\n","Atrial flutter is the most common arrhythmia seen by cardiologists. Atrial flutter typically has a saw-tooth appearance of flutter waves on the\n","baseline in the 12-lead ECG. Radiofrequency (catheter) ablation is recommended for long-term treatment of atrial flutter. Up to 30% of patients with\n","typical atrial flutter recur because of scarring of the atria. In patients with atypical atrial flutter, recurrences are more common because the atria\n","are more scarring than in patients with atrial fibrillation. Atrial fibrillation (AF) and atrial flutter often go together; AF and AF often go\n","together together.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01')\n","\n","Text:\n","Cigarettes as a nicotine delivery system . The cigarette . There are many different varieties of cigarette tobacco, each with its own flavor and\n","characteristics, and tobacco can be prepared in different ways that affect its taste, smell and pharmacological properties . Additives are included in\n","cigarettes by the manufacturers to engineer an attractive and efficient nicotine delivery system . Table 1.1 lists some of the many thousands of\n","chemicals in tobacco smoke . One thing that all cigarettes have in common is that they deliver nicotine to the lungs . A puff on a cigarette results\n","in rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation\n","(Figure 1.1); this process is repeated with every puff . In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette .\n","This is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply . In societies in\n","which cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more\n","nicotine from each cigarette, confirming that nicotine is the sought-after substance in tobacco . Control of the nicotine dose . As a drug delivery\n","system, cigarettes are very flexible because smokers can control the intensity and frequency of puffing . This 'fingertip control' of the nicotine\n","dose allows smokers to meet their current need while avoiding the acute adverse effects of too much nicotine . Many smokers, particularly older\n","smokers and women, choose so-called 'light' or 'low-tar' brands, believing that these are safer . According to the reported analyses of their\n","deliveries, these brands deliver as little as one-tenth of the tar and carbon monoxide of other brands . In fact, such reports are misleading: the\n","data are based on artificial measurements by smoking machines and do not mirror the actual delivery to a smoker . It is possible to extract as much\n","tar and nicotine from these cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that\n","would otherwise dilute the smoke - and that is exactly what smokers usually do . Each smoker appears to have a preferred level of nicotine intake and\n","will adjust the way he or she smokes to achieve that level . Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette\n","packaging and marketing in the USA and EU . Smokers who reduce the number of cigarettes they smoke typically compensate for the change by increasing\n","the intensity of smoking such that smoke exposure remains unchanged . An exception is when they use another nicotine product at the same time, such as\n","a nicotine patch or gum (see Chapter 7) . It also appears that if cigarette consumption drops below a threshold (perhaps around 5 cigarettes per day),\n","or if the cigarettes are designed to limit the potential for compensation (exempli gratia novel cigarettes in which the tobacco actually contains less\n","nicotine), compensation is very limited . Nicotine and its elimination from the body . Nicotine is an alkaloid obtained from tobacco plants and has\n","wide-ranging effects on the central nervous system (CNS) (see pages 37-8) . Its structure (Figure 1.2) resembles that of the major neurotransmitter\n","acetylcholine, and it activates cholinergic receptors in the brain, which accounts for many of the psychoactive effects . Once in the bloodstream,\n","nicotine is distributed around the body, readily crossing cell membranes and entering every tissue . It is eliminated quite rapidly, mainly through\n","metabolism, but partly by excretion in urine . It is metabolized mostly to the oxides cotinine and nicotine-1'-N-oxide . These appear to be largely\n","inactive and are further metabolized and excreted in urine . The plasma concentration of nicotine reduces by half every 90-120 minutes (its half-life;\n","see Figure 1.1) . Duration of withdrawal symptoms . All nicotine is cleared from the body within a day or two of abstinence . Some people think that\n","this must therefore be the period when smokers experience withdrawal symptoms (see Chapter 5) . However, the duration of withdrawal symptoms has\n","nothing to do with this; it is related to how long it takes the body to get used to not having nicotine in the system . The duration for most symptoms\n","is 2-4 weeks . Estimating nicotine intake . Nicotine concentrations in the blood could conceptually be a useful index of dependence, but its short\n","half-life means that a single measure does not give a particularly accurate picture of total intake over a day . Measurement of its metabolite,\n","cotinine, is used instead . Cotinine has a half-life of 14-20 hours, so its concentration in the blood is more stable than that of nicotine and it can\n","be easily measured in saliva, urine or even hair . Saliva samples are simple to obtain by means of a dental swab and are the method of choice for\n","accurate estimation of daily nicotine intake . A daily nicotine intake of 16 mg (approximately 16 cigarettes/day, or one every hour) corresponds on\n","average to a saliva cotinine concentration of 200 ng/mL; a daily nicotine intake of 10 mg generates a saliva cotinine concentration of about 125 ng/mL\n",". These estimations are not the same for urine or blood measurements . Monoamine oxidase inhibitors in cigarette smoke . There is evidence that\n","cigarette smoke contains other psychoactive compounds which some now believe may contribute to its addictive properties . Most notably, there is at\n","least one monoamine oxidase inhibitor (MAOI) . MAOIs reduce the rate at which monoamine neurotransmitters such as dopamine are broken down and have\n","been found to reduce depressive symptoms . In the case of smoking, they might contribute to the rewarding effect of cigarette smoke or act\n","synergistically with nicotine (which is primarily rewarding as it causes release of dopamine in the nucleus accumbens - see Chapter 5) . This may help\n","explain why people who suffer from depression are particularly likely to smoke . Research is in its early days, but if MAOIs play a role in cigarette\n","addiction, pure nicotine delivery systems may be less addictive, even if they deliver nicotine as rapidly as cigarettes .\n","\n","Bullets:\n","Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff. Smokers absorb an average 1-2 mg of nicotine per cigarette (more\n","when cigarettes are smoked more intensively). Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide. Smokers' intake of tar\n","and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes. Nicotine is rapidly\n","metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a day of abstinence. The\n","nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva or\n","urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.\n","\n","Predicted Summary:\n","In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. Each smoker appears to have a preferred level of nicotine\n","intake and will adjust the way he or she smokes to achieve that level. All nicotine is cleared from the body within a day or two of abstinence. The\n","duration of withdrawal symptoms has nothing to do with this; it is related to how long it takes the body to get used to not having nicotine in the\n","system. A daily nicotine intake of 16 mg (approximately 16 cigarettes/day, or one every hour) corresponds on average to a saliva cotinine\n","concentration of 200 ng/mL. Measurement of its metabolite, cotinine, is used instead. Monoamine oxidase inhibitors in cigarette smoke might contribute\n","to the rewarding effect of cigarette smoke.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n"],"name":"stdout"}]},{"cell_type":"markdown","metadata":{"id":"sbIyY3jQLdv5"},"source":["Summaries are more accurate than TextRank since this method introduces abstraction. However, because the first level is extractive, sometimes phrases are not collated in a very abstract way.\n","\n","Moreover, it can be noticed that sometimes the topic model does not keep some information that is present in the bullets. Thus, the generated summaries do not include some information in the bullets and generate info which is not present."]},{"cell_type":"markdown","metadata":{"id":"zufJSxeZvoxF"},"source":["### **LSI**"]},{"cell_type":"markdown","metadata":{"id":"X29XKbHHvoxF"},"source":["#### Loading data"]},{"cell_type":"code","metadata":{"id":"nMA55XQwvoxG","executionInfo":{"status":"ok","timestamp":1608648628777,"user_tz":-60,"elapsed":7052,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["input_path = drive_dir+'summarization/topic_modeling_output/'\n","df_lsi_redu = pd.read_csv(input_path+'df_lsi_redu.csv')\n","df_lsi_redu = df_lsi_redu.set_index(['book', 'chapter'])\n","\n","df_lsi_summ = pd.read_csv(input_path+'df_lsi_summ_'+MODEL+'.csv')\n","df_lsi_summ = df_lsi_summ.set_index(['book', 'chapter'])"],"execution_count":20,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"Pk6oYRBZvoxH"},"source":["#### Rouge"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/","height":0},"id":"fv_aQHoWvoxH","executionInfo":{"status":"ok","timestamp":1608648629465,"user_tz":-60,"elapsed":7719,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"bea60018-093e-41f5-95a6-a748054ae708"},"source":["plot_rouge(df_lsi_summ, 'topic_modeling', 'rougeL', submethod='lsi')"],"execution_count":21,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 720x432 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"markdown","metadata":{"id":"rup_5B24-oPx"},"source":["#### Print Random Summaries"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"-kfIk2wZ-oP2","executionInfo":{"status":"ok","timestamp":1608648629469,"user_tz":-60,"elapsed":7716,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"bf4ac696-e6c8-4175-8af0-681405ecc081"},"source":["print_random_summaries(df_lsi_summ, RANDOM_IDS, 'lsi_summary')"],"execution_count":22,"outputs":[{"output_type":"stream","text":["(9781908541994, 'ch05')\n","\n","Text:\n","Topical therapy . Topical therapy is useful in nearly all acne regimens . mild localized acne . moderate acne; in combination with, and following,\n","oral therapy . maintenance therapy; after stopping systemic agents for severe acne . Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics . The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance . Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-\n","dose combination product to enhance adherence . Topical agents differ in their efficacy against the various etiologic factors . Retinoids, azelaic\n","acid and BPO are effective for comedones and inflammatory acne . Topical antibiotics such as erythromycin and clindamycin are most effective for\n","inflammatory lesions . Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions . It is important to note\n","that topical antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P . acnes) strains . Patients often\n","seek medical attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels . Active\n","ingredients include BPO, salicylic acid and alpha-hydroxy acids . Topical therapy is generally applied after washing the face and allowing it to dry\n","for 10-15 minutes . It is important to cover the entire affected area with a thin film of product, avoiding the eyes . Benzoyl peroxide . BPO is the\n","most potent agent against P . acnes, an obligate anaerobe that will not grow in the presence of oxygen . Unlike antibiotics, BPO is bactericidal\n","against P . acnes through its release of free oxygen radicals in sebaceous follicles . BPO therefore reduces bacterial colonization of the follicle\n","and kills both sensitive and resistant strains of P . acnes, which translates into a reduction in new inflammatory lesions . acnes does not develop\n","resistance to BPO; for this reason, the drug is a valuable component of any acne treatment regimen . BPO is mostly available in over-the-counter and\n","prescription formulations, including bar soaps, washes, gels and lotions . It is chiefly available in concentrations of 2.5%, 4%, 5% and 10% .\n","However, there is no evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the\n","2.5-5% concentrations . BPO is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene\n","(see page 52) . Topical retinoids and retinoid-like molecules . Topical retinoids are effective agents in the treatment of acne . Although\n","dermatologists readily prescribe them, topical retinoids are underutilized by pediatricians and general practitioners . Tretinoin, or all-trans-\n","retinoic acid, is a vitamin A derivative that reverses the altered keratinization in follicles affected by acne . By inhibiting the formation of the\n","microcomedone, tretinoin prevents the development of comedones and early inflammatory lesions . Tretinoin is available as a cream, gel or solution in\n","a variety of concentrations of differing potencies, which vary between countries . % gel / 0.05% cream . % gel / 0.1% cream . Tretinoin is usually\n","applied once daily at bedtime after the face has had adequate time to dry . Night-time application is most effective as the active molecule is light\n","sensitive . Tretinoin is also available in formulations with novel delivery systems, such as microspheres . Choice of formulation depends upon whether\n","the patient has dry or oily skin . Patients with oily skin usually prefer gels and patients with dry skin usually prefer creams . Adapalene is a\n","synthetic acid derivative with retinoid-like activity but a distinctly different chemical structure . Adapalene is a potent modulator of cellular\n","differentiation, keratinization and inflammatory processes, and the mechanism of action is believed to be similar to that of retinoids . Adapalene\n","interacts with nuclear retinoic acid receptors (RARs) beta and gamma . It has been hypothesized that this receptor selectivity may account for its\n","better side-effect profile . Adapalene has been shown to possess anti-inflammatory activity in a number of in-vitro and in-vivo animal models . Along\n","with tretinoin, adapalene has been shown to decrease the expression of toll-like receptor-2 (TLR2) on inflammatory cells . Adapalene is available in\n","concentrations of 0.1% and 0.3% (in the USA), and also as a fixed combination of 0.1% adapalene with 2.5% BPO for daily use . Tazarotene is a\n","synthetic acetylenic retinoid that has been formulated into a topical gel and cream . Following topical application, tazarotene is converted to its\n","active metabolite tazarotenic acid . This compound then binds to nuclear RARs and can affect the expression of genes involved in cell proliferation,\n","cell differentiation and inflammation . At the cellular level this may result in the modification of several pathogenic factors in acne, including\n","corneocyte accumulation and cohesion . Tazarotene is specific for RARs, rather than retinoid X receptors (RXRs), and selectively activates RAR-beta\n","and RAR-gamma, as does adapalene . Tazarotene is very effective in comedonal and inflammatory acne . It may have greater potential for irritation in\n","some patients, more so with the gel formulation than the cream . Tazarotene is licensed for the treatment of acne in the USA but only licensed for the\n","treatment of psoriasis in the UK . Dapsone is a sulfone that targets neutrophil-mediated inflammation . Stability issues with a topical formulation\n","were overcome with the development of a novel topical gel . The gel has been shown to be effective against acne at 5% concentration; recent studies\n","suggest topical dapsone 5% gel may be particularly beneficial in regimens for adult women with acne (see pages 26-9) . Topical isotretinoin is an\n","alternative preparation, available as a 0.05% gel in the UK and Italy, but it is not available in the USA . This retinoid has been shown to be less\n","irritating than older retinoid preparations such as tretinoin . Salicylic, alpha-hydroxy and azelaic acids . Salicylic acid, a beta-hydroxy acid, is\n","keratolytic and an irritant; it may promote the resolution of inflammatory lesions through its drying effect . Salicylic acid has mild comedolytic\n","activity . It is available in a maximum concentration of 2% in over-the-counter preparations such as soaps, cleansers and gels . Some salicylic acid\n","products are tinted to help camouflage acne lesions . Combination products containing salicylic acid and BPO or sulfur are also available . alpha\n","-hydroxy acids such as lactic acid, glycolic acid and citric acid are available in a variety of cosmetic preparations, including cleansers, toners,\n","moisturizers and chemical peels . alpha-hydroxy acids are thought to reverse the altered keratinization of follicles affected by acne and improve the\n","appearance of the skin by promoting desquamation of the stratum corneum . The effectiveness of alpha-hydroxy acids in acne, however, has not yet been\n","demonstrated in controlled clinical trials . Azelaic acid is a naturally occurring dicarboxylic acid found in cereal grains . It is available as a\n","topical cream that has been shown to be effective in inflammatory and comedonal acne . By inhibiting the growth of P . acnes, azelaic acid reduces\n","inflammatory acne . It also reverses the altered keratinization of follicles seen in acne and thus demonstrates comedolytic activity . Azelaic acid\n","can affect melanosomes and has been used to treat postinflammatory hyperpigmentation . Azelaic acid is reported to have fewer local side effects than\n","topical retinoids . Topical antibiotics . Topical antibiotics such as erythromycin, clindamycin and sodium sulfacetamide inhibit the growth of P .\n","acnes and reduce inflammatory lesions . Products containing these antibiotics are often applied twice daily and are generally well tolerated . Topical\n","antibiotics such as erythromycin and clindamycin come in a variety of formulations and packaging: creams, lotions, ointments, gels and solutions .\n","Solutions are available in dab-on applicators and pads, which are packaged either individually or in bulk . The choice of formulation or packaging\n","depends on the patient's complexion and preference . Many teenagers enjoy the convenience of the pad preparations . Sodium sulfacetamide is a\n","sulfonamide, which is thought to inhibit the growth of P . acnes through competitive antagonism of para-aminobenzoic acid, an essential requirement\n","for bacterial growth . Sodium sulfacetamide (10%) is available in combination with sulfur (5%) in a prescription lotion, either with or without tint .\n","Topical tetracycline is available in Italy, but not the UK or USA . Antibiotic resistance . Since the 1970s, P . acnes has developed resistance to\n","both topical and oral antibiotics . It is important to bear this in mind when prescribing antibiotics . acnes resistance has been shown to affect\n","clinical outcomes of acne treatment . In addition, overuse of antibiotics can drive resistance in other commensal bacteria . For these reasons, the\n","use of topical antibiotics as single agents for acne is to be discouraged . Topical retinoids and BPO are useful as first-line agents . Any regimen\n","containing an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with BPO . Combination products .\n","Recent advances in topical acne therapy include the development of fixed combination products that target more than one pathogenic feature of the\n","disease and may also increase treatment adherence among patients . Combination products that include BPO offer excellent bactericidal effects and,\n","when combined with erythromycin or clindamycin, offset the emergence of antibiotic-resistant P . acnes (see pages 51 and) . A fixed combination of BPO\n","with adapalene targets three of the four pathogenic features of acne without the use of antibiotics . Other combinations include topical tretinoin\n","0.025% with clindamycin 1%, tretinoin 0.025% with erythromycin 4% and topical isotretinoin 0.05% with erythromycin 2% (none of these are available in\n","the USA) . Side effects . Local irritation . Most topical acne treatments, including salicylic acid, BPO and topical retinoids will cause some degree\n","of erythema, dryness and scaling of the skin . Contact dermatitis due to BPO has rarely been reported but should be considered if treated areas\n","develop an eczematous dermatitis . Use of topical antibiotics may also be associated with local irritation, but this tends to occur less often than\n","with other topical agents . The local side effects of topical retinoids include erythema, scaling, desquamation, burning or stinging, pruritus and\n","increased susceptibility to sunburn . Most patients will develop tolerance to the local side effects of topical retinoids within 3-4 weeks . If\n","patients are unable to tolerate daily application of a topical retinoid, an alternate-day or every-third-day regimen can be followed until tolerance\n","develops . Topical retinoids are not recommended in pregnancy because of the theoretical risk of teratogenicity . Fortunately, studies have shown that\n","the risk of birth defects from topical tretinoin is unlikely . Pharmacokinetic studies have shown that serum retinoid levels may be influenced more by\n","diet than by facial application of topical tretinoin for acne . Epidemiological studies have failed to demonstrate an increased risk of birth defects\n","in infants whose mothers used topical retinoids on the face during the first trimester of pregnancy . There have, however, been isolated case reports\n","of birth defects in infants whose mothers used topical tretinoin during pregnancy . For this reason, it is recommended that pregnant women cease using\n","topical retinoids . Bleaching and staining . BPO can bleach clothing or bedding, particularly when it is applied to the chest or back . It is\n","therefore best to advise use of this medication at bedtime and to recommend covering the treated areas with an old shirt . Management of side effects\n",". Excessive dryness of the skin is one of the main reasons why patients discontinue topical treatment . Thus, recommendations regarding effective ways\n","of managing facial dryness should be an integral part of any acne treatment plan . Regular use of moisturizers is especially important, but the\n","clinician should be aware of the reluctance of many patients to use them because of concerns that moisturizers might worsen their acne . These\n","patients need reassurance that this is not the case: most moisturizers from reputable companies are tested for comedogenicity in clinical trials and\n","are labeled 'non-comedogenic' . Studies show that moisturizers applied before or after topical retinoids do not alter efficacy . Moisturizers are\n","available as creams and lotions; most patients prefer to use lotions as they are easy to apply and do not feel greasy . Lotions containing sunscreens\n","should be recommended, particularly in patients using topical retinoids . For recalcitrant dry areas, a heavier cream may be needed . Sunscreens are\n","important, as the sun can exacerbate facial irritation caused by topical acne medications . Some topical preparations make patients more\n","photosensitive . Thus, regular use of a sunscreen or a moisturizer containing a sunscreen is recommended to avoid sunburn as a side effect from\n","thinning of the stratum corneum by topical retinoids or phototoxicity from oral doxycycline . Alternative regimens . If irritation remains a problem\n","despite adequate use of moisturizers, the treatment regimen can be temporarily altered . For example, topical retinoids could be used every other day\n","or every third day until they are tolerated, or the duration of application could be gradually increased . The goal is to gradually increase the\n","frequency of application until the patient can tolerate daily application .\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical therapy should be selected to help achieve medical adherence. Realistic\n","expectations of therapy should be explained. Combining therapies or using fixed combination topical products improves efficacy by targeting more than\n","one pathogenic feature and enhancing treatment adherence. Topical antibiotics can lead to the development of antimicrobial resistance. Topical\n","antibiotics should not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Any regimen containing\n","an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent\n","the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n","Benzoyl peroxide (BPO) is the most potent agent against P. Tretinoin is usually applied once daily at bedtime after the face has had adequate time to\n","dry. Dapsone is a sulfone that targets neutrophil-mediated inflammation. Salicylic, alpha-hydroxy and azelaic acids have mild comedolytic activity.\n","BPO can bleach clothing or bedding, particularly when it is applied to the chest or back. Topical retinoids are not recommended in pregnancy because\n","of the theoretical risk of teratogenicity. The risk of birth defects from topical tretinoin is unlikely, but there have been isolated case reports of\n","birth defects in infants whose mothers used topical retinoids during pregnancy.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9')\n","\n","Text:\n","Atrial flutter . Typical atrial flutter is a macro-entrant atrial rhythm, rotating counterclockwise, occasionally clockwise, within the right atrium\n","(see Figure 2.7) . Most common is a circuit confined to the anterior portion of the right atrium with a 2:1 atrioventricular (AV) block - an atrial\n","rate of 300 bpm and a regular ventricular response of 150 bpm related directly to the atrial rate . A QRS rate of exactly 150 bpm should raise\n","suspicion of atrial flutter . Other than atrial fibrillation (AF), atrial flutter is the most common arrhythmia seen by cardiologists . Patients who\n","have had AF may present with atypical atrial flutter at a later stage; patients who have had congenital abnormalities corrected at an early age may\n","present with atypical atrial flutter up to 10-20 years later . In typical atrial flutter, the circuit is critically dependent on an area of slow\n","conduction known as the cavotricuspid isthmus (see Figure 2.7) . Other rarer atypical forms occur, particularly in patients with scarring in the\n","atrium (exempli gratia after radiofrequency ablation [RFA] or previous heart surgery) . Atrial flutter typically has a saw-tooth appearance of flutter\n","waves on the baseline in the 12-lead ECG (see Figure 2.7) . Clinical presentation . Atrial flutter can be aysmptomatic or may present with\n","breathlessness, tiredness or frank heart failure . Persistent palpitations may be a feature . Anticoagulation therapy is based on the same risk\n","factors as those for AF (see Chapter 8) . Pharmacological treatment . In acute cases, cardioversion can be performed with intravenous ibutilide, or,\n","if there is no structural heart disease, a class 1c antiarrhythmic agent, such as flecainide or propafenone, combined with a beta-blocker .\n","Intravenous flecainide alone is sometimes used in Europe (but not in the USA) to slow conduction in the flutter circuit more than in the AV node\n","itself . However, in some cases this may slow the atrial rate from 300 to 200 bpm and may allow the AV node to conduct in a 1:1 fashion, producing a\n","paradoxical increase in the ventricular rate to 200 bpm, which may be associated with hemodynamic compromise; flecainide is often combined with a\n","beta-blocker to prevent the flutter being conducted to the ventricle in this 1:1 manner . The same principle applies for both intravenous and oral\n","flecainide . Oral sotalol is often used in patients with atrial flutter, as it has the combined action of an antiarrhythmic and a beta-blocker, but QT\n","considerations and renal excretion limit its use in women and the elderly . In the chronic setting, atrial flutter often responds poorly to drug\n","therapy . AV nodal-blocking drugs slow the ventricular response . Direct-current (DC) cardioversion is highly effective for atrial flutter . However,\n","persistent atrial flutter (lasting longer than 48 hours) is associated with significant embolic risk, and management before cardioversion should be as\n","for patients with AF - treatment with oral anticoagulant therapy (warfarin) for 4 weeks before cardioversion and for at least 1 month afterwards (see\n","Chapter 8) . Alternatively, a transesophageal echocardiogram can be performed in patients who are not taking warfarin, or in whom serial measurements\n","of the international normalized ratio (INR) over a month have not been documented, to exclude left atrial thrombus and enable immediate cardioversion\n",". Patients are then started, or continued, on warfarin, while heparin or low-molecular-weight heparin is given until the INR is greater than 2,\n","continuing warfarin for 1 month or more . In the acute setting, flutter often converts with a low-energy shock of about 50 J, sometimes as low as 25 J\n",". Radiofrequency (catheter) ablation is recommended for long-term treatment . RFA restores sinus rhythm by creating a linear destructive lesion,\n","across which the circulating depolarizing wavefront cannot pass . This is known as a line of block and is usually created at the inferior wall of the\n","right atrium (Figure 7.1) . This technique is in contrast to the ablation of accessory or slow pathways, which require highly localized lesions . The\n","procedure can be performed during constant atrial flutter or in sinus rhythm with pacing from the atrium or coronary sinus . Success rates are greater\n","than 90% in most centers . The cavotricuspid isthmus is not smooth throughout its length and has regions of thick muscle bundles . Ablation of these\n","areas is best achieved with technology capable of producing deep lesions, such as large-tip or cooled radiofrequency energy . Newer techniques\n","involving computerized mapping of the atria and catheter position are improving overall success . Most centers are now performing ablation as first-\n","line treatment . Apart from the usual complications associated with instrumentation of the venous circulation, heart block or cardiac tamponade are\n","rarely reported . After ablation, the prognosis for patients with typical atrial flutter is excellent . In patients with atypical atrial flutter\n","recurrences are more common because of scarring of the atria . Up to 30% of patients with either type of atrial flutter develop AF late after a\n","successful flutter ablation and may require further treatment; atrial flutter and AF often go together .\n","\n","Bullets:\n","Ablation for typical atrial flutter is highly successful and low risk, and should be considered first-line treatment. The risk of systemic\n","embolization in atrial flutter should be considered similar to that for atrial fibrillation (AF). Atypical atrial flutter usually includes right\n","atrial flutter circling around regions of scarring, or left atrial flutter following ablation of AF.\n","\n","Predicted Summary:\n","Atrial flutter is the most common arrhythmia seen by cardiologists. Atrial flutter typically has a saw-tooth appearance of flutter waves on the\n","baseline in the 12-lead ECG. Radiofrequency (catheter) ablation is recommended for long-term treatment. Up to 30% of patients with either type of\n","atrial flutter develop AF late after developing it. Atrial fibrillation (AF) and atrial flutter often go together; AF and flutter can be treated\n","separately or in combination with each other. In patients with AF, atypical atrial flutterrences are more common because of scarring of the atria, for\n","patients with atypical flutter, recur.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01')\n","\n","Text:\n","Cigarettes as a nicotine delivery system . The cigarette . There are many different varieties of cigarette tobacco, each with its own flavor and\n","characteristics, and tobacco can be prepared in different ways that affect its taste, smell and pharmacological properties . Additives are included in\n","cigarettes by the manufacturers to engineer an attractive and efficient nicotine delivery system . Table 1.1 lists some of the many thousands of\n","chemicals in tobacco smoke . One thing that all cigarettes have in common is that they deliver nicotine to the lungs . A puff on a cigarette results\n","in rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation\n","(Figure 1.1); this process is repeated with every puff . In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette .\n","This is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply . In societies in\n","which cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more\n","nicotine from each cigarette, confirming that nicotine is the sought-after substance in tobacco . Control of the nicotine dose . As a drug delivery\n","system, cigarettes are very flexible because smokers can control the intensity and frequency of puffing . This 'fingertip control' of the nicotine\n","dose allows smokers to meet their current need while avoiding the acute adverse effects of too much nicotine . Many smokers, particularly older\n","smokers and women, choose so-called 'light' or 'low-tar' brands, believing that these are safer . According to the reported analyses of their\n","deliveries, these brands deliver as little as one-tenth of the tar and carbon monoxide of other brands . In fact, such reports are misleading: the\n","data are based on artificial measurements by smoking machines and do not mirror the actual delivery to a smoker . It is possible to extract as much\n","tar and nicotine from these cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that\n","would otherwise dilute the smoke - and that is exactly what smokers usually do . Each smoker appears to have a preferred level of nicotine intake and\n","will adjust the way he or she smokes to achieve that level . Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette\n","packaging and marketing in the USA and EU . Smokers who reduce the number of cigarettes they smoke typically compensate for the change by increasing\n","the intensity of smoking such that smoke exposure remains unchanged . An exception is when they use another nicotine product at the same time, such as\n","a nicotine patch or gum (see Chapter 7) . It also appears that if cigarette consumption drops below a threshold (perhaps around 5 cigarettes per day),\n","or if the cigarettes are designed to limit the potential for compensation (exempli gratia novel cigarettes in which the tobacco actually contains less\n","nicotine), compensation is very limited . Nicotine and its elimination from the body . Nicotine is an alkaloid obtained from tobacco plants and has\n","wide-ranging effects on the central nervous system (CNS) (see pages 37-8) . Its structure (Figure 1.2) resembles that of the major neurotransmitter\n","acetylcholine, and it activates cholinergic receptors in the brain, which accounts for many of the psychoactive effects . Once in the bloodstream,\n","nicotine is distributed around the body, readily crossing cell membranes and entering every tissue . It is eliminated quite rapidly, mainly through\n","metabolism, but partly by excretion in urine . It is metabolized mostly to the oxides cotinine and nicotine-1'-N-oxide . These appear to be largely\n","inactive and are further metabolized and excreted in urine . The plasma concentration of nicotine reduces by half every 90-120 minutes (its half-life;\n","see Figure 1.1) . Duration of withdrawal symptoms . All nicotine is cleared from the body within a day or two of abstinence . Some people think that\n","this must therefore be the period when smokers experience withdrawal symptoms (see Chapter 5) . However, the duration of withdrawal symptoms has\n","nothing to do with this; it is related to how long it takes the body to get used to not having nicotine in the system . The duration for most symptoms\n","is 2-4 weeks . Estimating nicotine intake . Nicotine concentrations in the blood could conceptually be a useful index of dependence, but its short\n","half-life means that a single measure does not give a particularly accurate picture of total intake over a day . Measurement of its metabolite,\n","cotinine, is used instead . Cotinine has a half-life of 14-20 hours, so its concentration in the blood is more stable than that of nicotine and it can\n","be easily measured in saliva, urine or even hair . Saliva samples are simple to obtain by means of a dental swab and are the method of choice for\n","accurate estimation of daily nicotine intake . A daily nicotine intake of 16 mg (approximately 16 cigarettes/day, or one every hour) corresponds on\n","average to a saliva cotinine concentration of 200 ng/mL; a daily nicotine intake of 10 mg generates a saliva cotinine concentration of about 125 ng/mL\n",". These estimations are not the same for urine or blood measurements . Monoamine oxidase inhibitors in cigarette smoke . There is evidence that\n","cigarette smoke contains other psychoactive compounds which some now believe may contribute to its addictive properties . Most notably, there is at\n","least one monoamine oxidase inhibitor (MAOI) . MAOIs reduce the rate at which monoamine neurotransmitters such as dopamine are broken down and have\n","been found to reduce depressive symptoms . In the case of smoking, they might contribute to the rewarding effect of cigarette smoke or act\n","synergistically with nicotine (which is primarily rewarding as it causes release of dopamine in the nucleus accumbens - see Chapter 5) . This may help\n","explain why people who suffer from depression are particularly likely to smoke . Research is in its early days, but if MAOIs play a role in cigarette\n","addiction, pure nicotine delivery systems may be less addictive, even if they deliver nicotine as rapidly as cigarettes .\n","\n","Bullets:\n","Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff. Smokers absorb an average 1-2 mg of nicotine per cigarette (more\n","when cigarettes are smoked more intensively). Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide. Smokers' intake of tar\n","and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes. Nicotine is rapidly\n","metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a day of abstinence. The\n","nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva or\n","urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.\n","\n","Predicted Summary:\n","In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to one-third of what they could\n","obtain if they puffed more frequently and inhaled the smoke more deeply. This 'fingertip control' of the nicotine dose allows smokers to meet their\n","current need while avoiding the acute adverse effects of too much nicotine. Many smokers, particularly older smokers and women, choose so-called\n","'light' or 'low-tar' brands, believing that these are safer. These brands deliver as little as one-tenth of the tar and carbon monoxide of other\n","brands. The terms 'light' and 'low tar' have been banned from cigarette packaging and marketing in the USA and EU.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n"],"name":"stdout"}]},{"cell_type":"markdown","metadata":{"id":"JyMOjvJ7weXd"},"source":["### **TextRank**"]},{"cell_type":"markdown","metadata":{"id":"wWXn75l1weXe"},"source":["#### Loading data"]},{"cell_type":"code","metadata":{"id":"xtGGlXaGweXf","executionInfo":{"status":"ok","timestamp":1608648630979,"user_tz":-60,"elapsed":9221,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["input_path = drive_dir+'summarization/topic_modeling_output/'\n","df_textrank_redu = pd.read_csv(input_path+'df_textrank_redu.csv')\n","df_textrank_redu = df_textrank_redu.set_index(['book', 'chapter'])\n","\n","df_textrank_summ = pd.read_csv(input_path+'df_textrank_summ_'+MODEL+'.csv')\n","df_textrank_summ = df_textrank_summ.set_index(['book', 'chapter'])"],"execution_count":23,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"-tytAdjNweXg"},"source":["#### Rouge"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/","height":0},"id":"kefom7WOweXh","executionInfo":{"status":"ok","timestamp":1608648631944,"user_tz":-60,"elapsed":10167,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"c091cac6-28ab-4e76-ffda-e7bac05d15f5"},"source":["plot_rouge(df_textrank_summ, 'topic_modeling', 'rougeL', submethod='textrank')"],"execution_count":24,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 720x432 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"markdown","metadata":{"id":"_KwlG-cw-rG5"},"source":["#### Print Random Summaries"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"eKrta_cG-rG8","executionInfo":{"status":"ok","timestamp":1608648631946,"user_tz":-60,"elapsed":10156,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"b29a8732-90e9-471c-8fd8-5021635da79f"},"source":["print_random_summaries(df_textrank_summ, RANDOM_IDS, 'textrank_summary')"],"execution_count":25,"outputs":[{"output_type":"stream","text":["(9781908541994, 'ch05')\n","\n","Text:\n","Topical therapy . Topical therapy is useful in nearly all acne regimens . mild localized acne . moderate acne; in combination with, and following,\n","oral therapy . maintenance therapy; after stopping systemic agents for severe acne . Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics . The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance . Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-\n","dose combination product to enhance adherence . Topical agents differ in their efficacy against the various etiologic factors . Retinoids, azelaic\n","acid and BPO are effective for comedones and inflammatory acne . Topical antibiotics such as erythromycin and clindamycin are most effective for\n","inflammatory lesions . Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions . It is important to note\n","that topical antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P . acnes) strains . Patients often\n","seek medical attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels . Active\n","ingredients include BPO, salicylic acid and alpha-hydroxy acids . Topical therapy is generally applied after washing the face and allowing it to dry\n","for 10-15 minutes . It is important to cover the entire affected area with a thin film of product, avoiding the eyes . Benzoyl peroxide . BPO is the\n","most potent agent against P . acnes, an obligate anaerobe that will not grow in the presence of oxygen . Unlike antibiotics, BPO is bactericidal\n","against P . acnes through its release of free oxygen radicals in sebaceous follicles . BPO therefore reduces bacterial colonization of the follicle\n","and kills both sensitive and resistant strains of P . acnes, which translates into a reduction in new inflammatory lesions . acnes does not develop\n","resistance to BPO; for this reason, the drug is a valuable component of any acne treatment regimen . BPO is mostly available in over-the-counter and\n","prescription formulations, including bar soaps, washes, gels and lotions . It is chiefly available in concentrations of 2.5%, 4%, 5% and 10% .\n","However, there is no evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the\n","2.5-5% concentrations . BPO is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene\n","(see page 52) . Topical retinoids and retinoid-like molecules . Topical retinoids are effective agents in the treatment of acne . Although\n","dermatologists readily prescribe them, topical retinoids are underutilized by pediatricians and general practitioners . Tretinoin, or all-trans-\n","retinoic acid, is a vitamin A derivative that reverses the altered keratinization in follicles affected by acne . By inhibiting the formation of the\n","microcomedone, tretinoin prevents the development of comedones and early inflammatory lesions . Tretinoin is available as a cream, gel or solution in\n","a variety of concentrations of differing potencies, which vary between countries . % gel / 0.05% cream . % gel / 0.1% cream . Tretinoin is usually\n","applied once daily at bedtime after the face has had adequate time to dry . Night-time application is most effective as the active molecule is light\n","sensitive . Tretinoin is also available in formulations with novel delivery systems, such as microspheres . Choice of formulation depends upon whether\n","the patient has dry or oily skin . Patients with oily skin usually prefer gels and patients with dry skin usually prefer creams . Adapalene is a\n","synthetic acid derivative with retinoid-like activity but a distinctly different chemical structure . Adapalene is a potent modulator of cellular\n","differentiation, keratinization and inflammatory processes, and the mechanism of action is believed to be similar to that of retinoids . Adapalene\n","interacts with nuclear retinoic acid receptors (RARs) beta and gamma . It has been hypothesized that this receptor selectivity may account for its\n","better side-effect profile . Adapalene has been shown to possess anti-inflammatory activity in a number of in-vitro and in-vivo animal models . Along\n","with tretinoin, adapalene has been shown to decrease the expression of toll-like receptor-2 (TLR2) on inflammatory cells . Adapalene is available in\n","concentrations of 0.1% and 0.3% (in the USA), and also as a fixed combination of 0.1% adapalene with 2.5% BPO for daily use . Tazarotene is a\n","synthetic acetylenic retinoid that has been formulated into a topical gel and cream . Following topical application, tazarotene is converted to its\n","active metabolite tazarotenic acid . This compound then binds to nuclear RARs and can affect the expression of genes involved in cell proliferation,\n","cell differentiation and inflammation . At the cellular level this may result in the modification of several pathogenic factors in acne, including\n","corneocyte accumulation and cohesion . Tazarotene is specific for RARs, rather than retinoid X receptors (RXRs), and selectively activates RAR-beta\n","and RAR-gamma, as does adapalene . Tazarotene is very effective in comedonal and inflammatory acne . It may have greater potential for irritation in\n","some patients, more so with the gel formulation than the cream . Tazarotene is licensed for the treatment of acne in the USA but only licensed for the\n","treatment of psoriasis in the UK . Dapsone is a sulfone that targets neutrophil-mediated inflammation . Stability issues with a topical formulation\n","were overcome with the development of a novel topical gel . The gel has been shown to be effective against acne at 5% concentration; recent studies\n","suggest topical dapsone 5% gel may be particularly beneficial in regimens for adult women with acne (see pages 26-9) . Topical isotretinoin is an\n","alternative preparation, available as a 0.05% gel in the UK and Italy, but it is not available in the USA . This retinoid has been shown to be less\n","irritating than older retinoid preparations such as tretinoin . Salicylic, alpha-hydroxy and azelaic acids . Salicylic acid, a beta-hydroxy acid, is\n","keratolytic and an irritant; it may promote the resolution of inflammatory lesions through its drying effect . Salicylic acid has mild comedolytic\n","activity . It is available in a maximum concentration of 2% in over-the-counter preparations such as soaps, cleansers and gels . Some salicylic acid\n","products are tinted to help camouflage acne lesions . Combination products containing salicylic acid and BPO or sulfur are also available . alpha\n","-hydroxy acids such as lactic acid, glycolic acid and citric acid are available in a variety of cosmetic preparations, including cleansers, toners,\n","moisturizers and chemical peels . alpha-hydroxy acids are thought to reverse the altered keratinization of follicles affected by acne and improve the\n","appearance of the skin by promoting desquamation of the stratum corneum . The effectiveness of alpha-hydroxy acids in acne, however, has not yet been\n","demonstrated in controlled clinical trials . Azelaic acid is a naturally occurring dicarboxylic acid found in cereal grains . It is available as a\n","topical cream that has been shown to be effective in inflammatory and comedonal acne . By inhibiting the growth of P . acnes, azelaic acid reduces\n","inflammatory acne . It also reverses the altered keratinization of follicles seen in acne and thus demonstrates comedolytic activity . Azelaic acid\n","can affect melanosomes and has been used to treat postinflammatory hyperpigmentation . Azelaic acid is reported to have fewer local side effects than\n","topical retinoids . Topical antibiotics . Topical antibiotics such as erythromycin, clindamycin and sodium sulfacetamide inhibit the growth of P .\n","acnes and reduce inflammatory lesions . Products containing these antibiotics are often applied twice daily and are generally well tolerated . Topical\n","antibiotics such as erythromycin and clindamycin come in a variety of formulations and packaging: creams, lotions, ointments, gels and solutions .\n","Solutions are available in dab-on applicators and pads, which are packaged either individually or in bulk . The choice of formulation or packaging\n","depends on the patient's complexion and preference . Many teenagers enjoy the convenience of the pad preparations . Sodium sulfacetamide is a\n","sulfonamide, which is thought to inhibit the growth of P . acnes through competitive antagonism of para-aminobenzoic acid, an essential requirement\n","for bacterial growth . Sodium sulfacetamide (10%) is available in combination with sulfur (5%) in a prescription lotion, either with or without tint .\n","Topical tetracycline is available in Italy, but not the UK or USA . Antibiotic resistance . Since the 1970s, P . acnes has developed resistance to\n","both topical and oral antibiotics . It is important to bear this in mind when prescribing antibiotics . acnes resistance has been shown to affect\n","clinical outcomes of acne treatment . In addition, overuse of antibiotics can drive resistance in other commensal bacteria . For these reasons, the\n","use of topical antibiotics as single agents for acne is to be discouraged . Topical retinoids and BPO are useful as first-line agents . Any regimen\n","containing an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with BPO . Combination products .\n","Recent advances in topical acne therapy include the development of fixed combination products that target more than one pathogenic feature of the\n","disease and may also increase treatment adherence among patients . Combination products that include BPO offer excellent bactericidal effects and,\n","when combined with erythromycin or clindamycin, offset the emergence of antibiotic-resistant P . acnes (see pages 51 and) . A fixed combination of BPO\n","with adapalene targets three of the four pathogenic features of acne without the use of antibiotics . Other combinations include topical tretinoin\n","0.025% with clindamycin 1%, tretinoin 0.025% with erythromycin 4% and topical isotretinoin 0.05% with erythromycin 2% (none of these are available in\n","the USA) . Side effects . Local irritation . Most topical acne treatments, including salicylic acid, BPO and topical retinoids will cause some degree\n","of erythema, dryness and scaling of the skin . Contact dermatitis due to BPO has rarely been reported but should be considered if treated areas\n","develop an eczematous dermatitis . Use of topical antibiotics may also be associated with local irritation, but this tends to occur less often than\n","with other topical agents . The local side effects of topical retinoids include erythema, scaling, desquamation, burning or stinging, pruritus and\n","increased susceptibility to sunburn . Most patients will develop tolerance to the local side effects of topical retinoids within 3-4 weeks . If\n","patients are unable to tolerate daily application of a topical retinoid, an alternate-day or every-third-day regimen can be followed until tolerance\n","develops . Topical retinoids are not recommended in pregnancy because of the theoretical risk of teratogenicity . Fortunately, studies have shown that\n","the risk of birth defects from topical tretinoin is unlikely . Pharmacokinetic studies have shown that serum retinoid levels may be influenced more by\n","diet than by facial application of topical tretinoin for acne . Epidemiological studies have failed to demonstrate an increased risk of birth defects\n","in infants whose mothers used topical retinoids on the face during the first trimester of pregnancy . There have, however, been isolated case reports\n","of birth defects in infants whose mothers used topical tretinoin during pregnancy . For this reason, it is recommended that pregnant women cease using\n","topical retinoids . Bleaching and staining . BPO can bleach clothing or bedding, particularly when it is applied to the chest or back . It is\n","therefore best to advise use of this medication at bedtime and to recommend covering the treated areas with an old shirt . Management of side effects\n",". Excessive dryness of the skin is one of the main reasons why patients discontinue topical treatment . Thus, recommendations regarding effective ways\n","of managing facial dryness should be an integral part of any acne treatment plan . Regular use of moisturizers is especially important, but the\n","clinician should be aware of the reluctance of many patients to use them because of concerns that moisturizers might worsen their acne . These\n","patients need reassurance that this is not the case: most moisturizers from reputable companies are tested for comedogenicity in clinical trials and\n","are labeled 'non-comedogenic' . Studies show that moisturizers applied before or after topical retinoids do not alter efficacy . Moisturizers are\n","available as creams and lotions; most patients prefer to use lotions as they are easy to apply and do not feel greasy . Lotions containing sunscreens\n","should be recommended, particularly in patients using topical retinoids . For recalcitrant dry areas, a heavier cream may be needed . Sunscreens are\n","important, as the sun can exacerbate facial irritation caused by topical acne medications . Some topical preparations make patients more\n","photosensitive . Thus, regular use of a sunscreen or a moisturizer containing a sunscreen is recommended to avoid sunburn as a side effect from\n","thinning of the stratum corneum by topical retinoids or phototoxicity from oral doxycycline . Alternative regimens . If irritation remains a problem\n","despite adequate use of moisturizers, the treatment regimen can be temporarily altered . For example, topical retinoids could be used every other day\n","or every third day until they are tolerated, or the duration of application could be gradually increased . The goal is to gradually increase the\n","frequency of application until the patient can tolerate daily application .\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical therapy should be selected to help achieve medical adherence. Realistic\n","expectations of therapy should be explained. Combining therapies or using fixed combination topical products improves efficacy by targeting more than\n","one pathogenic feature and enhancing treatment adherence. Topical antibiotics can lead to the development of antimicrobial resistance. Topical\n","antibiotics should not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Any regimen containing\n","an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent\n","the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n","Mild acne is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical antibiotics.\n","The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial resistance. Topical\n","antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P. acnes) The gel has been shown to be effective\n","against acne at 5% concentration; recent studies suggest topical dapsone 5% gel may be particularly beneficial in regimens for adult women with acne\n","(see pages 26-9) and erythromycin and clindamycin are most effective for inflammatory lesions.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9')\n","\n","Text:\n","Atrial flutter . Typical atrial flutter is a macro-entrant atrial rhythm, rotating counterclockwise, occasionally clockwise, within the right atrium\n","(see Figure 2.7) . Most common is a circuit confined to the anterior portion of the right atrium with a 2:1 atrioventricular (AV) block - an atrial\n","rate of 300 bpm and a regular ventricular response of 150 bpm related directly to the atrial rate . A QRS rate of exactly 150 bpm should raise\n","suspicion of atrial flutter . Other than atrial fibrillation (AF), atrial flutter is the most common arrhythmia seen by cardiologists . Patients who\n","have had AF may present with atypical atrial flutter at a later stage; patients who have had congenital abnormalities corrected at an early age may\n","present with atypical atrial flutter up to 10-20 years later . In typical atrial flutter, the circuit is critically dependent on an area of slow\n","conduction known as the cavotricuspid isthmus (see Figure 2.7) . Other rarer atypical forms occur, particularly in patients with scarring in the\n","atrium (exempli gratia after radiofrequency ablation [RFA] or previous heart surgery) . Atrial flutter typically has a saw-tooth appearance of flutter\n","waves on the baseline in the 12-lead ECG (see Figure 2.7) . Clinical presentation . Atrial flutter can be aysmptomatic or may present with\n","breathlessness, tiredness or frank heart failure . Persistent palpitations may be a feature . Anticoagulation therapy is based on the same risk\n","factors as those for AF (see Chapter 8) . Pharmacological treatment . In acute cases, cardioversion can be performed with intravenous ibutilide, or,\n","if there is no structural heart disease, a class 1c antiarrhythmic agent, such as flecainide or propafenone, combined with a beta-blocker .\n","Intravenous flecainide alone is sometimes used in Europe (but not in the USA) to slow conduction in the flutter circuit more than in the AV node\n","itself . However, in some cases this may slow the atrial rate from 300 to 200 bpm and may allow the AV node to conduct in a 1:1 fashion, producing a\n","paradoxical increase in the ventricular rate to 200 bpm, which may be associated with hemodynamic compromise; flecainide is often combined with a\n","beta-blocker to prevent the flutter being conducted to the ventricle in this 1:1 manner . The same principle applies for both intravenous and oral\n","flecainide . Oral sotalol is often used in patients with atrial flutter, as it has the combined action of an antiarrhythmic and a beta-blocker, but QT\n","considerations and renal excretion limit its use in women and the elderly . In the chronic setting, atrial flutter often responds poorly to drug\n","therapy . AV nodal-blocking drugs slow the ventricular response . Direct-current (DC) cardioversion is highly effective for atrial flutter . However,\n","persistent atrial flutter (lasting longer than 48 hours) is associated with significant embolic risk, and management before cardioversion should be as\n","for patients with AF - treatment with oral anticoagulant therapy (warfarin) for 4 weeks before cardioversion and for at least 1 month afterwards (see\n","Chapter 8) . Alternatively, a transesophageal echocardiogram can be performed in patients who are not taking warfarin, or in whom serial measurements\n","of the international normalized ratio (INR) over a month have not been documented, to exclude left atrial thrombus and enable immediate cardioversion\n",". Patients are then started, or continued, on warfarin, while heparin or low-molecular-weight heparin is given until the INR is greater than 2,\n","continuing warfarin for 1 month or more . In the acute setting, flutter often converts with a low-energy shock of about 50 J, sometimes as low as 25 J\n",". Radiofrequency (catheter) ablation is recommended for long-term treatment . RFA restores sinus rhythm by creating a linear destructive lesion,\n","across which the circulating depolarizing wavefront cannot pass . This is known as a line of block and is usually created at the inferior wall of the\n","right atrium (Figure 7.1) . This technique is in contrast to the ablation of accessory or slow pathways, which require highly localized lesions . The\n","procedure can be performed during constant atrial flutter or in sinus rhythm with pacing from the atrium or coronary sinus . Success rates are greater\n","than 90% in most centers . The cavotricuspid isthmus is not smooth throughout its length and has regions of thick muscle bundles . Ablation of these\n","areas is best achieved with technology capable of producing deep lesions, such as large-tip or cooled radiofrequency energy . Newer techniques\n","involving computerized mapping of the atria and catheter position are improving overall success . Most centers are now performing ablation as first-\n","line treatment . Apart from the usual complications associated with instrumentation of the venous circulation, heart block or cardiac tamponade are\n","rarely reported . After ablation, the prognosis for patients with typical atrial flutter is excellent . In patients with atypical atrial flutter\n","recurrences are more common because of scarring of the atria . Up to 30% of patients with either type of atrial flutter develop AF late after a\n","successful flutter ablation and may require further treatment; atrial flutter and AF often go together .\n","\n","Bullets:\n","Ablation for typical atrial flutter is highly successful and low risk, and should be considered first-line treatment. The risk of systemic\n","embolization in atrial flutter should be considered similar to that for atrial fibrillation (AF). Atypical atrial flutter usually includes right\n","atrial flutter circling around regions of scarring, or left atrial flutter following ablation of AF.\n","\n","Predicted Summary:\n","Typical atrial flutter is a macro-entrant atrial rhythm, rotating counterclockwise, occasionally clockwise, within the right atrium. Other rarer\n","atypical forms occur, particularly in patients with scarring in the atrium. In acute cases, cardioversion can be performed with intravenous ibutilide,\n","or, if there is no structural heart disease, a class 1c antiarrhythmic agent, such as flecainide or propafenone, combined with a beta-blocker. Oral\n","sotalol is often used in patients with atrial flutter, but QT considerations and renal excretion limit its use in women and the elderly. In chronic\n","setting, atrial flutter often responds poorly to drug therapy.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01')\n","\n","Text:\n","Cigarettes as a nicotine delivery system . The cigarette . There are many different varieties of cigarette tobacco, each with its own flavor and\n","characteristics, and tobacco can be prepared in different ways that affect its taste, smell and pharmacological properties . Additives are included in\n","cigarettes by the manufacturers to engineer an attractive and efficient nicotine delivery system . Table 1.1 lists some of the many thousands of\n","chemicals in tobacco smoke . One thing that all cigarettes have in common is that they deliver nicotine to the lungs . A puff on a cigarette results\n","in rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation\n","(Figure 1.1); this process is repeated with every puff . In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette .\n","This is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply . In societies in\n","which cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more\n","nicotine from each cigarette, confirming that nicotine is the sought-after substance in tobacco . Control of the nicotine dose . As a drug delivery\n","system, cigarettes are very flexible because smokers can control the intensity and frequency of puffing . This 'fingertip control' of the nicotine\n","dose allows smokers to meet their current need while avoiding the acute adverse effects of too much nicotine . Many smokers, particularly older\n","smokers and women, choose so-called 'light' or 'low-tar' brands, believing that these are safer . According to the reported analyses of their\n","deliveries, these brands deliver as little as one-tenth of the tar and carbon monoxide of other brands . In fact, such reports are misleading: the\n","data are based on artificial measurements by smoking machines and do not mirror the actual delivery to a smoker . It is possible to extract as much\n","tar and nicotine from these cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that\n","would otherwise dilute the smoke - and that is exactly what smokers usually do . Each smoker appears to have a preferred level of nicotine intake and\n","will adjust the way he or she smokes to achieve that level . Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette\n","packaging and marketing in the USA and EU . Smokers who reduce the number of cigarettes they smoke typically compensate for the change by increasing\n","the intensity of smoking such that smoke exposure remains unchanged . An exception is when they use another nicotine product at the same time, such as\n","a nicotine patch or gum (see Chapter 7) . It also appears that if cigarette consumption drops below a threshold (perhaps around 5 cigarettes per day),\n","or if the cigarettes are designed to limit the potential for compensation (exempli gratia novel cigarettes in which the tobacco actually contains less\n","nicotine), compensation is very limited . Nicotine and its elimination from the body . Nicotine is an alkaloid obtained from tobacco plants and has\n","wide-ranging effects on the central nervous system (CNS) (see pages 37-8) . Its structure (Figure 1.2) resembles that of the major neurotransmitter\n","acetylcholine, and it activates cholinergic receptors in the brain, which accounts for many of the psychoactive effects . Once in the bloodstream,\n","nicotine is distributed around the body, readily crossing cell membranes and entering every tissue . It is eliminated quite rapidly, mainly through\n","metabolism, but partly by excretion in urine . It is metabolized mostly to the oxides cotinine and nicotine-1'-N-oxide . These appear to be largely\n","inactive and are further metabolized and excreted in urine . The plasma concentration of nicotine reduces by half every 90-120 minutes (its half-life;\n","see Figure 1.1) . Duration of withdrawal symptoms . All nicotine is cleared from the body within a day or two of abstinence . Some people think that\n","this must therefore be the period when smokers experience withdrawal symptoms (see Chapter 5) . However, the duration of withdrawal symptoms has\n","nothing to do with this; it is related to how long it takes the body to get used to not having nicotine in the system . The duration for most symptoms\n","is 2-4 weeks . Estimating nicotine intake . Nicotine concentrations in the blood could conceptually be a useful index of dependence, but its short\n","half-life means that a single measure does not give a particularly accurate picture of total intake over a day . Measurement of its metabolite,\n","cotinine, is used instead . Cotinine has a half-life of 14-20 hours, so its concentration in the blood is more stable than that of nicotine and it can\n","be easily measured in saliva, urine or even hair . Saliva samples are simple to obtain by means of a dental swab and are the method of choice for\n","accurate estimation of daily nicotine intake . A daily nicotine intake of 16 mg (approximately 16 cigarettes/day, or one every hour) corresponds on\n","average to a saliva cotinine concentration of 200 ng/mL; a daily nicotine intake of 10 mg generates a saliva cotinine concentration of about 125 ng/mL\n",". These estimations are not the same for urine or blood measurements . Monoamine oxidase inhibitors in cigarette smoke . There is evidence that\n","cigarette smoke contains other psychoactive compounds which some now believe may contribute to its addictive properties . Most notably, there is at\n","least one monoamine oxidase inhibitor (MAOI) . MAOIs reduce the rate at which monoamine neurotransmitters such as dopamine are broken down and have\n","been found to reduce depressive symptoms . In the case of smoking, they might contribute to the rewarding effect of cigarette smoke or act\n","synergistically with nicotine (which is primarily rewarding as it causes release of dopamine in the nucleus accumbens - see Chapter 5) . This may help\n","explain why people who suffer from depression are particularly likely to smoke . Research is in its early days, but if MAOIs play a role in cigarette\n","addiction, pure nicotine delivery systems may be less addictive, even if they deliver nicotine as rapidly as cigarettes .\n","\n","Bullets:\n","Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff. Smokers absorb an average 1-2 mg of nicotine per cigarette (more\n","when cigarettes are smoked more intensively). Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide. Smokers' intake of tar\n","and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes. Nicotine is rapidly\n","metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a day of abstinence. The\n","nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva or\n","urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.\n","\n","Predicted Summary:\n","A puff on a cigarette results in rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the\n","brain by the arterial circulation. In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. Each smoker appears to\n","have a preferred level of nicotine intake and will adjust the way he or she smokes to achieve that level. There is evidence that cigarette smoke\n","contains other psychoactive compounds which some believe may contribute to its addictive properties. MAOIs reduce the rate at which monoamine\n","neurotransmitters such as dopamine are broken down and have been found to reduce depressive symptoms. If MAOIs play a role in cigarette addiction,\n","pure nicotine delivery systems may be less addictive, even if they deliver nicotine as rapidly as cigarettes.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n"],"name":"stdout"}]},{"cell_type":"markdown","metadata":{"id":"wn8hnTWEp6Tl"},"source":["### **LDA vs LSI vs TextRank**"]},{"cell_type":"code","metadata":{"id":"PnsjAU6op6UP","colab":{"base_uri":"https://localhost:8080/","height":0},"executionInfo":{"status":"ok","timestamp":1608648633239,"user_tz":-60,"elapsed":11436,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"fea9ac01-763d-4982-ef8b-564571c79bff"},"source":["plot_compare_rouge(\n","    [df_lda_summ, df_lsi_summ, df_textrank_summ],\n","    ['lda', 'lsi', 'textrank'],\n","    'rougeL',\n","    folder='topic_modeling')"],"execution_count":26,"outputs":[{"output_type":"display_data","data":{"image/png":"iVBORw0KGgoAAAANSUhEUgAAAtQAAAHqCAYAAAAktdmwAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAADh0RVh0U29mdHdhcmUAbWF0cGxvdGxpYiB2ZXJzaW9uMy4yLjIsIGh0dHA6Ly9tYXRwbG90bGliLm9yZy+WH4yJAAAgAElEQVR4nOzde5hdZXnw/++dMDHBkBHDIc05V0iI04lSDCBFAcFWkQoeW0A5aJG2itbyVg1qyQ6tSsXag+KvttYS2iooVquCglUOiq+VYHmdMORozoEkRJgkJiFD8vz+WHuGyWQmmZ21z/P9XNe+Zvbaa9a613722nOvZ93rWZFSQpIkSdKRGVHrACRJkqRGZkItSZIk5WBCLUmSJOVgQi1JkiTlYEItSZIk5WBCLUmSJOVgQi3piEREISKG/bibEXF/RNxf6ziUiYhzIyJFxNW1jkXS8GFCLQ1T9ZR4RMRREfFkRHQeZr6bizG/Iuf6qrrtEfFIRDwdES84xDzvLcZ0SY71rCku43CP+490HYOs97qIuKqcy1Q+EXFVsa1fU+tYpOHgqFoHIEkppeci4ivAByLi5SmlR/rPExEjgcuA5Smln1Y9yMH97hDmuQ34O+D3gK8PMs8VwHbgmzli+QAwts/zVwHXADcBj/WZvjnHOgZyHbASuLXMy5WkhmBCLaleLCJLCC8HDkqogfOBicDHqhnU4aSU9g5hti8DN5Nt20EJdUTMBk4HvphS2pMjlgOS8Yg4iiyh/kFK6b+PdLnlFBEBjE4p7a51LEMVES9MKf261nFIql+WfEg6rIh4e0R0RsSeiFgaEe8cZL6LIuKbEbE+Ip4tlnEsioiJh1tHSulRoAO4tJgI9ncFkIB/67O+cyPivojYFhG7I2JtRPxHRBxzhJvaf3tOiYhvR8Tm4rZvjIj/jIipfeY5bA11Smkr8D3g9RExfpBtg6wne8jrzrFdx0fELcV22lt83/46Ikb3mefzEbEvIs7p97cfKpYSXFF8noBJwDl9SkrWFF+bXnz+V8UShMeAZ4E/KL5+VUTcExGbinGsi4jPRsS4fuvsLdGJiGsjYlXx8/VoRLx6iNv8V8Vl/Plh5ru1ON+UiLg9Ip4GlvR5/YKIeCgifh0R24vxnzFIvOcOsPw1EXFrv2njIuIfi5/jncVlzh5o3uL8V0fEzyNiV0R0FT8n7UN5HyRVhj3Ukg4pIt4O/DvwC+AjwDiy3tb1A8z+LiCAzwNPAXOAdwOviIiXDaH3dRHwaeC1wF19YhgLvAm4P6W0rjjtJcB3gaXAXwE7gKnAG4ox7jiCze0VEccD/w08A3ymuD0TyUo8pgDrSlzkomJslwC39FlPAO8Afgn8uELr7lVM6H9K9h79E7AWeDnwf4CXRcQFKaUE/DlwHnBbRLw0pdQVEacAfwl8LaXUk/xfDvwDWRnJx4vTdvZb7cXAcWSfi63AsuL0a4HlwN8CXcCpZD3qLwXO4WB/TFbS8k/AXrIzGv8VEdNSSk8Psr0jgM8BfwS8O6X0xcO+SZmez9ZHgNHFZf0+cHsx/gIwqhjTAxFxfkrpoSEuu298AXyD4nsN/A9wGln7jxlg/r8D3l+M44tAK/Be4CcRcVpKaVn/v5FUBSklHz58DMMHcC5Zj+/Vh5jnKGATsAoY22d6O7Av+wo5YP6jB1jGOcX1XDqEmCYAzwG395t+ZXEZV/WZ9qfFacdXaNsvLs5z2mGWdT9Zon+4dY4CfgX8dJD3p1DquoewzquKy3lNn2mfB54GpvWb99rivK/rM20e0E12QDWarKd2A/Difn+7YaD3AJheXOazwIwBXh/o89LT1mcO0F7r+30OTylOf89AbVv8/P5Hcf1vG+J7dmvx7/9pkH1hPfCiPtMnkx28LR4ghnMHWP4a4NY+z99QnPcT/eb7y+L0vvOeUZz2/n7zTiI7ILm9z7SD2t6HDx+Ve1jyIelQ5gG/QVbb29vrmFJaAtzTf+aU0i7Iet2Kp7GPI7sY7hmyXrdDSik9CdwLXNTvtP8VwK+BO/tMe6b4882RXbBYbj3LvygOMTrHUKWs1vp24IyImNXnpZ5Sltv6TCvrunsUe0P/gOw9/nVEHNfzKE6DrFa9J+bFwELg7cAPgTayg5pflbjq76aUVvef2OfzMiIiWotxPFh8eaDPy7/1+xw+SnYh58wB5h1DdoHnG4GLUkpfKzHmz/d73rMvfCGl1NM+pJQ2kNXIvzyGUNo0gAuLP/++3/T+zyE7u7EX+Hq/tnuW7KzD+QP8jaQqMKGWdCjTiz8HOo180LRi3ed/kiU5XWSn97cCLyo+huI2smTobcVlTibr8ftG32QKuAN4APhH4KnIarevLpaHlMODZAnwx4BfRcT3IuL9xQTmSPUkzT31x6OBtwIPpZR+WeF1AxwPvBj4fZ5vm55HT3ue0O9vPgn8L3AmcEs6sosbVw00MSJOj4jvkx0sPVOMo+d9GOjzsnaAaU+TbVN/HydLVt+cUjro4G8I+sc8vfjz8QHm7RnuccYRrGc6sCOldMDIKymlp8i2ra+Tyc50bODg9vtd4LhiiYukKrOGWlJZFHuUHyTrQVsIrAB2kfW+3s7QD+C/SZaMXw78C1l98QiyGuReKaU9xQvSzgIuAH4H+GfgLyLit1NKG/NsT0opkV0geTNZYvYasnrmGyLiNcXe0VKX+dOIWA68IyJuIOs9HTfAtpV93UVR/PlN+tRx9/NEv+czyRI5gPaIGJFS2l/ieg8a0SMipgP3kZVAfKj4czcwkuwCzoE+L/sGWX4MMO07ZHX310fEj3p6w/PEXIJD3fAoz9mUINunLj7CdUuqEBNqSYeypvjz5AFe6z/t1cCJwKtTSvf3TIyIMcCxQ11hMVH+GvCHETGNLLHeQFZy0H/eRHYh34+Bj0bEBcDdZBdpfWSo6zxMPD8Hfg78ZUS8lGxIvw+RjYl9JG4ju4jylWQ91XuAAcsRKrDurWRnD0YPpac5stFW/q0Y48eLj+vILhw9INQjiOVi4GjgwpTSmj7rHOizdiR+SHag8l/AtyLi91KOIQmBnpKVlwzw2kv6zdPTs3zA5754RuI3+v3tGuC1EXFi317q4tmI/vvNSuB1QEf/Hm1JteWpIUmHshh4Erg6Il7YM7E4RNdr+83b03vYv7fwQ5T+XbOouJzPkNXt/nv/XtEYePi5/y3+HHICP5iIOLZYc9zX42Q9l3mW/29kCeifk52m/2ZKqasa6y6+h3eQJXAHjaIREaPjwCEH/4JsfOw/Sil9gmw0ir+KiLn9/nTnEcQ12OdlfonLGVSx1OOtZDe4+WbOevRHyC5KvKZvfX+xbvrtwCMppU3FyWvILq49r98y3s/BPdR3F3/+ab/p/Z8DfKX48+MDfD56RoeRVAP2UEu6MCImDDD9RymlByLiw2QJ7k+KY+KOA95HNmb0y/rM/xBZD+htEfE5spEPziO7uGxbKQGllH4cEb8E3lycdNsAs/1FRJxHdmp/Ddlwau8E9pOVmAzFoNsO/Bbwvoj4BlnP4FFkF4UdQ3YR2hFJKa2LbNzqi4qTBtq2Kyux7qLryUYW+X5ELCLrAR8DzCarW38LcH9kt3f/KHBbSqnnYtBryNr934tDtPXc1OZhsjKWBWTD4O1MKX37MHF8j6zn++6I+AJZu72Bgeuhj1hK6TsR8QdkZwG+HhFvTkO7GU//5TwXEX9G9tn6aUR8ieeHzWuhTwKcUtoeEf8BvKeY+C4hq0F/FdkQiH19m2ykmOuLyfn/kB3EnFecN/VZ7k8i4jNkZwnmRMS3yWrPp5H1XP+CbHSPvt5ebMv+vpOjdEhSf7UeZsSHDx+1efD80F6DPf6qz7yXk43J+2zx5zvJxuFN/ZZ5Ktmp9u1kp73/k+xCrTX0Gf5riPEtKMbx8CCvv5rsroPri3FtIRt55NxybDtZQv3vZKfxd5MdFPyI7CK3vsu6nyEMm9fvb3qGhnsCGDnA60Na9xDWcxUDDJ1GdsHfp8jq3J8lS9weLrbpi4EXFl9bDYzr97evLy7zU32mTSIbN3x78bU1xenT+3+W+i3rfLIE8tdkB2O3kl042X8YwZ72OmiYw/6frcHmJTtYeI6sBKTlEO/ZrcW/P2qQ119PdvC4i+yg8V7gFQPM96JiG3YV5/svssT3gHiL87aSja39K7Le/u8CJxXb5f8bYNmXkpU57Si+dyuAf+0bR5+2H+wx6JCRPnz4KP0RKXn9giRJ9SQiXkx2IPXRlJXbSKpj1lBLklRDxQt3+/tg8edBF+NKqj/WUEuSVFufLtby/5isLOXVZEP+fTul9NOaRiZpSCz5kCSphiLirWQ90rPJ6tc3AF8FFqaU8oyHLalKTKglSZKkHKyhliRJknJo+Brq4447Lk2fPr3WYUiSJKnJPfLII0+llA66iVLDJ9TTp09n8eLFtQ5DkiRJTS4i1g403ZIPSZIkKQcTakmSJCkHE2pJkiQph4avoZYkSdLguru72bBhA3v27Kl1KA1j9OjRTJ48mZaWliHNb0ItSZLUxDZs2MAxxxzD9OnTiYhah1P3Ukps27aNDRs2MGPGjCH9jSUfkiRJTWzPnj2MHz/eZHqIIoLx48eX1KNvQi1JktTkTKZLU+r7ZUItSZKkiho7duyA06+66iruvPPOKkdTfibUkiRJUg4m1JIkSaqKlBLXXnstJ598Mq95zWvYsmVL72s33ngjp512Gu3t7VxzzTWklGoYaWkc5UOSJGmYWPjtx+jctL2sy2ybOI4Fb/jNIc37jW98g2XLltHZ2cnmzZtpa2vjXe96FwDXXnstN9xwAwCXX3453/nOd3jDG95Q1lgrxR5qSZIkVcWDDz7IpZdeysiRI5k4cSLnnXde72v33XcfZ5xxBnPnzuWHP/whjz32WA0jLY091JIkScPEUHuSq23Pnj285z3vYfHixUyZMoVCodBQN6Kxh1qSJElVcfbZZ3PHHXewb98+nnjiCe677z6A3uT5uOOOY+fOnQ038oc91JIkSaqKN73pTfzwhz+kra2NqVOncuaZZwLwohe9iHe/+920t7czYcIETjvttBpHWppopCsoBzJv3ry0ePHiWochaZgoFAoUCoVah5Fbs2yHpMN7/PHHeclLXlLrMBrOQO9bRDySUprXf15LPiSpBAsXLqx1CGXRLNshSfXAhFqSJEnKwYRakg6jUCgQEUQEQO/vjVYy0SzbIUn1xhpqSSpBRDTU3bsG0yzbIenwrKE+MtZQS5IkSVViQi1JJViwYEGtQyiLZtkOSaoHJtSSVIJmqTdulu2Q1BjGjh17yNdf//rX88wzz1QpmvLzxi6SJEmqqbvvvrvWIeRiD7UkSZKq4oknnuDss8/mlFNOob29nR/96EcATJ8+naeeeqrG0R05e6glSZKGi+/Ohyc7yrvMCXPhgpuGNOuXv/xlXvva1/LRj36Uffv2sWvXrvLGUiMm1JIkSaqK0047jXe96110d3fzxje+kVNOOaXWIZWFCbUkSdJwMcSe5Eo5++yzefDBB7nrrru46qqruO6667jiiitqGlM5WEMtSZKkqli7di0nnngi7373u7n66qv5+c9/XuuQysIeakmSJFXF/fffz80330xLSwtjx47ltttuq3VIZWFCLUmSpIrauXMnAFdeeSVXXnnlQa+vWbOmyhGVlyUfkiRJUg4m1JIkSVIOJtSSJElSDibUkiRJUg4m1JIkSVIOJtSSJElSDibUkiRJqphnnnmGz3/+80f0t48++ih33313WeOZPn06Tz31VFmXWdWEOiJeFxHLImJlRMwfZJ7fj4jOiHgsIr5czfgkSZJUXpVKqJ977rk8YZVV1RLqiBgJ3AJcALQBl0ZEW795ZgHXA2ellH4T+EC14pMkSVL5zZ8/n1WrVnHKKafwwQ9+kJtvvpnTTjuNl770pSxYsACAb3zjG5x//vmklHjiiSeYPXs269at44YbbuCOO+7glFNO4Y477qBQKHD55Zdz1llncfnll7NmzRpe9apXceqpp3Lqqafyk5/8BMjuyHjuuefy1re+lTlz5vD2t7+dlNIBce3evZsLLriAf/7nf869jdW8U+LpwMqU0i8BIuJ24GKgs8887wZuSSk9DZBS2lLF+CRJkpraX//sr1n6q6VlXeacF8/hw6d/eNDXb7rpJpYsWcKjjz7Kvffey5133snPfvYzUkpcdNFFPPjgg7zpTW/i61//Orfccgvf+973WLhwIVOnTuXGG29k8eLFfO5znwOgUCjQ2dnJj3/8Y8aMGcOuXbv4/ve/z+jRo1mxYgWXXnopixcvBuB///d/eeyxx5g4cSJnnXUWDz30EK985SuB7M6Nl1xyCVdccQVXXHFF7vegmgn1JGB9n+cbgDP6zTMbICIeAkYChZTS96oTniRJkirp3nvv5d577+W3fuu3gCyxXbFiBWeffTaf/exnaW9v5xWveAWXXnrpoMu46KKLGDNmDADd3d1ce+21PProo4wcOZLly5f3znf66aczefJkAE455RTWrFnTm1BffPHFfOhDH+Ltb397Wbarmgn1UBwFzALOBSYDD0bE3JTSM31niohrgGsAJk+eTEdHBwATJkxgzJgxrF69GoBx48YxdepUlixZAsDIkSNpa2tj1apV7Nq1C4CTTjqJrq4utm7dCsDEiRNpaWlh7dq1ALS2tjJp0iQ6O7OO9JaWFubMmcOKFSvYs2cPALNnz2bbtm1s27YNgEmTJjFixAjWr8+OH4499lhOPPFEli7NjghHjRrFySefzLJly9i7dy8Ac+bMYfPmzTz99NMATJkyhf3797Nx40YAxo8fz/jx43s/KKNHj2bWrFksXbqU7u5uANra2ti4cSNdXV0ATJs2je7ubjZt2gTA8ccfT2trKytXrgTg6KOPZubMmXR2drJv3z4A2tvbWbduHdu3bwdgxowZ7N69myeffBKAE044gWOOOYZVq1YBMHbsWGbMmMGSJUtIKRERtLe3s3r1anbu3AnAzJkz2bFjB1u2bLGdbCfbyXaynWwn26nK7bR//3727t3LUUcdxfva3wfAiBEjGD16NLt37+4thRgzZgx79+7tfc9f8IIXkFLqXUdLSwsjR47sjbvvMnrej4GW0d3dzf79+9m1axf79u3jwx/+MFdeeWXve/qCF7yA3bt3s2LFCiKCzZs398b17LPPklKiu7u79zFu3Dj27dvHs88+y6c+9SmOO+44Hn30UX7961/z4he/mN27d/fG2xPXiBEjePbZZ9m1axcpJc4880y++93v8sY3vpGIYOTIkYwaNar3byMC4KB2GlRKqSoP4Ezgnj7Prweu7zfPPwLv7PP8B8Bph1ruy1/+8iRJkqSBdXZ21nT9Tz31VJo6dWpKKaV77rknnX766WnHjh0ppZQ2bNiQNm/enLq7u9O8efPSj370o3T11Venm2++OaWU0p133pmuuOKK3mUtWLCg97WUUvrABz6QPv3pT6eUUvrSl76UstQ2pfvuuy9deOGFvfO9973vTf/6r/+aUkpp2rRpaevWrel973tf+pM/+ZNB4x7ofQMWpwHy0WqO8vEwMCsiZkTEKOAS4Fv95vkmWe80EXEcWQnIL6sYoyRJkspo/PjxnHXWWbS3t/P973+fyy67jDPPPJO5c+fy1re+lR07dvCJT3yCV73qVbzyla/kM5/5DF/84hd5/PHHefWrX01nZ2fvRYn9vec972HRokW87GUvY+nSpbzwhS8cclx///d/z+7du/nQhz6Uexsj9bvisZIi4vXA35HVR38ppfTxiLiRLNv/VmT9638DvA7YB3w8pXT7oZY5b9681FN8LkmSpAM9/vjjvOQlL6l1GA1noPctIh5JKc3rP29Va6hTSncDd/ebdkOf3xNwXfEhSZIk1T3vlChJkiTlYEItSZIk5WBCLUmS1OSqec1cMyj1/TKhliRJamKjR49m27ZtJtVDlFJi27ZtjB49esh/U283dpEkSVIZTZ48mQ0bNvTefEaHN3r06N67LA6FCbUkSVITa2lpYcaMGbUOo6lZ8iFJkiTlYEItSZIk5WBCLUmSJOVgQi1JkiTlYEItSZIk5WBCLUmSJOVgQi1JkiTlYEItSZIk5WBCLUmSJOVgQi1JkiTlYEItSZIk5WBCLUmSJOVgQi1JkiTlYEItSZIk5WBCLUmSJOVgQi1JakiFQqHWIUgSYEItSWpQCxcurHUIkgSYUEuSJEm5mFBLkhpGoVAgIogIgN7fLf+QVEuRUqp1DLnMmzcvLV68uNZhSJKqLCJo9P9hkhpLRDySUprXf7o91JIkSVIOJtSSpIa0YMGCWocgSYAJtSSpQVk3LalemFBLkiRJOZhQS5IkSTmYUEuSJEk5mFBLkiRJOZhQS5IkSTmYUEuSJEk5mFBL0jDkkHOSVD4m1JI0DC1cuLDWIUhS0zChliRJknIwoZakYaJQKBARRARA7++Wf0hSPibUklQCk09JUn+RUqp1DLnMmzcvLV68uNZhSBomIoJG/96E5tkOSaqmiHgkpTSv/3R7qCVJkqQcTKilIfA0//DWjLXHCxYsqHUIktQ0LPmQhsDT4+rhZ0GSDq1QKDR0h8OhWPIhSZKkihuO49ybUEuDaMbT/FIzcV+UVC9MqKVBFAoFUkq9p/d7fvefuFQfhmMvmFSvhnsnlAm1JB3GcP9HIUmHM9w7oUyopSFwRIThbbj/o6gnHtxIqkeO8iFJJXCUj/phW0j1yVE+JEmH5NkKSTq0Zk2mD8WEWpJKMBz/UdQrD24k1QsTaklSQ/LgRlK9MKGWJEmScjChliRJknIwoZYkSZJyMKGWJEmScqhqQh0Rr4uIZRGxMiLmD/D6VRGxNSIeLT6urmZ8kiRJUqmqllBHxEjgFuACoA24NCLaBpj1jpTSKcXHF6sVnyQNJ46QIUnlU80e6tOBlSmlX6aU9gK3AxdXcf2SpKKFCxfWOgRJahrVTKgnAev7PN9QnNbfWyLiFxFxZ0RMqU5okiRJ0pE5qtYB9PNt4CsppWcj4o+ARcB5/WeKiGuAawAmT55MR0cHABMmTGDMmDGsXr0agHHjxjF16lSWLFkCwMiRI2lra2PVqlXs2rULgJNOOomuri62bt0KwMSJE2lpaWHt2rUAtLa2MmnSJDo7OwFoaWlhzpw5rFixgj179gAwe/Zstm3bxrZt2wCYNGkSI0aMYP367Pjh2GOP5cQTT2Tp0qUAjBo1ipNPPplly5axd+9eAObMmcPmzZt5+umnAZgyZQr79+9n48aNAIwfP57x48ezfPlyAEaPHs2sWbNYunQp3d3dALS1tbFx40a6uroAmDZtGt3d3WzatAmA448/ntbWVlauXAnA0UcfzcyZM+ns7GTfvn0AtLe3s27dOrZv3w7AjBkz2L17N08++SQAJ5xwAscccwyrVq0CYOzYscyYMYMlS5aQUiIiaG9vZ/Xq1ezcuROAmTNnsmPHDrZs2WI72U62Uw3b6dOf/jT/+I//SI+IAOCDH/wgH/vYx2ynOmkn9yfbyXaq33YaTKSUBn2xnCLiTKCQUnpt8fn1ACmlTw4y/0jgVyml1kMtd968eWnx4sXlDleSmlpEUK3vf0lqFhHxSEppXv/p1Sz5eBiYFREzImIUcAnwrb4zRMRv9Hl6EfB4FeOTJEmSSla1ko+U0nMRcS1wDzAS+FJK6bGIuBFYnFL6FvD+iLgIeA74FXBVteKTpOFkwYIFtQ5BkppG1Uo+KsWSD0nVVCgUHHJOkoapeij5kKSG53BzkqT+TKglSZKkHEyoJekwCoUCEdE7zFzP75Z+1Jbvv6R6YQ21JJXA4ebqh20hqdqsoZZysCdMkiQNxoRaGgIvRFMPh5urLctvJNUjSz6kIfDUslR/3C8lVZslH1KJ7AnTQGx/SVJ/JtR1zH/ctVUoFEgp9faA9fxuuwxvlv/UD8tvJNULSz7qmKcz64dtoR5+FiRp+LLkQ5KOkOU/kqRDMaGuM/7jrh+2hXpY/iNJOpSjah2AVK8KhUJvwuRpfkmSNBgT6jpjEifVNy+EkyT1Z8mHNAQmUephmYdUn9w3VUsm1HXMJK5++EUtSfXNIS1VSybUdcwkTpIkqf6ZUEuSpIbkaEyqF97YRZIkNTwv5Fc1eGMXSSoDe74kSf2ZUEtSCbzwSapPXsivWjKhliRJDc+zR6olE2pJOgwvfJIkHYoXJUpSCbzwSZKGLy9KVE3YgydJkpqdCbUqygu41GzOOeecWodQFh7sSlL5WPKhivL0uJpNs3ymm2U7JKmaLPlQ1XgBlyRJGk5MqFV2hUKBlFJv71fP7ybUalTNcpDYLNshSfXGkg9VlKeV1Wya5TPdLNshSdVkyYdqwjtXSZKkZmdCrYryVLKaTbMcJDbLdkhSPTChlqQSNMtBYrNsh9SjGT7TzbANw5U11JIkqeE1w3UBzbANzc4aakmSJKkCTKglSVJDaoahIJthG2TJhyRJagLNUC7RDNvQ7Cz5kCQ1FXvwJNULE2pVlP/wJFXKwoULax2C6kgzDAXZDNswXFnyoYry9JWkSvH7RVK1WfIhSWp4XsAlqR6ZUKvs/IcnqVIKhQIppd6e6Z7f/X6RVEuWfKiiPCUrqVL8fpFUbZZ8SJKaihdwSaoXR9U6AA2uUCg0/GlM/+FJKsXcRXOHPvMM+Pqirw959o4rO44gIkk6PEs+6pinM6X60wwHus1i7qK5Jsnq5b6parDkQ5LKwLGPpfrkvqlaMqGuM46QIUnS8OT/+sZlQi1Jh9GMB7qNHLvUo9n2TXvZG5c11HXMGmqp/jTLftkM22ENtfpqhs90M2xDs7OGukE029G21AzcLyVVit8vzcEe6jrmkapUfxp5vywUCgOeUl6wYEFD/vO2h1p9NcMoH438/TJcDNZDbUJdx9yxpPrTLPtlM2yHCbWaTTPsl83Oko8G5E1R6kej93qofNwvJVWK3y+Ny4S6jpnE1Q+vvFYzsFZTkirDhFqSSuDBlaRK8fulcZlQS4OwN0/NplAokFLqrdHs+d3PtCTlU9WEOiJeFxHLImJlRMw/xHxviYgUEQcVfUvVYvKhHh5cSaoUv1+aQ9VG+YiIkcBy4HeADcDDwKUppc5+8x0D3FGfkmwAACAASURBVAWMAq5NKR1yCI9mHuVD9cMrr9WjWT4LzTDEmKN8qNk0y/dLM6uHUT5OB1amlH6ZUtoL3A5cPMB8fwn8NbCnirFJh+SV12o2jZ5MS1I9qWZCPQlY3+f5huK0XhFxKjAlpXRXFeOSDsvkY3jzlKykarDzpnEdVesAekTECOAzwFVDmPca4BqAyZMn09GRnfKbMGECY8aMYfXq1QCMGzeOqVOnsmTJEgBGjhxJW1sbq1atYteuXQCcdNJJdHV1sXXrVgAmTpxIS0sLa9euBaC1tZVJkybR2ZlVprS0tDBnzhxWrFjBnj1ZJ/rs2bPZtm0b27ZtA2DSpEmMGDGC9euz44djjz2WE088kaVLlwIwatQoTj75ZJYtW8bevXsBmDNnDps3b+bpp58GYMqUKezfv5+NGzcCMH78eMaPH8/y5csBGD16NLNmzWLp0qV0d3cD0NbWxsaNG+nq6gJg2rRpdHd3s2nTJgCOP/54WltbWblyJQBHH300M2fOpLOzk3379gHQ3t7OunXr2L59OwAzZsxg9+7dPPnkkwCccMIJHHPMMaxatQqAsWPHMmPGDJYsWUJKiYigvb2d1atXs3PnTgBmzpzJjh072LJli+1kOzVkO73lLW/huuuuo7u7m+OOO45f/OIXve3U8/1jO9Wmnfbt2+f+1ADt5Pfe0NrpLW95Cx0dHbZTHbfTYKpZQ30mUEgpvbb4/HqAlNIni89bgVXAzuKfTAB+BVx0qDpqa6glVZM1jvXDGmpJ1VYPNdQPA7MiYkZEjAIuAb7V82JKqSuldFxKaXpKaTrwUw6TTKv+eUpczcZTspKk/qqWUKeUngOuBe4BHge+mlJ6LCJujIiLqhWHqstB6tVsPEiU6pP7pmqpaiUflWLJR33z9LgaxfT5lbkWes1NF1ZkubLkQwfy/42qYbCSj7q5KFHNo1AoHNAz3TMywoIFC+xBUN0aauI7ff5dJsmSpAN463GVnXcYlOrfueeeW+sQpNwc0lL1wh5qDVtzF82t2LI9Da1698ADD9Q6BCm3vnf8tORDtWRCrYqq5xERSkl6rdWUJEmDseRDFeVpN6l+nHvuuQOeHrf8Q82gnjtw1PxMqCVpmLj//vsHvL7h/vvvr21gUhnYgVM/hmNbmFBL0jDhBVySqmE43oPCGmpJGia8gEuSKsMeakmSJOUy3M+A2UMtScOQF3BJKqfhfgbMhFqSmkWhdeizAhT+toRld5UajSQNGybUVTZ9/l0VW7a3Q5aGuVKS3kKrSbJUZ/r28jay4XgGzIS6ykpJeqfPv6s+k+QSesFKX7b/4CVJw9PChQubIqEejkyoVTp7wSRJ0iCG44FB7lE+ImJMRJxejmAkSZKGk+E+OkazKMewebOB/1uG5UiSJA0rhUJhwDuYNlpCPdwPDCz5kCRJUi7Dfdg8b+wiSZIk5WBCLUmSVCPNWCrhsHkDiIiJh5nlhDLFIkmSNKw0Y6lEIx8MHKmh9FBvANYf4nFPxaKTJEkaguGYxKl+DOWixFdXPApJkqQcmmHs4+FYKtEsDptQp5QeqEYgkiRJw1mjHxAMZyVdlBgR4yPi/RHx2YgYX5z2ioiYVpnwJEmSBtaMF/SpMQ15HOqIaAfuA7qAacDfAtuA3wOmAldUIkBJkiSpnpXSQ/03wJeBWcCePtO/B7yqnEFJkiQdTrPcZVCNr5SE+jTgc+ng8VzWAxPKF5IkSdLwc+6559Y6hLIYjgc0pSTUAbQMMH0KsL084UiSJJXunHPOqXUIuT3wQHOMA7Fw4cJah1B1pSTUPwDe0+d5iohRwMeAe8salSRJUgmaJRlVYyolof4w8JaI+AnwAuAWYAXQDnykArFJkiQ1tXPPPXfAkUoarfxjuI+4MuSEOqW0CngZWW90T4/0IuDUlNL6CsQmSZI0qGZI4u6///4BL6y8//77axuYSjLkYfMAUkpbgEJlQpEkSRq6QqHQmzxHBAePm6BqGe5tUco41L89yEuJbBi9VSklL06UJEk6As1wYeVwVUoP9Y/JkmfIRvyg3/N9EfFV4A9TSnv6/7EkSVKlLFiwoNYh5GaZR+Mq5aLENwC/JBvp45Ti4z3ASuD3gT8EXo0lIZIkqcoaqW5azaeUhPp64P+klL6QUvpF8fEF4IPAn6WUbgM+ALy5EoFKkiSpPjXDBaJ5lJJQvxx4fIDpjwOnFn//GdmNXiRJklSCRk4+h/tt4EtJqDcC7xhg+juADcXfXwz8Km9QkiRJpWiGxG043mGwWZSSUP8F8LGIeCAi/joiboqIB4CPkt0tEbIa6v8ud5CSJEmHYjJaP5rhAtFSlXJjl68ApwPrgd8Bfrf4++kppTuK8/xNSunKSgQqSZLUbJqx9riRYz9SpfRQk1J6JKX0jpTSqcXHO1JKP69UcJIkSYNphmR0uNceN4tSbuwy9VCvp5TW5Q9HkiRpaIb73flUP0q5scsanr+Ry0BG5gtFkiRJajyllHy8Cji7z+N84ENkifalZY9MkiSpyTVD2YpK6KFOKT00wOT7I2IdcBXw1XIFJUmSdDiFQuGA0T16ktIFCxY0TELaKGUrcxfNrdiyO67sqNiyq6WUko/BPALcWoblSJIkDSuNclBQStI7d9HcpkiSS5EroY6s1d8FPFGecCRJkoaPRumh1qENuYY6IlZExPI+jxXAM8CHgb+qWISSJEkDuPXWW0uaLlVKKRcl/jvwH30et5FdlPibKaVbyx+aJEnS4NasWTPgGM5r1qypbWAl8KLE5lDKnRIX9nv8ZUrpCyml5ZUMUJIkaSDNkIx6Y5fmUHINdUS8EvjN4tOOlNJPyhuSJEnS4Vl/rHpRyp0Sjwe+RjYGdVdxcmtEPAC8LaX0VAXikyRJGhYWLFhQ6xB0hEqpof474FjglJTSsSmlY4HfAl4M/G0lgpMkSRqKZkhGLfNoXKWUfFwA/F5K6Rc9E1JK/y8i3gt8q+yRSZIkDZHJqGqplIR6NNkwef09DbygPOFIkiRlps+/q2LLXnPThRVbtoafUhLqxcD1EfHOlNJzABFxFHA98HAlgpMkScNXKUnv9Pl31WeSXGit4LK7Dj+PqqKUhPqDwL3ALyPip8VprwDGAb9b7sAkSZIaXilJb6HVJLlBDemixIhoAb4BXAgsAkYWH7cCs1NKP6tUgJIkSVI9G1IPdUqpuzho+lMppb840pVFxOuAvydLxr+YUrqp3+t/DLwX2AfsBK5JKXUe6fokSZKkSitl2LwvAu8/0hVFxEjgFrLRQtqASyOird9sX04pzU0pnQJ8CvjMka5PkiRJqoZSaqgnAm+LiPOAR4Bf930xpXTNYf7+dGBlSumXABFxO3Ax0NsDnVLa3mf+FwLe8kiSJEl1rZSEeibw8+LvE/u9NpTEdxKwvs/zDcAZ/Wcqjmt9HTAKOG+gBUXENcA1AJMnT6ajowOACRMmMGbMGFavXg3AuHHjmDp1KkuWLAFg5MiRtLW1sWrVKnbt2gXASSedRFdXF1u3bs02bOJEWlpaWLt2LQCtra1MmjSJzs4s729paWHOnDmsWLGCPXv2ADB79my2bdvGtm3bsg2dNIkRI0awfn22ucceeywnnngiS5cuBWDUqFGcfPLJLFu2jL179wIwZ84cNm/ezNNPPw3AlClTAHq3bfz48YwfP57ly5cDMHr0aGbNmsXSpUvp7u4GoK2tjY0bN9LVlV3QMG3aNLq7u9m0aRMAxx9/PK2traxcuRKAo48+mpkzZ9LZ2cm+ffsAaG9vZ926dWzfnh3bzJgxg927d/Pkk08CcMIJJ3DMMcewatUqAMaOHcuMGTNYsmQJKSUigvb2dlavXs3OnTuZC+zatYsdO3awZcuWhm2nnrYYqJ3279/Pxo0bG7qdAGbOnNnw7XSo/alc7dTzWWj0dhrD898vjdxO+/btc39qgHaqxvceZP9vGrmdJpLtl43eTvD890uz7U+DiWrd9z4i3gq8LqV0dfH55cAZKaVrB5n/MuC1KaUrD7XcefPmpcWLF5c93npQt0MAlaJJrlieu2guHVd21DoM1YGm2C+hKfZN90v11RT7ZhPsl9Dc+2ZEPJJSmtd/eik11HltBKb0eT65OG0wtwNvrGhEkiRJUk7VTKgfBmZFxIyIGAVcQr9blkfErD5PLwRWVDE+SZIkqWSl1FDnklJ6LiKuBe4hGzbvSymlxyLiRmBxSulbwLUR8Rqgm+yW5ocs95AkSZJqrWoJNUBK6W7g7n7Tbujz+59WMx5JkiQpr2qWfEiSJElNx4RakiRJysGEWpIkScrBhFqSJEnKwYRakiRJysGEWpIkScrBhFqSJEnKwYRakiRJysGEWpIkScrBhFqSJEnKwYRakiRJysGEWpIkScrBhFqSJEnKwYRakiRJysGEWpIkScrBhFqSJEnKwYRakiRJysGEWpIkScrBhFqSJEnK4ahaByBJam5nfeUstu/dXpFlz100t+zLHDdqHA9d+lDZlyupeZlQS5Iqavve7XRc2VHrMIasEkm6pOZmyYckSZKUgwm1JEmSlIMJtSRJkpSDCbUkSZKUgwm1JEmSlIOjfEhqWi9beC9du7vLvtzp8+8q+zJbx7Tw/xb8btmXK0mqPBNqSU2ra3c3a266sNZhDEklknRJUnVY8iFJkiTlYEItSZIk5WBCLUmSJOVgQi1JkiTlYEItSZIk5eAoH2oqZ33lLLbv3V6RZc9dNLfsyxw3ahwPXfpQ2ZerJnLTNNjzTGWWXWgt/zJHvwjmry3/ciWpjplQq6ls37udjis7ah3GkFUiSVeT2fMMFLpqHcXQVSJJl6Q6Z8mHJEmSlIMJtSRJkpSDJR9lUKnbG4O3OJYkSap3JtRl0Ei3NwZvcSxJklROlnxIkiRJOdhDrYxDc0mSJB0RE2plHJpLkiTpiFjyIUmSJOVgQi1JkiTlYMmHJEnSMHTWV85i+97tFVl2Je4EPG7UOB669KGyL7ccTKglSZKGoe17t9NxZUetwxiySiTp5WLJhyRJkpSDPdSSJKlqvLuwmpEJtSRJqhrvLqxmZMmHJEmSlIMJtSRJkpSDJR+Smlrf07XfvvaVALzhcz/unfan58/iz35nNqd//L/ZsuNZANonjeM773sV1//nL/jKz9b3zvs/Hzmfjg1dXH3b4t5pn3jTXC47Y+oB6zl/zgn8y1Wn8Ye3PswPlm7pnb7mpgv58v+s4yPfeP6q+i9eMY+5k73zpyQ1MhNqSU1toFrNgab97KOvOWjaJ9/8Uj755pceMO3EttFDXua/XHXaQdMuO2Mql50x9ZAxN6O+w13d/nu3A3DJdy7pnfYnL/sT3nPKezjvq+exdfdWAF7y4pfw1Td8lcJPCnx9xdd75/3B235A57ZO3vfD9/VOu+HMG3jb7LcdsJ5zJp/D587/HNf+4Foe2PBA7/SOKzv42vKvceP/vbF32mfP+yxt49s4/2vnl3GrJQ0XJtSSpIobaKzbgab98Pd/eNC0wm8XKPx24YBpJxx9wpCX+bnzP3fQtLfNfhtvm/22Af++nse6lVSfTKglSZJKcdM02PNMZZZdqEAJ2OgXwfy15V+ueplQS5IklWLPM1DoqnUUQ1eJJF0HcJQPSZIkKYeqJtQR8bqIWBYRKyNi/gCvXxcRnRHxi4j4QURMq2Z8kiRJUqmqllBHxEjgFuACoA24NCLa+s32v8C8lNJLgTuBT1UrPkmSJOlIVLOG+nRgZUrplwARcTtwMdDZM0NK6b4+8/8UeEcV45PUhLxtsCSp0qqZUE8C1vd5vgE44xDz/yHw3YpGJKnpDTQ+dD06ZOLf94Kia+7Pfv7Tuc9PO2c+vPp6+PTJsPPJbNpvvAz+6EH41vvh54uen/e6pfDEo/CV58eA5vf+Dua988D1zH4dXHYHfPkPYPn3+sTSBYv/Fb7zgeenXXo7/MYp8Jk5Q9xaSWoudTnKR0S8A5gHnDPI69cA1wBMnjyZjo5s3NEJEyYwZswYVq9eDcC4ceOYOnUqS5YsAWDkyJG0tbWxatUqdu3aBcBJJ51EV1cXW7dmNxKYOHEiLS0trF2bDS/T2trKpEmT6OzMOtJbWlqYM2cOK1asYM+ePb0xbdq0iW3btgEwadIkRowYwfr12fHDsccey4knnsjSpUsBGDVqFCeffDLLli1j7969AMyZM4fNmzfz9NNPAzBlyhT279/Pxo0bARg/fjzjx49n+fLlAIwePZpZs2axdOlSuru7AWhra2Pjxo10dWVXHk+bNo3u7m42bdoEwPHHH09ra/YPs6Ojg6OPPpqZM2fS2dlJW3Fae3s769atY/v27QDMmDGD3bt38+ST2T/pE044gWOOOYZVq1YBMHbsWGbMmMGSJUtIKRERtLe3s3r1anbu3AnAzJkz2bFjB1u2bClbO80Ftm/fflA79WzbQO00e/Zstm3bVnfttH379gHbaeXKlQAHtNO+ffsAGqadjmR/Kmc79XweKrk/lbOdVq9efXA7AauvfPT5dnpRsZ3e8uMD26mjA15754Ht1NHByJP+mLaL/uH5dlr7FCeddC5df7zswHbavp21xWX2tlNHB8z9GC2nLny+nTo64AXzmH39lufbaS9Meu4FjPjAWl70d9Po6Og4qJ2WLVtW0++9UtoJYOvWre5Pfu8xbtw4gN48o6ed+k5rhHaaS5an9G8noObfe6W0U8/7Xsv9aVAppao8gDOBe/o8vx64foD5XgM8DpwwlOW+/OUvT7U27cPfqXUIJRkw3gXjqh9IHoPE235re5UDyafR4m00jbRvDhprE+ybjfY5b7R4G00j7Zcp+T+zntRDvMDiNEA+Ws0e6oeBWRExA9gIXAJc1neGiPgt4AvA61JKW6oYm5qItziW6o93H5TUzKqWUKeUnouIa4F7gJHAl1JKj0XEjWTZ/reAm4GxwNciAmBdSumiasWYR9/6x29f+0oA3vC5H/dO+9PzZ/FnvzOb0z/+32zZ8SwA7ZPG8Z33vYrr//MXfOVnz5eX/89HzqdjQxdX37a4d9on3jSXy86YesB6zp9zAv9y1Wn84a0P84Olzx9/rLnpQr78P+v4yDeevwXvF6+Yx9zJrZzxiR+Ucavrk7c4lurPQPtLvXK/lFSqqtZQp5TuBu7uN+2GPr+/pprxlNNAFz4NNO1nHz14Ez/55pfyyTe/9IBpJ7aNHvIy/+Wq0w6adtkZU7nsjKkD/r2jHkiSaslOKDWburwosRGZpEqSNDR2QtUPyyTLw4S6TBplaC4w+ZckSRnLJMujqrcelyRJkpqNPdSSVO/63nBFklR3TKj1vCa5G1s9nxKSjkihq9YRDJ3Jv6RhyIRazxvon/ZA0/582cHTLvqH7NHXuN8Y+jIvu+PgafPemT0G+vtD/NN2eC5JklRNJtSSJEnDlB075WFCred5qlaSVAVNMdpUk5RJela3PEyo9TzrNCVJVdAUQ802SZmkysNh8yRJkqQcTKglSZKkHEyoJUmSpBysoZYkSSqVdcnqw4RakiSpVF7Irz4s+ZAkSZJyMKGWJEmScjChliRJknIwoZYkSZJyMKGWJEmScjChliRJknIwoZYkSZJyMKGWJEmScjChliRJknLwTomSmtr0+XfVOoQhaR3TUusQJElHyIRaUtNac9OFZV/m9Pl3VWS50nDSKAe64MGuhsaEWpIkVU2lDkg92FUtWUMtSZIk5WAPtSTVu0JrrSMYutEvGnDy3EVzqxzIkRs3alytQ5Cqxn2zPEyoJameFboqtNzWyi27n44rOyqy3LmL5lZs2dJw4L5ZPpZ8SJIkSTmYUEuSJEk5mFBLkiRJOVhDLUmSVKomuFhY5WNCLUmSVIomuFhY5WXJhyRJkpSDPdRqOo6pKUmSqsmEukymz7+r1iEMWeuYllqHUDGOqSlJkqrNhLoM1tx0YUWWO33+XRVbtiRJksrDhFrP84plSZKkkplQK+MVy5IkSUfEUT4kSZKkHEyoJUmSpBxMqCVJkqQcTKglSZKkHEyoJUmSpBxMqCVJkqQcTKglSZKkHEyoJUmSpBxMqCVJkqQcTKglSZKkHEyoJUmSpBxMqCVJkqQcTKglSZKkHEyoJUmSpBxMqCVJkqQcTKglSZKkHEyoJUmSpByqmlBHxOsiYllErIyI+QO8fnZE/DwinouIt1YzNkmSJOlIVC2hjoiRwC3ABUAbcGlEtPWbbR1wFfDlasUlSZIk5XFUFdd1OrAypfRLgIi4HbgY6OyZIaW0pvja/irGJUmSJB2xapZ8TALW93m+oThNkiRJaljV7KEum4i4BrgGYPLkyXR0dAAwYcIExowZw+rVqwEYN24cU6dOZcmSJQCMHDmStrY2Vq1axa5duwA46aST6OrqYuvWrQBMnDiRlpYW1q5dC0BrayuTJk2iszPrSG9paWHOnDmsWLGCPXv2ADB79my2bdvGtm3bAJg0aRIjRoxg/frs+OHYY4/lxBNPZOnSpQCMGjWKk08+mWXLlrF3714A5syZw+bNm3n66acBmDJlCkDvto0fP57x48ezfPlyAEaPHs2sWbNYunQp3d3dALS1tbFx40a6uroAmDZtGt3d3WzatAmA448/ntbWVlauXAnA0UcfzcyZM+ns7GTfvn0AtLe3s27dOrZv3w7AjBkz2L17N08++SQAJ5xwAscccwyrVq0CYOzYscyYMYMlS5aQUiIiaG9vZ/Xq1ezcuZO5wK5du9ixYwdbtmxp2HbqaYuB2mn//v1s3LixodsJYObMmQ3fTofan8rVTj2fhUZvpzE8//3SyO20b98+96cGaKdqfO9B9v+mkdtpItl+2ejtBM9/vzTb/jSYSCkN+mI5RcSZQCGl9Nri8+sBUkqfHGDeW4HvpJTuPNxy582blxYvXlzmaOvD9Pl3seamC2sdRj6FVih01TqK3OYumkvHlR21DkN1oCn2S2iKfdP9Un01xb7ZBPslNPe+GRGPpJTm9Z9ezZKPh4FZETEjIkYBlwDfquL6JUmSpLKrWkKdUnoOuBa4B3gc+GpK6bGIuDEiLgKIiNMiYgPwNuALEfFYteKTJEmSjkRVa6hTSncDd/ebdkOf3x8GJlczJkmSJCkP75QoSZIk5WBCLUmSJOVgQi1JkiTlYEItSZIk5WBCLUmSJOVgQi1JkiTl0JC3HpckSVL1zF00t2LzN8NdFU2oJYnstsWVmLfhb4UsSTRH0ltJJtSShImvJOnIWUMtSZIk5WBCLUmSJOVgyYckNYtCa+XmL3SVtmxJGkZMqCWpWZj0SlJNWPIhSZIk5WAPtSSpbjjWraRGZEItSaobJr2SGpElH5IkSVIOJtSSJElSDibUkiRJUg4m1JIkSVIOJtSSJElSDo7yIUmS6tL0+XdVbP41N11YajjSoEyoJUlSXTLpVaMwoZYkSaqUQmvl5i90lbZsVYwJtSRJUqWY9A4LXpQoSZIk5WAPtYatuYvmVmx+b58sSdLwYUKtYcukV5IklYMlH5IkSVIOJtSSJElSDibUkiRJUg4m1JIkSVIOJtSSJElSDibUkiRJUg4m1JIkSVIOjkNdZdPn31Wx+dfcdGGp4RyZQmvl5vcWrZIkqcGYUFdZ1ZLeSjLplSRJ6mXJhyRJkpSDCbUkSZKUgwm1JEmSlIMJtSRJkpSDCbUkSZKUgwm1JEmSlIMJtSRJkpSDCbUkSZKUgwm1JEmSlIMJtSRJkpSDCbUkSZKUgwm1JEmSlIMJtSRJkpSDCbUkSZKUgwm1JEmSlIMJtSRJkpSDCbUkSZKUgwm1JEmSlEOklGodQy4RsRVYW+s4NKjjgKdqHYSkg7hvSvXH/bL+TUspHd9/YsMn1KpvEbE4pTSv1nFIOpD7plR/3C8blyUfkiRJUg4m1JIkSVIOJtSqtH+qdQCSBuS+KdUf98sGZQ21JEmSlIM91JIkSVIOJtSqmIi4KiKeK2H+WyPivysZk6TS9d83I6IQEStrGZNUKRHxyYjYHBEpIq6qdTxqDP9/e/cfZGVVx3H8/Vl+iFQ4Y1HTj1H8gYE7pQnKSGIZNWlNo+Nk0y9LLbHSDTBnZGQogjKxTJ1+mBDCjDGUgbWO5MJEbA5NaTDSEBEpCAGiweAPVgRCvv1xztbTw+7O7t6rd7z385p5hn2e59xzz3Od7/2e5zznXAfWugFW134BPNSH8pPxTZ6ZmdWIpHHANOAS4BHg+dq2yF4r3KG2o0gaHBGHKq0nIl4CXupDeX9xmfVBtWLVzP5rJHAkIlpr3ZBXgiQBAyPi37VuS73xaGADkNQu6R5Jt0jaI+kFSXMlDSmcny9ptqRdwD/z8VMlLZX0nKRnJa2Q9K5S3WMkteU6OyQ9mu/wj5ryIWmYpAWSnpZ0UNJ2Sd8vnC8/VpakGyRtkXRI0mZJU0rvv1XSLEl3StqbH9PdLsk3i1Z3uorVKsTpSZLul/SUpP2S1ku6vCYXaFZDkhYC9wJNebpHdOYlSS2SduT4+amkQZK+JGlbjru5kgaX6muR9HdJByQ9Lml6MTdJ+rSkRyQ9n3PzMkmnleq4KefAg5J2S1ou6dh87qipV5LOy+0ekfevkHRY0gWSHgMOAh/M7Z8p6cncvg2SrnkFPtaG4U5H4/g4aQrGBOBUYD7wIjA1n/8EsAiYCAyQ9BZgNfCr/JpDwHVAu6RREbFbUjPwMPAA8AHSo7GxdH+j9i3gLOBiYBfwDqC5hzZ/BZhNmgqyKrftDkn7ImJ+oVwLMAcYB7wnX8df8zWa1ZtirA6n8jh9PfA74JtAB/ARYIGkHRGx6lW7KrPamww8BtxGyk8AtwDnADuBD5Hy5y+BtwO7gQuBk4El+bV3QersAlcCU4B1wGjgJ8AQYEau+xhSXvwbMIwUg8skNUfEIUmXkqaffAb4C3A88P5+XFcTKUdeD2wD9gHzSPn4GuDxfI13Szpcyq/WWxHhrc43oB3YCgwoHJsEHABel8//A2gqnJ8J/KlUj4DNkFGF6QAABGBJREFUwJS8fy8pyJu6ed8rgMOF/VZgYQ/tXAj8trC/Hbi1VOZ2YEthfyvwQKnMQ8DiWn/u3rxVeyvHajXitJv3aQXmFfbLsTkTeKLWn4c3b9XeushbC4F/AYMLx5YBe4BjCsdagSX576HAfuDCUt2fA57r4b2PBwJ4b96fmuN9UDflj4pD4Lxcx4jC9QQwoVDmJOAIMKr02q8D62r93+C1unmEunE8GhEvF/b/QLo7PiXvr42II4XzZwNjJHWU6jmWNMcMYAzQVnpdT34MLJU0FlgJtAHLu3q9pGGkEYKHS6d+D0yWNDQi9udj60plniJ9YZjVo2KsVhynkoaSEunHgLcCg0nfDR6dNks2xv+vVXga2BQRB0vHRue/m0kxuFRS8X/2MQAYIml4pKdHZwLfAM4E3kS6GQY4kZSj7wO+CmyTtIKUN38dEfv6cQ1/Lvw9Nr/XGknFMgOBYj/B+sAdauv0Ymm/iRS813VRtl+LByNiuaQTgA+THlv9DFgvaWKps99X5UVZgdcHWP0qxmo14vS7pGlY1wObcv23AcdV0EazelJewBfdHOvMO53/XkYaYS7bm29kV5CmbF0JPJPPbSDd1BIROyWNAi4gTdeaAcyRNC4itpNGmVWqe1AX7/dyRBwo7He2bzxpJL18HdYP7lA3jrMlDSh0XMeTFids7qb8GtKjoh2lQCxaC0yU1NTbUeqI2AssBhZLWgD8ETgdWF8q94KkHcD5wIOFU+8DniyMTps1smrE6fnAooi4D0BSE3Aa/0vwZtY3G0hTKk+OiN90VUDSaNIaiOkRsTEfG0+pg5xHwduANkkzSHF5CfAD0lSUN5dy+1m9aN/a/O8JEfFgjyWt1zyK1zjeCPxI0mhJHyUt9rs7Isoj051+SHo81SppgqQRefXwt3PQA9xKeqy8SNJYSadIukzSuV1VmF97qaR3ShpJWmjRQf5VkS58B2iRdLWkkXkF8peBm/vzAZjVoWrE6SbgYknnSDodmAu87VW/ErM6EREdpDx1s6Rrc85rlvRJSXNysW2kQa2WHJMTgTspjBBL+kLOf2dIOpGUM99AWsQIaVrWUGBWZ1wD1/aifU8A9wDzJF2u9EtBZ0i6StKN1fkUGo871I1jCWll72rg56RR32ndFY6IZ4BzSQsv7icl3UWkuV27cpn1pKkbw0lzm9cBX6P7OVgHgFmku+M1wLuBi6L735++izS38ybSF8iNwLTwCmQzoGpxOpWU3FeRpo/sJH1fmFk/RcRs0jSqq0mLgleTYm1rPr8H+Czpl0M2AN8DbiBN4+j0LGk6SDuwMdc3KSJW5jo25fo/Rfplq6tI+bI3JpEW+U8n5deVwOeBLX2/WgNQXtlpdUxSO2kl8Bdr3RYzMzOzeuMRajMzMzOzCrhDbWZmZmZWAU/5MDMzMzOrgEeozczMzMwq4A61mZmZmVkF3KE2MzMzM6uAO9RmZmZmZhVwh9rMzMzMrALuUJuZmZmZVeA/fp/socyMCEQAAAAASUVORK5CYII=\n","text/plain":["<Figure size 864x576 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"markdown","metadata":{"id":"IzORzb_nYb0E"},"source":["### **Summary vs Reduction**\n","\n","We can notice that summaries always improve over reductions. Moreover, considering the recall, one can see that on average the reductions get a Rouge L score higher than 0.3. This means the main points in the bullets are not completely lost during the reduction phase."]},{"cell_type":"code","metadata":{"id":"Y65wEdWwb0Fi","colab":{"base_uri":"https://localhost:8080/","height":0},"executionInfo":{"status":"ok","timestamp":1608648633829,"user_tz":-60,"elapsed":11986,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"de74308b-0049-456e-9a11-d375ee58ff4f"},"source":["plot_compare_rouge(\n","    [df_lda_redu, df_lda_summ],\n","    ['lda_reduction', 'lda_summary'],\n","    'rougeL',\n","    folder = 'topic_modeling')"],"execution_count":27,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 864x576 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"markdown","metadata":{"id":"Hebp4KgsfCZ3"},"source":["## **Merge or Chunk**"]},{"cell_type":"markdown","metadata":{"id":"ioM6TYCJhgQy"},"source":["#### Loading data"]},{"cell_type":"code","metadata":{"id":"GIiv9xDOhgQz","executionInfo":{"status":"ok","timestamp":1608648634240,"user_tz":-60,"elapsed":11142,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["input_path = drive_dir+'summarization/moc_output/'\n","df_moc = pd.read_csv(input_path+'df_summ_'+MODEL+'.csv')\n","df_moc = df_moc.set_index(['book', 'chapter', 'merge'])"],"execution_count":28,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"j9K2GIPifCZ6"},"source":["#### Rouge"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/","height":0},"id":"uFIRYcs7cS_7","executionInfo":{"status":"ok","timestamp":1608648635478,"user_tz":-60,"elapsed":12371,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"9cf2b573-8fd8-41f4-f98e-efd30d99103a"},"source":["plot_rouge(df_moc, 'merge_or_chunk', 'rougeL')"],"execution_count":29,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 720x432 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"markdown","metadata":{"id":"_afGnaAA-wMk"},"source":["#### Print Random Summaries"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"vk-bO-fD-wMm","executionInfo":{"status":"ok","timestamp":1608648635483,"user_tz":-60,"elapsed":12370,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"e4b6ba45-2cab-49c1-a7ee-9d0c038caf15"},"source":["print_random_summaries(df_moc, RANDOM_IDS)"],"execution_count":30,"outputs":[{"output_type":"stream","text":["(9781908541994, 'ch05') chunk 1\n","\n","Text:\n","Topical therapy. Topical therapy is useful in nearly all acne regimens. mild localized acne. moderate acne; in combination with, and following, oral\n","therapy. maintenance therapy; after stopping systemic agents for severe acne. Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics. The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance. Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose\n","combination product to enhance adherence. Topical agents differ in their efficacy against the various etiologic factors. Retinoids, azelaic acid and\n","BPO are effective for comedones and inflammatory acne. Topical antibiotics such as erythromycin and clindamycin are most effective for inflammatory\n","lesions. Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions. It is important to note that topical\n","antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P. acnes) strains. Patients often seek medical\n","attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels. Active ingredients\n","include BPO, salicylic acid and alpha-hydroxy acids. Topical therapy is generally applied after washing the face and allowing it to dry for 10-15\n","minutes. It is important to cover the entire affected area with a thin film of product, avoiding the eyes. Benzoyl peroxide. BPO is the most potent\n","agent against P. acnes, an obligate anaerobe that will not grow in the presence of oxygen. Unlike antibiotics, BPO is bactericidal against P. acnes\n","through its release of free oxygen radicals in sebaceous follicles. BPO therefore reduces bacterial colonization of the follicle and kills both\n","sensitive and resistant strains of P. acnes, which translates into a reduction in new inflammatory lesions. acnes does not develop resistance to BPO;\n","for this reason, the drug is a valuable component of any acne treatment regimen. BPO is mostly available in over-the-counter and prescription\n","formulations, including bar soaps, washes, gels and lotions. It is chiefly available in concentrations of 2.5%, 4%, 5% and 10%. However, there is no\n","evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the 2.5-5% concentrations. BPO\n","is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene (see page 52). Topical\n","retinoids and retinoid-like molecules. Topical retinoids are effective agents in the treatment of acne. Although dermatologists readily prescribe\n","them, topical retinoids are underutilized by pediatricians and general practitioners. Tretinoin, or all-trans-retinoic acid, is a vitamin A derivative\n","that reverses the altered keratinization in follicles affected by acne. By inhibiting the formation of the microcomedone, tretinoin prevents the\n","development of comedones and early inflammatory lesions.\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical therapy should be selected to help achieve medical adherence. Realistic\n","expectations of therapy should be explained. Combining therapies or using fixed combination topical products improves efficacy by targeting more than\n","one pathogenic feature and enhancing treatment adherence. Topical antibiotics can lead to the development of antimicrobial resistance. Topical\n","antibiotics should not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Any regimen containing\n","an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent\n","the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. Topical\n","antibiotics such as erythromycin and clindamycin are most effective for inflammatory lesions. Tretinoin, or all-trans-retinoic acid, is a vitamin A\n","derivative that reverses the altered keratinization in follicles affected by acne. The use of topical antibiotics as single agents for acne is\n","discouraged because of the potential for the development of bacterial resistance. It is important to note that topical antibiotics should be combined\n","with BPO to reduce the emergence of resistant strains of Propionibacterium acnes (P. acnes) strains.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') chunk 2\n","\n","Text:\n","Tretinoin is available as a cream, gel or solution in a variety of concentrations of differing potencies, which vary between countries. % gel / 0.05%\n","cream. % gel / 0.1% cream. Tretinoin is usually applied once daily at bedtime after the face has had adequate time to dry. Night-time application is\n","most effective as the active molecule is light sensitive. Tretinoin is also available in formulations with novel delivery systems, such as\n","microspheres. Choice of formulation depends upon whether the patient has dry or oily skin. Patients with oily skin usually prefer gels and patients\n","with dry skin usually prefer creams. Adapalene is a synthetic acid derivative with retinoid-like activity but a distinctly different chemical\n","structure. Adapalene is a potent modulator of cellular differentiation, keratinization and inflammatory processes, and the mechanism of action is\n","believed to be similar to that of retinoids. Adapalene interacts with nuclear retinoic acid receptors (RARs) beta and gamma. It has been hypothesized\n","that this receptor selectivity may account for its better side-effect profile. Adapalene has been shown to possess anti-inflammatory activity in a\n","number of in-vitro and in-vivo animal models. Along with tretinoin, adapalene has been shown to decrease the expression of toll-like receptor-2 (TLR2)\n","on inflammatory cells. Adapalene is available in concentrations of 0.1% and 0.3% (in the USA), and also as a fixed combination of 0.1% adapalene with\n","2.5% BPO for daily use. Tazarotene is a synthetic acetylenic retinoid that has been formulated into a topical gel and cream. Following topical\n","application, tazarotene is converted to its active metabolite tazarotenic acid. This compound then binds to nuclear RARs and can affect the expression\n","of genes involved in cell proliferation, cell differentiation and inflammation. At the cellular level this may result in the modification of several\n","pathogenic factors in acne, including corneocyte accumulation and cohesion. Tazarotene is specific for RARs, rather than retinoid X receptors (RXRs),\n","and selectively activates RAR-beta and RAR-gamma, as does adapalene. Tazarotene is very effective in comedonal and inflammatory acne. It may have\n","greater potential for irritation in some patients, more so with the gel formulation than the cream. Tazarotene is licensed for the treatment of acne\n","in the USA but only licensed for the treatment of psoriasis in the UK. Dapsone is a sulfone that targets neutrophil-mediated inflammation. Stability\n","issues with a topical formulation were overcome with the development of a novel topical gel. The gel has been shown to be effective against acne at 5%\n","concentration; recent studies suggest topical dapsone 5% gel may be particularly beneficial in regimens for adult women with acne (see pages 26-9).\n","Topical isotretinoin is an alternative preparation, available as a 0.05% gel in the UK and Italy, but it is not available in the USA. This retinoid\n","has been shown to be less irritating than older retinoid preparations such as tretinoin.\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical therapy should be selected to help achieve medical adherence. Realistic\n","expectations of therapy should be explained. Combining therapies or using fixed combination topical products improves efficacy by targeting more than\n","one pathogenic feature and enhancing treatment adherence. Topical antibiotics can lead to the development of antimicrobial resistance. Topical\n","antibiotics should not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Any regimen containing\n","an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent\n","the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n","Tretinoin is usually applied once daily at bedtime after the face has had adequate time to dry. Night-time application is most effective as the active\n","molecule is light sensitive. Tretinoin is also available in formulations with novel delivery systems, such as microspheres. Choice of formulation\n","depends upon whether the patient has dry or oily skin. Patients with oily skin usually prefer gels and patients with dry skin usually prefer creams.\n","Topical isotretinoin is an alternative preparation, available as a 0.05% gel in the UK and Italy, but it is not available in the USA. Dapsone is a\n","sulfone that targets neutrophil-mediated inflammation. The gel has been shown to be effective against acne at 5% concentration.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') chunk 3\n","\n","Text:\n","Salicylic, alpha-hydroxy and azelaic acids. Salicylic acid, a beta-hydroxy acid, is keratolytic and an irritant; it may promote the resolution of\n","inflammatory lesions through its drying effect. Salicylic acid has mild comedolytic activity. It is available in a maximum concentration of 2% in\n","over-the-counter preparations such as soaps, cleansers and gels. Some salicylic acid products are tinted to help camouflage acne lesions. Combination\n","products containing salicylic acid and BPO or sulfur are also available. alpha -hydroxy acids such as lactic acid, glycolic acid and citric acid are\n","available in a variety of cosmetic preparations, including cleansers, toners, moisturizers and chemical peels. alpha-hydroxy acids are thought to\n","reverse the altered keratinization of follicles affected by acne and improve the appearance of the skin by promoting desquamation of the stratum\n","corneum. The effectiveness of alpha-hydroxy acids in acne, however, has not yet been demonstrated in controlled clinical trials. Azelaic acid is a\n","naturally occurring dicarboxylic acid found in cereal grains. It is available as a topical cream that has been shown to be effective in inflammatory\n","and comedonal acne. By inhibiting the growth of P. acnes, azelaic acid reduces inflammatory acne. It also reverses the altered keratinization of\n","follicles seen in acne and thus demonstrates comedolytic activity. Azelaic acid can affect melanosomes and has been used to treat postinflammatory\n","hyperpigmentation. Azelaic acid is reported to have fewer local side effects than topical retinoids. Topical antibiotics. Topical antibiotics such as\n","erythromycin, clindamycin and sodium sulfacetamide inhibit the growth of P. acnes and reduce inflammatory lesions. Products containing these\n","antibiotics are often applied twice daily and are generally well tolerated. Topical antibiotics such as erythromycin and clindamycin come in a variety\n","of formulations and packaging: creams, lotions, ointments, gels and solutions. Solutions are available in dab-on applicators and pads, which are\n","packaged either individually or in bulk. The choice of formulation or packaging depends on the patient's complexion and preference. Many teenagers\n","enjoy the convenience of the pad preparations. Sodium sulfacetamide is a sulfonamide, which is thought to inhibit the growth of P. acnes through\n","competitive antagonism of para-aminobenzoic acid, an essential requirement for bacterial growth. Sodium sulfacetamide (10%) is available in\n","combination with sulfur (5%) in a prescription lotion, either with or without tint. Topical tetracycline is available in Italy, but not the UK or USA.\n","Antibiotic resistance. Since the 1970s, P. acnes has developed resistance to both topical and oral antibiotics. It is important to bear this in mind\n","when prescribing antibiotics. acnes resistance has been shown to affect clinical outcomes of acne treatment. In addition, overuse of antibiotics can\n","drive resistance in other commensal bacteria. For these reasons, the use of topical antibiotics as single agents for acne is to be discouraged.\n","Topical retinoids and BPO are useful as first-line agents. Any regimen containing an antibiotic (topical or oral), including a topical\n","antibiotic/retinoid combination should be combined with BPO.\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical therapy should be selected to help achieve medical adherence. Realistic\n","expectations of therapy should be explained. Combining therapies or using fixed combination topical products improves efficacy by targeting more than\n","one pathogenic feature and enhancing treatment adherence. Topical antibiotics can lead to the development of antimicrobial resistance. Topical\n","antibiotics should not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Any regimen containing\n","an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent\n","the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n","Salicylic acid, a beta-hydroxy acid, is keratolytic and an irritant. It may promote the resolution of inflammatory lesions through its drying effect.\n","Azelaic acid is a naturally occurring dicarboxylic acid found in cereal grains. It is available as a topical cream that has been shown to be effective\n","in inflammatory and comedonal acne. Topical antibiotics such as erythromycin, clindamycin and sodium sulfacetamide inhibit the growth of P. acnes and\n","reduce inflammatory lesions. Topical retinoids and BPO are useful as first-line agents. Any regimen containing an antibiotic (topical or oral),\n","including a topical antibiotic/retinoid combination should be combined with BPO.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') chunk 4\n","\n","Text:\n","Combination products. Recent advances in topical acne therapy include the development of fixed combination products that target more than one\n","pathogenic feature of the disease and may also increase treatment adherence among patients. Combination products that include BPO offer excellent\n","bactericidal effects and, when combined with erythromycin or clindamycin, offset the emergence of antibiotic-resistant P. acnes (see pages 51 and). A\n","fixed combination of BPO with adapalene targets three of the four pathogenic features of acne without the use of antibiotics. Other combinations\n","include topical tretinoin 0.025% with clindamycin 1%, tretinoin 0.025% with erythromycin 4% and topical isotretinoin 0.05% with erythromycin 2% (none\n","of these are available in the USA). Side effects. Local irritation. Most topical acne treatments, including salicylic acid, BPO and topical retinoids\n","will cause some degree of erythema, dryness and scaling of the skin. Contact dermatitis due to BPO has rarely been reported but should be considered\n","if treated areas develop an eczematous dermatitis. Use of topical antibiotics may also be associated with local irritation, but this tends to occur\n","less often than with other topical agents. The local side effects of topical retinoids include erythema, scaling, desquamation, burning or stinging,\n","pruritus and increased susceptibility to sunburn. Most patients will develop tolerance to the local side effects of topical retinoids within 3-4\n","weeks. If patients are unable to tolerate daily application of a topical retinoid, an alternate-day or every-third-day regimen can be followed until\n","tolerance develops. Topical retinoids are not recommended in pregnancy because of the theoretical risk of teratogenicity. Fortunately, studies have\n","shown that the risk of birth defects from topical tretinoin is unlikely. Pharmacokinetic studies have shown that serum retinoid levels may be\n","influenced more by diet than by facial application of topical tretinoin for acne. Epidemiological studies have failed to demonstrate an increased risk\n","of birth defects in infants whose mothers used topical retinoids on the face during the first trimester of pregnancy. There have, however, been\n","isolated case reports of birth defects in infants whose mothers used topical tretinoin during pregnancy. For this reason, it is recommended that\n","pregnant women cease using topical retinoids. Bleaching and staining. BPO can bleach clothing or bedding, particularly when it is applied to the chest\n","or back. It is therefore best to advise use of this medication at bedtime and to recommend covering the treated areas with an old shirt. Management of\n","side effects. Excessive dryness of the skin is one of the main reasons why patients discontinue topical treatment. Thus, recommendations regarding\n","effective ways of managing facial dryness should be an integral part of any acne treatment plan. Regular use of moisturizers is especially important,\n","but the clinician should be aware of the reluctance of many patients to use them because of concerns that moisturizers might worsen their acne. These\n","patients need reassurance that this is not the case: most moisturizers from reputable companies are tested for comedogenicity in clinical trials and\n","are labeled 'non-comedogenic'. Studies show that moisturizers applied before or after topical retinoids do not alter efficacy. Moisturizers are\n","available as creams and lotions; most patients prefer to use lotions as they are easy to apply and do not feel greasy. Lotions containing sunscreens\n","should be recommended, particularly in patients using topical retinoids. For recalcitrant dry areas, a heavier cream may be needed. Sunscreens are\n","important, as the sun can exacerbate facial irritation caused by topical acne medications. Some topical preparations make patients more\n","photosensitive. Thus, regular use of a sunscreen or a moisturizer containing a sunscreen is recommended to avoid sunburn as a side effect from\n","thinning of the stratum corneum by topical retinoids or phototoxicity from oral doxycycline. Alternative regimens. If irritation remains a problem\n","despite adequate use of moisturizers, the treatment regimen can be temporarily altered. For example, topical retinoids could be used every other day\n","or every third day until they are tolerated, or the duration of application could be gradually increased. The goal is to gradually increase the\n","frequency of application until the patient can tolerate daily application.\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical therapy should be selected to help achieve medical adherence. Realistic\n","expectations of therapy should be explained. Combining therapies or using fixed combination topical products improves efficacy by targeting more than\n","one pathogenic feature and enhancing treatment adherence. Topical antibiotics can lead to the development of antimicrobial resistance. Topical\n","antibiotics should not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Any regimen containing\n","an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent\n","the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n","Most topical acne treatments will cause some degree of erythema, dryness and scaling of the skin. Contact dermatitis due to BPO has rarely been\n","reported but should be considered if treated areas develop an eczematous dermatitis. Topical retinoids are not recommended in pregnancy because of the\n","theoretical risk of teratogenicity. Moisturizers are available as creams and lotions; most patients prefer to use lotions as they are easy to apply\n","and do not feel greasy. Lotions containing sunscreens should be recommended, particularly in patients using topical retinoids. For recalcitrant dry\n","areas, a heavier cream may be needed. Sunscreens are important, as the sun can exacerbate facial irritation caused by topical acne medications.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9') chunk 1\n","\n","Text:\n","Atrial flutter. Typical atrial flutter is a macro-entrant atrial rhythm, rotating counterclockwise, occasionally clockwise, within the right atrium\n","(see Figure 2.7). Most common is a circuit confined to the anterior portion of the right atrium with a 2:1 atrioventricular (AV) block - an atrial\n","rate of 300 bpm and a regular ventricular response of 150 bpm related directly to the atrial rate. A QRS rate of exactly 150 bpm should raise\n","suspicion of atrial flutter. Other than atrial fibrillation (AF), atrial flutter is the most common arrhythmia seen by cardiologists. Patients who\n","have had AF may present with atypical atrial flutter at a later stage; patients who have had congenital abnormalities corrected at an early age may\n","present with atypical atrial flutter up to 10-20 years later. In typical atrial flutter, the circuit is critically dependent on an area of slow\n","conduction known as the cavotricuspid isthmus (see Figure 2.7). Other rarer atypical forms occur, particularly in patients with scarring in the atrium\n","(exempli gratia after radiofrequency ablation [RFA] or previous heart surgery). Atrial flutter typically has a saw-tooth appearance of flutter waves\n","on the baseline in the 12-lead ECG (see Figure 2.7). Clinical presentation. Atrial flutter can be aysmptomatic or may present with breathlessness,\n","tiredness or frank heart failure. Persistent palpitations may be a feature. Anticoagulation therapy is based on the same risk factors as those for AF\n","(see Chapter 8). Pharmacological treatment. In acute cases, cardioversion can be performed with intravenous ibutilide, or, if there is no structural\n","heart disease, a class 1c antiarrhythmic agent, such as flecainide or propafenone, combined with a beta-blocker. Intravenous flecainide alone is\n","sometimes used in Europe (but not in the USA) to slow conduction in the flutter circuit more than in the AV node itself. However, in some cases this\n","may slow the atrial rate from 300 to 200 bpm and may allow the AV node to conduct in a 1:1 fashion, producing a paradoxical increase in the\n","ventricular rate to 200 bpm, which may be associated with hemodynamic compromise; flecainide is often combined with a beta-blocker to prevent the\n","flutter being conducted to the ventricle in this 1:1 manner. The same principle applies for both intravenous and oral flecainide. Oral sotalol is\n","often used in patients with atrial flutter, as it has the combined action of an antiarrhythmic and a beta-blocker, but QT considerations and renal\n","excretion limit its use in women and the elderly.\n","\n","Bullets:\n","Ablation for typical atrial flutter is highly successful and low risk, and should be considered first-line treatment. The risk of systemic\n","embolization in atrial flutter should be considered similar to that for atrial fibrillation (AF). Atypical atrial flutter usually includes right\n","atrial flutter circling around regions of scarring, or left atrial flutter following ablation of AF.\n","\n","Predicted Summary:\n","Atrial flutter is the most common arrhythmia seen by cardiologists. Patients who have had AF may present with atypical atrial flutter at a later\n","stage. Atrial flutter typically has a saw-tooth appearance of flutter waves on the baseline in the 12-lead ECG. Intravenous flecainide alone is\n","sometimes used in Europe (but not in the USA) to slow conduction in the flutter circuit more than in the AV node itself. Oral sotalol is often used in\n","patients with atrial flutter as it has the combined action of an antiarrhythmic and a beta-blocker, but QT considerations and renal excretion limit\n","its use in women and the elderly.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9') chunk 2\n","\n","Text:\n","In the chronic setting, atrial flutter often responds poorly to drug therapy. AV nodal-blocking drugs slow the ventricular response. Direct-current\n","(DC) cardioversion is highly effective for atrial flutter. However, persistent atrial flutter (lasting longer than 48 hours) is associated with\n","significant embolic risk, and management before cardioversion should be as for patients with AF - treatment with oral anticoagulant therapy (warfarin)\n","for 4 weeks before cardioversion and for at least 1 month afterwards (see Chapter 8). Alternatively, a transesophageal echocardiogram can be performed\n","in patients who are not taking warfarin, or in whom serial measurements of the international normalized ratio (INR) over a month have not been\n","documented, to exclude left atrial thrombus and enable immediate cardioversion. Patients are then started, or continued, on warfarin, while heparin or\n","low-molecular-weight heparin is given until the INR is greater than 2, continuing warfarin for 1 month or more. In the acute setting, flutter often\n","converts with a low-energy shock of about 50 J, sometimes as low as 25 J. Radiofrequency (catheter) ablation is recommended for long-term treatment.\n","RFA restores sinus rhythm by creating a linear destructive lesion, across which the circulating depolarizing wavefront cannot pass. This is known as a\n","line of block and is usually created at the inferior wall of the right atrium (Figure 7.1). This technique is in contrast to the ablation of accessory\n","or slow pathways, which require highly localized lesions. The procedure can be performed during constant atrial flutter or in sinus rhythm with pacing\n","from the atrium or coronary sinus. Success rates are greater than 90% in most centers. The cavotricuspid isthmus is not smooth throughout its length\n","and has regions of thick muscle bundles. Ablation of these areas is best achieved with technology capable of producing deep lesions, such as large-tip\n","or cooled radiofrequency energy. Newer techniques involving computerized mapping of the atria and catheter position are improving overall success.\n","Most centers are now performing ablation as first-line treatment. Apart from the usual complications associated with instrumentation of the venous\n","circulation, heart block or cardiac tamponade are rarely reported. After ablation, the prognosis for patients with typical atrial flutter is\n","excellent. In patients with atypical atrial flutter recurrences are more common because of scarring of the atria. Up to 30% of patients with either\n","type of atrial flutter develop AF late after a successful flutter ablation and may require further treatment; atrial flutter and AF often go together.\n","\n","Bullets:\n","Ablation for typical atrial flutter is highly successful and low risk, and should be considered first-line treatment. The risk of systemic\n","embolization in atrial flutter should be considered similar to that for atrial fibrillation (AF). Atypical atrial flutter usually includes right\n","atrial flutter circling around regions of scarring, or left atrial flutter following ablation of AF.\n","\n","Predicted Summary:\n"," direct-current (DC) cardioversion is highly effective for atrial flutter. persistent atrial flutter (lasting longer than 48 hours) is associated with\n","significant embolic risk. Radiofrequency (catheter) ablation is recommended for long-term treatment. Up to 30% of patients with either type of atrial\n","flutter develop AF late after a successful flutter ablation and may require further treatment. Atrial flutter and AF often go together. After\n","ablation, the prognosis for patients with typical atrial flutter is excellent. In patients with atypical atrial flutter recurrences are more common\n","because of scarring of the atria. Newer techniques involving computerized mapping of the atria and catheter position are improving overall success.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') chunk 1\n","\n","Text:\n","Cigarettes as a nicotine delivery system. The cigarette. There are many different varieties of cigarette tobacco, each with its own flavor and\n","characteristics, and tobacco can be prepared in different ways that affect its taste, smell and pharmacological properties. Additives are included in\n","cigarettes by the manufacturers to engineer an attractive and efficient nicotine delivery system. Table 1.1 lists some of the many thousands of\n","chemicals in tobacco smoke. One thing that all cigarettes have in common is that they deliver nicotine to the lungs. A puff on a cigarette results in\n","rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation\n","(Figure 1.1); this process is repeated with every puff. In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This\n","is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply. In societies in which\n","cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more nicotine\n","from each cigarette, confirming that nicotine is the sought-after substance in tobacco. Control of the nicotine dose. As a drug delivery system,\n","cigarettes are very flexible because smokers can control the intensity and frequency of puffing. This 'fingertip control' of the nicotine dose allows\n","smokers to meet their current need while avoiding the acute adverse effects of too much nicotine. Many smokers, particularly older smokers and women,\n","choose so-called 'light' or 'low-tar' brands, believing that these are safer. According to the reported analyses of their deliveries, these brands\n","deliver as little as one-tenth of the tar and carbon monoxide of other brands. In fact, such reports are misleading: the data are based on artificial\n","measurements by smoking machines and do not mirror the actual delivery to a smoker. It is possible to extract as much tar and nicotine from these\n","cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that would otherwise dilute the\n","smoke - and that is exactly what smokers usually do. Each smoker appears to have a preferred level of nicotine intake and will adjust the way he or\n","she smokes to achieve that level. Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette packaging and marketing in the USA\n","and EU. Smokers who reduce the number of cigarettes they smoke typically compensate for the change by increasing the intensity of smoking such that\n","smoke exposure remains unchanged. An exception is when they use another nicotine product at the same time, such as a nicotine patch or gum (see\n","Chapter 7). It also appears that if cigarette consumption drops below a threshold (perhaps around 5 cigarettes per day), or if the cigarettes are\n","designed to limit the potential for compensation (exempli gratia novel cigarettes in which the tobacco actually contains less nicotine), compensation\n","is very limited. Nicotine and its elimination from the body. Nicotine is an alkaloid obtained from tobacco plants and has wide-ranging effects on the\n","central nervous system (CNS) (see pages 37-8).\n","\n","Bullets:\n","Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff. Smokers absorb an average 1-2 mg of nicotine per cigarette (more\n","when cigarettes are smoked more intensively). Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide. Smokers' intake of tar\n","and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes. Nicotine is rapidly\n","metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a day of abstinence. The\n","nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva or\n","urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.\n","\n","Predicted Summary:\n","In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to one-third of what they could\n","obtain if they puffed more frequently and inhaled the smoke more deeply. Each smoker appears to have a preferred level of nicotine intake and will\n","adjust the way he or she smokes to achieve that level. Many smokers, particularly older smokers and women, choose so-called 'light' or 'low-tar'\n","brands, believing that these are safer. These brands deliver as little as one-tenth of the tar and carbon monoxide of other brands, according to\n","reports. The terms 'light' and 'low tar' have been banned from cigarette packaging and marketing in the USA and EU.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') chunk 2\n","\n","Text:\n","Its structure (Figure 1.2) resembles that of the major neurotransmitter acetylcholine, and it activates cholinergic receptors in the brain, which\n","accounts for many of the psychoactive effects. Once in the bloodstream, nicotine is distributed around the body, readily crossing cell membranes and\n","entering every tissue. It is eliminated quite rapidly, mainly through metabolism, but partly by excretion in urine. It is metabolized mostly to the\n","oxides cotinine and nicotine-1'-N-oxide. These appear to be largely inactive and are further metabolized and excreted in urine. The plasma\n","concentration of nicotine reduces by half every 90-120 minutes (its half-life; see Figure 1.1). Duration of withdrawal symptoms. All nicotine is\n","cleared from the body within a day or two of abstinence. Some people think that this must therefore be the period when smokers experience withdrawal\n","symptoms (see Chapter 5). However, the duration of withdrawal symptoms has nothing to do with this; it is related to how long it takes the body to get\n","used to not having nicotine in the system. The duration for most symptoms is 2-4 weeks. Estimating nicotine intake. Nicotine concentrations in the\n","blood could conceptually be a useful index of dependence, but its short half-life means that a single measure does not give a particularly accurate\n","picture of total intake over a day. Measurement of its metabolite, cotinine, is used instead. Cotinine has a half-life of 14-20 hours, so its\n","concentration in the blood is more stable than that of nicotine and it can be easily measured in saliva, urine or even hair. Saliva samples are simple\n","to obtain by means of a dental swab and are the method of choice for accurate estimation of daily nicotine intake. A daily nicotine intake of 16 mg\n","(approximately 16 cigarettes/day, or one every hour) corresponds on average to a saliva cotinine concentration of 200 ng/mL; a daily nicotine intake\n","of 10 mg generates a saliva cotinine concentration of about 125 ng/mL. These estimations are not the same for urine or blood measurements. Monoamine\n","oxidase inhibitors in cigarette smoke. There is evidence that cigarette smoke contains other psychoactive compounds which some now believe may\n","contribute to its addictive properties. Most notably, there is at least one monoamine oxidase inhibitor (MAOI). MAOIs reduce the rate at which\n","monoamine neurotransmitters such as dopamine are broken down and have been found to reduce depressive symptoms. In the case of smoking, they might\n","contribute to the rewarding effect of cigarette smoke or act synergistically with nicotine (which is primarily rewarding as it causes release of\n","dopamine in the nucleus accumbens - see Chapter 5). This may help explain why people who suffer from depression are particularly likely to smoke.\n","Research is in its early days, but if MAOIs play a role in cigarette addiction, pure nicotine delivery systems may be less addictive, even if they\n","deliver nicotine as rapidly as cigarettes.\n","\n","Bullets:\n","Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff. Smokers absorb an average 1-2 mg of nicotine per cigarette (more\n","when cigarettes are smoked more intensively). Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide. Smokers' intake of tar\n","and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes. Nicotine is rapidly\n","metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a day of abstinence. The\n","nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva or\n","urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.\n","\n","Predicted Summary:\n","All nicotine is cleared from the body within a day or two of abstinence. The duration of withdrawal symptoms is related to how long it takes the body\n","to get used to not having nicotine in the system. There is evidence that cigarette smoke contains other psychoactive compounds which some believe may\n","contribute to its addictive properties. Monoamine oxidase inhibitors (MAOIs) reduce the rate at which monoamine neurotransmitters such as dopamine are\n","broken down. MAOIs might contribute to the rewarding effect of cigarette smoke or act synergistically with nicotine. This may help explain why people\n","who suffer from depression are particularly likely to smoke. If MAOIs play a role in cigarette addiction, pure nicotine delivery systems may be less\n","addictive, even if they deliver nicotine as rapidly as cigarettes.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n"],"name":"stdout"}]},{"cell_type":"markdown","metadata":{"id":"0V7ebHe7M7mw"},"source":["Very similar to the baseline situation."]},{"cell_type":"markdown","metadata":{"id":"TKqXxUqnu2HR"},"source":["## **Assign Bullets**"]},{"cell_type":"markdown","metadata":{"id":"Q5cRG2NTwQeK"},"source":["### **Chunk Chapter (Baseline)**"]},{"cell_type":"markdown","metadata":{"id":"MqlsNBG9u2HW"},"source":["#### Loading data"]},{"cell_type":"code","metadata":{"id":"jHM1_DPeu2HZ","executionInfo":{"status":"ok","timestamp":1608648636688,"user_tz":-60,"elapsed":12291,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["input_path = drive_dir+'summarization/baseline_output/assign_bullets/'\n","df_base_assign = pd.read_csv(input_path+'df_summ_'+MODEL+'.csv')\n","df_base_assign = df_base_assign.set_index(['book', 'chapter'])\n","\n","df_base_assign.bullets = df_base_assign.bullets.map(eval)\n","df_base_assign.text = df_base_assign.text.map(eval)\n","df_base_assign.summary = df_base_assign.summary.map(eval)"],"execution_count":31,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"79qTAM8Pu2Hd"},"source":["#### Rouge"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/","height":0},"id":"BChoELbSu2Hg","executionInfo":{"status":"ok","timestamp":1608648637695,"user_tz":-60,"elapsed":13286,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"5aacc23d-bd55-4f02-faad-1aef70a6f8a1"},"source":["plot_rouge(df_base_assign, 'assign_bullets', 'rougeL', submethod='baseline')"],"execution_count":32,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 720x432 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"markdown","metadata":{"id":"bJP_unAY_Iaf"},"source":["#### Print Random Summaries"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"2ybuz4FP_Iak","executionInfo":{"status":"ok","timestamp":1608648637699,"user_tz":-60,"elapsed":13279,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"9b3e511b-3391-4620-8b78-16861e923057"},"source":["print_random_summaries(df_base_assign, RANDOM_IDS)"],"execution_count":33,"outputs":[{"output_type":"stream","text":["(9781908541994, 'ch05') bullet 1\n","\n","Text:\n","Topical therapy . Topical therapy is useful in nearly all acne regimens . mild localized acne . moderate acne; in combination with, and following,\n","oral therapy . maintenance therapy; after stopping systemic agents for severe acne . Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics . The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance . Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-\n","dose combination product to enhance adherence . Topical agents differ in their efficacy against the various etiologic factors . Retinoids, azelaic\n","acid and BPO are effective for comedones and inflammatory acne . Topical antibiotics such as erythromycin and clindamycin are most effective for\n","inflammatory lesions . Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions . It is important to note\n","that topical antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P . acnes) strains . Patients often\n","seek medical attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels . Active\n","ingredients include BPO, salicylic acid and alpha-hydroxy acids . Topical therapy is generally applied after washing the face and allowing it to dry\n","for 10-15 minutes . It is important to cover the entire affected area with a thin film of product, avoiding the eyes . Benzoyl peroxide . BPO is the\n","most potent agent against P . acnes, an obligate anaerobe that will not grow in the presence of oxygen . Unlike antibiotics, BPO is bactericidal\n","against P . acnes through its release of free oxygen radicals in sebaceous follicles . BPO therefore reduces bacterial colonization of the follicle\n","and kills both sensitive and resistant strains of P . acnes, which translates into a reduction in new inflammatory lesions . acnes does not develop\n","resistance to BPO; for this reason, the drug is a valuable component of any acne treatment regimen . BPO is mostly available in over-the-counter and\n","prescription formulations, including bar soaps, washes, gels and lotions . It is chiefly available in concentrations of 2.5%, 4%, 5% and 10% .\n","However, there is no evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the\n","2.5-5% concentrations . BPO is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene\n","(see page 52) . Topical retinoids and retinoid-like molecules . Topical retinoids are effective agents in the treatment of acne . Although\n","dermatologists readily prescribe them, topical retinoids are underutilized by pediatricians and general practitioners . Tretinoin, or all-trans-\n","retinoic acid, is a vitamin A derivative that reverses the altered keratinization in follicles affected by acne . By inhibiting the formation of the\n","microcomedone, tretinoin prevents the development of comedones and early inflammatory lesions . Tretinoin is available as a cream, gel or solution in\n","a variety of concentrations of differing potencies, which vary between countries . % gel / 0.05% cream . % gel / 0.1% cream .\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. Retinoids\n","and combination preparations can be used to treat non-inflammatory and inflammatory lesions.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 2\n","\n","Text:\n","Topical therapy . Topical therapy is useful in nearly all acne regimens . mild localized acne . moderate acne; in combination with, and following,\n","oral therapy . maintenance therapy; after stopping systemic agents for severe acne . Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics . The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance . Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-\n","dose combination product to enhance adherence . Topical agents differ in their efficacy against the various etiologic factors . Retinoids, azelaic\n","acid and BPO are effective for comedones and inflammatory acne . Topical antibiotics such as erythromycin and clindamycin are most effective for\n","inflammatory lesions . Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions . It is important to note\n","that topical antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P . acnes) strains . Patients often\n","seek medical attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels . Active\n","ingredients include BPO, salicylic acid and alpha-hydroxy acids . Topical therapy is generally applied after washing the face and allowing it to dry\n","for 10-15 minutes . It is important to cover the entire affected area with a thin film of product, avoiding the eyes . Benzoyl peroxide . BPO is the\n","most potent agent against P . acnes, an obligate anaerobe that will not grow in the presence of oxygen . Unlike antibiotics, BPO is bactericidal\n","against P . acnes through its release of free oxygen radicals in sebaceous follicles . BPO therefore reduces bacterial colonization of the follicle\n","and kills both sensitive and resistant strains of P . acnes, which translates into a reduction in new inflammatory lesions . acnes does not develop\n","resistance to BPO; for this reason, the drug is a valuable component of any acne treatment regimen . BPO is mostly available in over-the-counter and\n","prescription formulations, including bar soaps, washes, gels and lotions . It is chiefly available in concentrations of 2.5%, 4%, 5% and 10% .\n","However, there is no evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the\n","2.5-5% concentrations . BPO is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene\n","(see page 52) . Topical retinoids and retinoid-like molecules . Topical retinoids are effective agents in the treatment of acne . Although\n","dermatologists readily prescribe them, topical retinoids are underutilized by pediatricians and general practitioners . Tretinoin, or all-trans-\n","retinoic acid, is a vitamin A derivative that reverses the altered keratinization in follicles affected by acne . By inhibiting the formation of the\n","microcomedone, tretinoin prevents the development of comedones and early inflammatory lesions . Tretinoin is available as a cream, gel or solution in\n","a variety of concentrations of differing potencies, which vary between countries . % gel / 0.05% cream . % gel / 0.1% cream .\n","\n","Bullets:\n","Topical therapy should be selected to help achieve medical adherence. Realistic expectations of therapy should be explained.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. Retinoids\n","and combination preparations can be used to treat non-inflammatory and inflammatory lesions.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 3\n","\n","Text:\n","Topical therapy . Topical therapy is useful in nearly all acne regimens . mild localized acne . moderate acne; in combination with, and following,\n","oral therapy . maintenance therapy; after stopping systemic agents for severe acne . Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics . The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance . Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-\n","dose combination product to enhance adherence . Topical agents differ in their efficacy against the various etiologic factors . Retinoids, azelaic\n","acid and BPO are effective for comedones and inflammatory acne . Topical antibiotics such as erythromycin and clindamycin are most effective for\n","inflammatory lesions . Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions . It is important to note\n","that topical antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P . acnes) strains . Patients often\n","seek medical attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels . Active\n","ingredients include BPO, salicylic acid and alpha-hydroxy acids . Topical therapy is generally applied after washing the face and allowing it to dry\n","for 10-15 minutes . It is important to cover the entire affected area with a thin film of product, avoiding the eyes . Benzoyl peroxide . BPO is the\n","most potent agent against P . acnes, an obligate anaerobe that will not grow in the presence of oxygen . Unlike antibiotics, BPO is bactericidal\n","against P . acnes through its release of free oxygen radicals in sebaceous follicles . BPO therefore reduces bacterial colonization of the follicle\n","and kills both sensitive and resistant strains of P . acnes, which translates into a reduction in new inflammatory lesions . acnes does not develop\n","resistance to BPO; for this reason, the drug is a valuable component of any acne treatment regimen . BPO is mostly available in over-the-counter and\n","prescription formulations, including bar soaps, washes, gels and lotions . It is chiefly available in concentrations of 2.5%, 4%, 5% and 10% .\n","However, there is no evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the\n","2.5-5% concentrations . BPO is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene\n","(see page 52) . Topical retinoids and retinoid-like molecules . Topical retinoids are effective agents in the treatment of acne . Although\n","dermatologists readily prescribe them, topical retinoids are underutilized by pediatricians and general practitioners . Tretinoin, or all-trans-\n","retinoic acid, is a vitamin A derivative that reverses the altered keratinization in follicles affected by acne . By inhibiting the formation of the\n","microcomedone, tretinoin prevents the development of comedones and early inflammatory lesions . Tretinoin is available as a cream, gel or solution in\n","a variety of concentrations of differing potencies, which vary between countries . % gel / 0.05% cream . % gel / 0.1% cream .\n","\n","Bullets:\n","Topical antibiotics can lead to the development of antimicrobial resistance.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. Retinoids\n","and combination preparations can be used to treat non-inflammatory and inflammatory lesions.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 4\n","\n","Text:\n","Topical therapy . Topical therapy is useful in nearly all acne regimens . mild localized acne . moderate acne; in combination with, and following,\n","oral therapy . maintenance therapy; after stopping systemic agents for severe acne . Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics . The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance . Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-\n","dose combination product to enhance adherence . Topical agents differ in their efficacy against the various etiologic factors . Retinoids, azelaic\n","acid and BPO are effective for comedones and inflammatory acne . Topical antibiotics such as erythromycin and clindamycin are most effective for\n","inflammatory lesions . Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions . It is important to note\n","that topical antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P . acnes) strains . Patients often\n","seek medical attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels . Active\n","ingredients include BPO, salicylic acid and alpha-hydroxy acids . Topical therapy is generally applied after washing the face and allowing it to dry\n","for 10-15 minutes . It is important to cover the entire affected area with a thin film of product, avoiding the eyes . Benzoyl peroxide . BPO is the\n","most potent agent against P . acnes, an obligate anaerobe that will not grow in the presence of oxygen . Unlike antibiotics, BPO is bactericidal\n","against P . acnes through its release of free oxygen radicals in sebaceous follicles . BPO therefore reduces bacterial colonization of the follicle\n","and kills both sensitive and resistant strains of P . acnes, which translates into a reduction in new inflammatory lesions . acnes does not develop\n","resistance to BPO; for this reason, the drug is a valuable component of any acne treatment regimen . BPO is mostly available in over-the-counter and\n","prescription formulations, including bar soaps, washes, gels and lotions . It is chiefly available in concentrations of 2.5%, 4%, 5% and 10% .\n","However, there is no evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the\n","2.5-5% concentrations . BPO is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene\n","(see page 52) . Topical retinoids and retinoid-like molecules . Topical retinoids are effective agents in the treatment of acne . Although\n","dermatologists readily prescribe them, topical retinoids are underutilized by pediatricians and general practitioners . Tretinoin, or all-trans-\n","retinoic acid, is a vitamin A derivative that reverses the altered keratinization in follicles affected by acne . By inhibiting the formation of the\n","microcomedone, tretinoin prevents the development of comedones and early inflammatory lesions . Tretinoin is available as a cream, gel or solution in\n","a variety of concentrations of differing potencies, which vary between countries . % gel / 0.05% cream . % gel / 0.1% cream .\n","\n","Bullets:\n","Topical antibiotics should not be used as single agents for the treatment of acne.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. Retinoids\n","and combination preparations can be used to treat non-inflammatory and inflammatory lesions.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 5\n","\n","Text:\n","Topical therapy . Topical therapy is useful in nearly all acne regimens . mild localized acne . moderate acne; in combination with, and following,\n","oral therapy . maintenance therapy; after stopping systemic agents for severe acne . Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics . The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance . Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-\n","dose combination product to enhance adherence . Topical agents differ in their efficacy against the various etiologic factors . Retinoids, azelaic\n","acid and BPO are effective for comedones and inflammatory acne . Topical antibiotics such as erythromycin and clindamycin are most effective for\n","inflammatory lesions . Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions . It is important to note\n","that topical antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P . acnes) strains . Patients often\n","seek medical attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels . Active\n","ingredients include BPO, salicylic acid and alpha-hydroxy acids . Topical therapy is generally applied after washing the face and allowing it to dry\n","for 10-15 minutes . It is important to cover the entire affected area with a thin film of product, avoiding the eyes . Benzoyl peroxide . BPO is the\n","most potent agent against P . acnes, an obligate anaerobe that will not grow in the presence of oxygen . Unlike antibiotics, BPO is bactericidal\n","against P . acnes through its release of free oxygen radicals in sebaceous follicles . BPO therefore reduces bacterial colonization of the follicle\n","and kills both sensitive and resistant strains of P . acnes, which translates into a reduction in new inflammatory lesions . acnes does not develop\n","resistance to BPO; for this reason, the drug is a valuable component of any acne treatment regimen . BPO is mostly available in over-the-counter and\n","prescription formulations, including bar soaps, washes, gels and lotions . It is chiefly available in concentrations of 2.5%, 4%, 5% and 10% .\n","However, there is no evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the\n","2.5-5% concentrations . BPO is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene\n","(see page 52) . Topical retinoids and retinoid-like molecules . Topical retinoids are effective agents in the treatment of acne . Although\n","dermatologists readily prescribe them, topical retinoids are underutilized by pediatricians and general practitioners . Tretinoin, or all-trans-\n","retinoic acid, is a vitamin A derivative that reverses the altered keratinization in follicles affected by acne . By inhibiting the formation of the\n","microcomedone, tretinoin prevents the development of comedones and early inflammatory lesions . Tretinoin is available as a cream, gel or solution in\n","a variety of concentrations of differing potencies, which vary between countries . % gel / 0.05% cream . % gel / 0.1% cream .\n","\n","Bullets:\n","Topical retinoids are useful as first-line agents.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. Retinoids\n","and combination preparations can be used to treat non-inflammatory and inflammatory lesions.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 6\n","\n","Text:\n","alpha -hydroxy acids such as lactic acid, glycolic acid and citric acid are available in a variety of cosmetic preparations, including cleansers,\n","toners, moisturizers and chemical peels . alpha-hydroxy acids are thought to reverse the altered keratinization of follicles affected by acne and\n","improve the appearance of the skin by promoting desquamation of the stratum corneum . The effectiveness of alpha-hydroxy acids in acne, however, has\n","not yet been demonstrated in controlled clinical trials . Azelaic acid is a naturally occurring dicarboxylic acid found in cereal grains . It is\n","available as a topical cream that has been shown to be effective in inflammatory and comedonal acne . By inhibiting the growth of P . acnes, azelaic\n","acid reduces inflammatory acne . It also reverses the altered keratinization of follicles seen in acne and thus demonstrates comedolytic activity .\n","Azelaic acid can affect melanosomes and has been used to treat postinflammatory hyperpigmentation . Azelaic acid is reported to have fewer local side\n","effects than topical retinoids . Topical antibiotics . Topical antibiotics such as erythromycin, clindamycin and sodium sulfacetamide inhibit the\n","growth of P . acnes and reduce inflammatory lesions . Products containing these antibiotics are often applied twice daily and are generally well\n","tolerated . Topical antibiotics such as erythromycin and clindamycin come in a variety of formulations and packaging: creams, lotions, ointments, gels\n","and solutions . Solutions are available in dab-on applicators and pads, which are packaged either individually or in bulk . The choice of formulation\n","or packaging depends on the patient's complexion and preference . Many teenagers enjoy the convenience of the pad preparations . Sodium sulfacetamide\n","is a sulfonamide, which is thought to inhibit the growth of P . acnes through competitive antagonism of para-aminobenzoic acid, an essential\n","requirement for bacterial growth . Sodium sulfacetamide (10%) is available in combination with sulfur (5%) in a prescription lotion, either with or\n","without tint . Topical tetracycline is available in Italy, but not the UK or USA . Antibiotic resistance . Since the 1970s, P . acnes has developed\n","resistance to both topical and oral antibiotics . It is important to bear this in mind when prescribing antibiotics . acnes resistance has been shown\n","to affect clinical outcomes of acne treatment . In addition, overuse of antibiotics can drive resistance in other commensal bacteria . For these\n","reasons, the use of topical antibiotics as single agents for acne is to be discouraged . Topical retinoids and BPO are useful as first-line agents .\n","Any regimen containing an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with BPO . Combination\n","products . Recent advances in topical acne therapy include the development of fixed combination products that target more than one pathogenic feature\n","of the disease and may also increase treatment adherence among patients . Combination products that include BPO offer excellent bactericidal effects\n","and, when combined with erythromycin or clindamycin, offset the emergence of antibiotic-resistant P . acnes (see pages 51 and) . A fixed combination\n","of BPO with adapalene targets three of the four pathogenic features of acne without the use of antibiotics . Other combinations include topical\n","tretinoin 0.025% with clindamycin 1%, tretinoin 0.025% with erythromycin 4% and topical isotretinoin 0.05% with erythromycin 2% (none of these are\n","available in the USA) .\n","\n","Bullets:\n","Combining therapies or using fixed combination topical products improves efficacy by targeting more than one pathogenic feature and enhancing\n","treatment adherence.\n","\n","Predicted Summary:\n"," alpha-hydroxy acids are thought to reverse the altered keratinization of follicles affected by acne. Azelaic acid is a naturally occurring\n","dicarboxylic acid found in cereal grains. Topical antibiotics such as erythromycin, clindamycin and sodium sulfacetamide inhibit the growth of P.\n","acnes and reduce inflammatory lesions.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 7\n","\n","Text:\n","alpha -hydroxy acids such as lactic acid, glycolic acid and citric acid are available in a variety of cosmetic preparations, including cleansers,\n","toners, moisturizers and chemical peels . alpha-hydroxy acids are thought to reverse the altered keratinization of follicles affected by acne and\n","improve the appearance of the skin by promoting desquamation of the stratum corneum . The effectiveness of alpha-hydroxy acids in acne, however, has\n","not yet been demonstrated in controlled clinical trials . Azelaic acid is a naturally occurring dicarboxylic acid found in cereal grains . It is\n","available as a topical cream that has been shown to be effective in inflammatory and comedonal acne . By inhibiting the growth of P . acnes, azelaic\n","acid reduces inflammatory acne . It also reverses the altered keratinization of follicles seen in acne and thus demonstrates comedolytic activity .\n","Azelaic acid can affect melanosomes and has been used to treat postinflammatory hyperpigmentation . Azelaic acid is reported to have fewer local side\n","effects than topical retinoids . Topical antibiotics . Topical antibiotics such as erythromycin, clindamycin and sodium sulfacetamide inhibit the\n","growth of P . acnes and reduce inflammatory lesions . Products containing these antibiotics are often applied twice daily and are generally well\n","tolerated . Topical antibiotics such as erythromycin and clindamycin come in a variety of formulations and packaging: creams, lotions, ointments, gels\n","and solutions . Solutions are available in dab-on applicators and pads, which are packaged either individually or in bulk . The choice of formulation\n","or packaging depends on the patient's complexion and preference . Many teenagers enjoy the convenience of the pad preparations . Sodium sulfacetamide\n","is a sulfonamide, which is thought to inhibit the growth of P . acnes through competitive antagonism of para-aminobenzoic acid, an essential\n","requirement for bacterial growth . Sodium sulfacetamide (10%) is available in combination with sulfur (5%) in a prescription lotion, either with or\n","without tint . Topical tetracycline is available in Italy, but not the UK or USA . Antibiotic resistance . Since the 1970s, P . acnes has developed\n","resistance to both topical and oral antibiotics . It is important to bear this in mind when prescribing antibiotics . acnes resistance has been shown\n","to affect clinical outcomes of acne treatment . In addition, overuse of antibiotics can drive resistance in other commensal bacteria . For these\n","reasons, the use of topical antibiotics as single agents for acne is to be discouraged . Topical retinoids and BPO are useful as first-line agents .\n","Any regimen containing an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with BPO . Combination\n","products . Recent advances in topical acne therapy include the development of fixed combination products that target more than one pathogenic feature\n","of the disease and may also increase treatment adherence among patients . Combination products that include BPO offer excellent bactericidal effects\n","and, when combined with erythromycin or clindamycin, offset the emergence of antibiotic-resistant P . acnes (see pages 51 and) . A fixed combination\n","of BPO with adapalene targets three of the four pathogenic features of acne without the use of antibiotics . Other combinations include topical\n","tretinoin 0.025% with clindamycin 1%, tretinoin 0.025% with erythromycin 4% and topical isotretinoin 0.05% with erythromycin 2% (none of these are\n","available in the USA) .\n","\n","Bullets:\n","Any regimen containing an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide\n","to reduce and prevent the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n"," alpha-hydroxy acids are thought to reverse the altered keratinization of follicles affected by acne. Azelaic acid is a naturally occurring\n","dicarboxylic acid found in cereal grains. Topical antibiotics such as erythromycin, clindamycin and sodium sulfacetamide inhibit the growth of P.\n","acnes and reduce inflammatory lesions.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05')\n","\n","All Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical therapy should be selected to help achieve medical adherence. Realistic\n","expectations of therapy should be explained. Topical antibiotics can lead to the development of antimicrobial resistance. Topical antibiotics should\n","not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Combining therapies or using fixed\n","combination topical products improves efficacy by targeting more than one pathogenic feature and enhancing treatment adherence. Any regimen containing\n","an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent\n","the development of antibiotic-resistant strains of P. acnes.\n","\n","All Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. Retinoids\n","and combination preparations can be used to treat non-inflammatory and inflammatory lesions. Topical therapy is useful in nearly all acne regimens.\n","Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. Retinoids and combination preparations can be used to treat non-\n","inflammatory and inflammatory lesions. Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for\n","comedones and inflammatory acne. Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions. Topical\n","therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. Retinoids and\n","combination preparations can be used to treat non-inflammatory and inflammatory lesions. Topical therapy is useful in nearly all acne regimens.\n","Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. Retinoids and combination preparations can be used to treat non-\n","inflammatory and inflammatory lesions.  alpha-hydroxy acids are thought to reverse the altered keratinization of follicles affected by acne. Azelaic\n","acid is a naturally occurring dicarboxylic acid found in cereal grains. Topical antibiotics such as erythromycin, clindamycin and sodium sulfacetamide\n","inhibit the growth of P. acnes and reduce inflammatory lesions.  alpha-hydroxy acids are thought to reverse the altered keratinization of follicles\n","affected by acne. Azelaic acid is a naturally occurring dicarboxylic acid found in cereal grains. Topical antibiotics such as erythromycin,\n","clindamycin and sodium sulfacetamide inhibit the growth of P. acnes and reduce inflammatory lesions.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9') bullet 1\n","\n","Text:\n","Atrial flutter . Typical atrial flutter is a macro-entrant atrial rhythm, rotating counterclockwise, occasionally clockwise, within the right atrium\n","(see Figure 2.7) . Most common is a circuit confined to the anterior portion of the right atrium with a 2:1 atrioventricular (AV) block - an atrial\n","rate of 300 bpm and a regular ventricular response of 150 bpm related directly to the atrial rate . A QRS rate of exactly 150 bpm should raise\n","suspicion of atrial flutter . Other than atrial fibrillation (AF), atrial flutter is the most common arrhythmia seen by cardiologists . Patients who\n","have had AF may present with atypical atrial flutter at a later stage; patients who have had congenital abnormalities corrected at an early age may\n","present with atypical atrial flutter up to 10-20 years later . In typical atrial flutter, the circuit is critically dependent on an area of slow\n","conduction known as the cavotricuspid isthmus (see Figure 2.7) . Other rarer atypical forms occur, particularly in patients with scarring in the\n","atrium (exempli gratia after radiofrequency ablation [RFA] or previous heart surgery) . Atrial flutter typically has a saw-tooth appearance of flutter\n","waves on the baseline in the 12-lead ECG (see Figure 2.7) . Clinical presentation . Atrial flutter can be aysmptomatic or may present with\n","breathlessness, tiredness or frank heart failure . Persistent palpitations may be a feature . Anticoagulation therapy is based on the same risk\n","factors as those for AF (see Chapter 8) . Pharmacological treatment . In acute cases, cardioversion can be performed with intravenous ibutilide, or,\n","if there is no structural heart disease, a class 1c antiarrhythmic agent, such as flecainide or propafenone, combined with a beta-blocker .\n","Intravenous flecainide alone is sometimes used in Europe (but not in the USA) to slow conduction in the flutter circuit more than in the AV node\n","itself . However, in some cases this may slow the atrial rate from 300 to 200 bpm and may allow the AV node to conduct in a 1:1 fashion, producing a\n","paradoxical increase in the ventricular rate to 200 bpm, which may be associated with hemodynamic compromise; flecainide is often combined with a\n","beta-blocker to prevent the flutter being conducted to the ventricle in this 1:1 manner . The same principle applies for both intravenous and oral\n","flecainide . Oral sotalol is often used in patients with atrial flutter, as it has the combined action of an antiarrhythmic and a beta-blocker, but QT\n","considerations and renal excretion limit its use in women and the elderly .\n","\n","Bullets:\n","The risk of systemic embolization in atrial flutter should be considered similar to that for atrial fibrillation (AF).\n","\n","Predicted Summary:\n","Atrial flutter is the most common arrhythmia seen by cardiologists. Patients who have had AF may present with atypical atrial flutter at a later\n","stage. Atrial flutter typically has a saw-tooth appearance of flutter waves in the 12-lead ECG.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9') bullet 2\n","\n","Text:\n","In the chronic setting, atrial flutter often responds poorly to drug therapy . AV nodal-blocking drugs slow the ventricular response . Direct-current\n","(DC) cardioversion is highly effective for atrial flutter . However, persistent atrial flutter (lasting longer than 48 hours) is associated with\n","significant embolic risk, and management before cardioversion should be as for patients with AF - treatment with oral anticoagulant therapy (warfarin)\n","for 4 weeks before cardioversion and for at least 1 month afterwards (see Chapter 8) . Alternatively, a transesophageal echocardiogram can be\n","performed in patients who are not taking warfarin, or in whom serial measurements of the international normalized ratio (INR) over a month have not\n","been documented, to exclude left atrial thrombus and enable immediate cardioversion . Patients are then started, or continued, on warfarin, while\n","heparin or low-molecular-weight heparin is given until the INR is greater than 2, continuing warfarin for 1 month or more . In the acute setting,\n","flutter often converts with a low-energy shock of about 50 J, sometimes as low as 25 J . Radiofrequency (catheter) ablation is recommended for long-\n","term treatment . RFA restores sinus rhythm by creating a linear destructive lesion, across which the circulating depolarizing wavefront cannot pass .\n","This is known as a line of block and is usually created at the inferior wall of the right atrium (Figure 7.1) . This technique is in contrast to the\n","ablation of accessory or slow pathways, which require highly localized lesions . The procedure can be performed during constant atrial flutter or in\n","sinus rhythm with pacing from the atrium or coronary sinus . Success rates are greater than 90% in most centers . The cavotricuspid isthmus is not\n","smooth throughout its length and has regions of thick muscle bundles . Ablation of these areas is best achieved with technology capable of producing\n","deep lesions, such as large-tip or cooled radiofrequency energy . Newer techniques involving computerized mapping of the atria and catheter position\n","are improving overall success . Most centers are now performing ablation as first-line treatment . Apart from the usual complications associated with\n","instrumentation of the venous circulation, heart block or cardiac tamponade are rarely reported . After ablation, the prognosis for patients with\n","typical atrial flutter is excellent . In patients with atypical atrial flutter recurrences are more common because of scarring of the atria . Up to\n","30% of patients with either type of atrial flutter develop AF late after a successful flutter ablation and may require further treatment; atrial\n","flutter and AF often go together .\n","\n","Bullets:\n","Ablation for typical atrial flutter is highly successful and low risk, and should be considered first-line treatment.\n","\n","Predicted Summary:\n"," direct-current (DC) cardioversion is highly effective for atrial flutter. Radiofrequency (catheter) ablation is recommended for long-term treatment.\n","Success rates are greater than 90% in most centers.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9') bullet 3\n","\n","Text:\n","In the chronic setting, atrial flutter often responds poorly to drug therapy . AV nodal-blocking drugs slow the ventricular response . Direct-current\n","(DC) cardioversion is highly effective for atrial flutter . However, persistent atrial flutter (lasting longer than 48 hours) is associated with\n","significant embolic risk, and management before cardioversion should be as for patients with AF - treatment with oral anticoagulant therapy (warfarin)\n","for 4 weeks before cardioversion and for at least 1 month afterwards (see Chapter 8) . Alternatively, a transesophageal echocardiogram can be\n","performed in patients who are not taking warfarin, or in whom serial measurements of the international normalized ratio (INR) over a month have not\n","been documented, to exclude left atrial thrombus and enable immediate cardioversion . Patients are then started, or continued, on warfarin, while\n","heparin or low-molecular-weight heparin is given until the INR is greater than 2, continuing warfarin for 1 month or more . In the acute setting,\n","flutter often converts with a low-energy shock of about 50 J, sometimes as low as 25 J . Radiofrequency (catheter) ablation is recommended for long-\n","term treatment . RFA restores sinus rhythm by creating a linear destructive lesion, across which the circulating depolarizing wavefront cannot pass .\n","This is known as a line of block and is usually created at the inferior wall of the right atrium (Figure 7.1) . This technique is in contrast to the\n","ablation of accessory or slow pathways, which require highly localized lesions . The procedure can be performed during constant atrial flutter or in\n","sinus rhythm with pacing from the atrium or coronary sinus . Success rates are greater than 90% in most centers . The cavotricuspid isthmus is not\n","smooth throughout its length and has regions of thick muscle bundles . Ablation of these areas is best achieved with technology capable of producing\n","deep lesions, such as large-tip or cooled radiofrequency energy . Newer techniques involving computerized mapping of the atria and catheter position\n","are improving overall success . Most centers are now performing ablation as first-line treatment . Apart from the usual complications associated with\n","instrumentation of the venous circulation, heart block or cardiac tamponade are rarely reported . After ablation, the prognosis for patients with\n","typical atrial flutter is excellent . In patients with atypical atrial flutter recurrences are more common because of scarring of the atria . Up to\n","30% of patients with either type of atrial flutter develop AF late after a successful flutter ablation and may require further treatment; atrial\n","flutter and AF often go together .\n","\n","Bullets:\n","Atypical atrial flutter usually includes right atrial flutter circling around regions of scarring, or left atrial flutter following ablation of AF.\n","\n","Predicted Summary:\n"," direct-current (DC) cardioversion is highly effective for atrial flutter. Radiofrequency (catheter) ablation is recommended for long-term treatment.\n","Success rates are greater than 90% in most centers.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9')\n","\n","All Bullets:\n","The risk of systemic embolization in atrial flutter should be considered similar to that for atrial fibrillation (AF). Ablation for typical atrial\n","flutter is highly successful and low risk, and should be considered first-line treatment. Atypical atrial flutter usually includes right atrial\n","flutter circling around regions of scarring, or left atrial flutter following ablation of AF.\n","\n","All Predicted Summary:\n","Atrial flutter is the most common arrhythmia seen by cardiologists. Patients who have had AF may present with atypical atrial flutter at a later\n","stage. Atrial flutter typically has a saw-tooth appearance of flutter waves in the 12-lead ECG.  direct-current (DC) cardioversion is highly effective\n","for atrial flutter. Radiofrequency (catheter) ablation is recommended for long-term treatment. Success rates are greater than 90% in most centers.\n","direct-current (DC) cardioversion is highly effective for atrial flutter. Radiofrequency (catheter) ablation is recommended for long-term treatment.\n","Success rates are greater than 90% in most centers.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 1\n","\n","Text:\n","Cigarettes as a nicotine delivery system . The cigarette . There are many different varieties of cigarette tobacco, each with its own flavor and\n","characteristics, and tobacco can be prepared in different ways that affect its taste, smell and pharmacological properties . Additives are included in\n","cigarettes by the manufacturers to engineer an attractive and efficient nicotine delivery system . Table 1.1 lists some of the many thousands of\n","chemicals in tobacco smoke . One thing that all cigarettes have in common is that they deliver nicotine to the lungs . A puff on a cigarette results\n","in rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation\n","(Figure 1.1); this process is repeated with every puff . In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette .\n","This is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply . In societies in\n","which cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more\n","nicotine from each cigarette, confirming that nicotine is the sought-after substance in tobacco . Control of the nicotine dose . As a drug delivery\n","system, cigarettes are very flexible because smokers can control the intensity and frequency of puffing . This 'fingertip control' of the nicotine\n","dose allows smokers to meet their current need while avoiding the acute adverse effects of too much nicotine . Many smokers, particularly older\n","smokers and women, choose so-called 'light' or 'low-tar' brands, believing that these are safer . According to the reported analyses of their\n","deliveries, these brands deliver as little as one-tenth of the tar and carbon monoxide of other brands . In fact, such reports are misleading: the\n","data are based on artificial measurements by smoking machines and do not mirror the actual delivery to a smoker . It is possible to extract as much\n","tar and nicotine from these cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that\n","would otherwise dilute the smoke - and that is exactly what smokers usually do . Each smoker appears to have a preferred level of nicotine intake and\n","will adjust the way he or she smokes to achieve that level . Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette\n","packaging and marketing in the USA and EU . Smokers who reduce the number of cigarettes they smoke typically compensate for the change by increasing\n","the intensity of smoking such that smoke exposure remains unchanged . An exception is when they use another nicotine product at the same time, such as\n","a nicotine patch or gum (see Chapter 7) . It also appears that if cigarette consumption drops below a threshold (perhaps around 5 cigarettes per day),\n","or if the cigarettes are designed to limit the potential for compensation (exempli gratia novel cigarettes in which the tobacco actually contains less\n","nicotine), compensation is very limited . Nicotine and its elimination from the body . Nicotine is an alkaloid obtained from tobacco plants and has\n","wide-ranging effects on the central nervous system (CNS) (see pages 37-8) .\n","\n","Bullets:\n","Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff.\n","\n","Predicted Summary:\n","Cigarettes are very flexible because smokers can control the intensity and frequency of puffing. This 'fingertip control' of the nicotine dose allows\n","smokers to meet their current need while avoiding the acute adverse effects of too much nicotine. Each smoker appears to have a preferred level of\n","nicotine intake and will adjust the way he or she smokes to achieve that level.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 2\n","\n","Text:\n","Cigarettes as a nicotine delivery system . The cigarette . There are many different varieties of cigarette tobacco, each with its own flavor and\n","characteristics, and tobacco can be prepared in different ways that affect its taste, smell and pharmacological properties . Additives are included in\n","cigarettes by the manufacturers to engineer an attractive and efficient nicotine delivery system . Table 1.1 lists some of the many thousands of\n","chemicals in tobacco smoke . One thing that all cigarettes have in common is that they deliver nicotine to the lungs . A puff on a cigarette results\n","in rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation\n","(Figure 1.1); this process is repeated with every puff . In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette .\n","This is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply . In societies in\n","which cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more\n","nicotine from each cigarette, confirming that nicotine is the sought-after substance in tobacco . Control of the nicotine dose . As a drug delivery\n","system, cigarettes are very flexible because smokers can control the intensity and frequency of puffing . This 'fingertip control' of the nicotine\n","dose allows smokers to meet their current need while avoiding the acute adverse effects of too much nicotine . Many smokers, particularly older\n","smokers and women, choose so-called 'light' or 'low-tar' brands, believing that these are safer . According to the reported analyses of their\n","deliveries, these brands deliver as little as one-tenth of the tar and carbon monoxide of other brands . In fact, such reports are misleading: the\n","data are based on artificial measurements by smoking machines and do not mirror the actual delivery to a smoker . It is possible to extract as much\n","tar and nicotine from these cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that\n","would otherwise dilute the smoke - and that is exactly what smokers usually do . Each smoker appears to have a preferred level of nicotine intake and\n","will adjust the way he or she smokes to achieve that level . Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette\n","packaging and marketing in the USA and EU . Smokers who reduce the number of cigarettes they smoke typically compensate for the change by increasing\n","the intensity of smoking such that smoke exposure remains unchanged . An exception is when they use another nicotine product at the same time, such as\n","a nicotine patch or gum (see Chapter 7) . It also appears that if cigarette consumption drops below a threshold (perhaps around 5 cigarettes per day),\n","or if the cigarettes are designed to limit the potential for compensation (exempli gratia novel cigarettes in which the tobacco actually contains less\n","nicotine), compensation is very limited . Nicotine and its elimination from the body . Nicotine is an alkaloid obtained from tobacco plants and has\n","wide-ranging effects on the central nervous system (CNS) (see pages 37-8) .\n","\n","Bullets:\n","Smokers absorb an average 1-2 mg of nicotine per cigarette (more when cigarettes are smoked more intensively).\n","\n","Predicted Summary:\n","Cigarettes are very flexible because smokers can control the intensity and frequency of puffing. This 'fingertip control' of the nicotine dose allows\n","smokers to meet their current need while avoiding the acute adverse effects of too much nicotine. Each smoker appears to have a preferred level of\n","nicotine intake and will adjust the way he or she smokes to achieve that level.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 3\n","\n","Text:\n","Cigarettes as a nicotine delivery system . The cigarette . There are many different varieties of cigarette tobacco, each with its own flavor and\n","characteristics, and tobacco can be prepared in different ways that affect its taste, smell and pharmacological properties . Additives are included in\n","cigarettes by the manufacturers to engineer an attractive and efficient nicotine delivery system . Table 1.1 lists some of the many thousands of\n","chemicals in tobacco smoke . One thing that all cigarettes have in common is that they deliver nicotine to the lungs . A puff on a cigarette results\n","in rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation\n","(Figure 1.1); this process is repeated with every puff . In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette .\n","This is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply . In societies in\n","which cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more\n","nicotine from each cigarette, confirming that nicotine is the sought-after substance in tobacco . Control of the nicotine dose . As a drug delivery\n","system, cigarettes are very flexible because smokers can control the intensity and frequency of puffing . This 'fingertip control' of the nicotine\n","dose allows smokers to meet their current need while avoiding the acute adverse effects of too much nicotine . Many smokers, particularly older\n","smokers and women, choose so-called 'light' or 'low-tar' brands, believing that these are safer . According to the reported analyses of their\n","deliveries, these brands deliver as little as one-tenth of the tar and carbon monoxide of other brands . In fact, such reports are misleading: the\n","data are based on artificial measurements by smoking machines and do not mirror the actual delivery to a smoker . It is possible to extract as much\n","tar and nicotine from these cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that\n","would otherwise dilute the smoke - and that is exactly what smokers usually do . Each smoker appears to have a preferred level of nicotine intake and\n","will adjust the way he or she smokes to achieve that level . Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette\n","packaging and marketing in the USA and EU . Smokers who reduce the number of cigarettes they smoke typically compensate for the change by increasing\n","the intensity of smoking such that smoke exposure remains unchanged . An exception is when they use another nicotine product at the same time, such as\n","a nicotine patch or gum (see Chapter 7) . It also appears that if cigarette consumption drops below a threshold (perhaps around 5 cigarettes per day),\n","or if the cigarettes are designed to limit the potential for compensation (exempli gratia novel cigarettes in which the tobacco actually contains less\n","nicotine), compensation is very limited . Nicotine and its elimination from the body . Nicotine is an alkaloid obtained from tobacco plants and has\n","wide-ranging effects on the central nervous system (CNS) (see pages 37-8) .\n","\n","Bullets:\n","Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide.\n","\n","Predicted Summary:\n","Cigarettes are very flexible because smokers can control the intensity and frequency of puffing. This 'fingertip control' of the nicotine dose allows\n","smokers to meet their current need while avoiding the acute adverse effects of too much nicotine. Each smoker appears to have a preferred level of\n","nicotine intake and will adjust the way he or she smokes to achieve that level.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 4\n","\n","Text:\n","Cigarettes as a nicotine delivery system . The cigarette . There are many different varieties of cigarette tobacco, each with its own flavor and\n","characteristics, and tobacco can be prepared in different ways that affect its taste, smell and pharmacological properties . Additives are included in\n","cigarettes by the manufacturers to engineer an attractive and efficient nicotine delivery system . Table 1.1 lists some of the many thousands of\n","chemicals in tobacco smoke . One thing that all cigarettes have in common is that they deliver nicotine to the lungs . A puff on a cigarette results\n","in rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation\n","(Figure 1.1); this process is repeated with every puff . In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette .\n","This is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply . In societies in\n","which cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more\n","nicotine from each cigarette, confirming that nicotine is the sought-after substance in tobacco . Control of the nicotine dose . As a drug delivery\n","system, cigarettes are very flexible because smokers can control the intensity and frequency of puffing . This 'fingertip control' of the nicotine\n","dose allows smokers to meet their current need while avoiding the acute adverse effects of too much nicotine . Many smokers, particularly older\n","smokers and women, choose so-called 'light' or 'low-tar' brands, believing that these are safer . According to the reported analyses of their\n","deliveries, these brands deliver as little as one-tenth of the tar and carbon monoxide of other brands . In fact, such reports are misleading: the\n","data are based on artificial measurements by smoking machines and do not mirror the actual delivery to a smoker . It is possible to extract as much\n","tar and nicotine from these cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that\n","would otherwise dilute the smoke - and that is exactly what smokers usually do . Each smoker appears to have a preferred level of nicotine intake and\n","will adjust the way he or she smokes to achieve that level . Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette\n","packaging and marketing in the USA and EU . Smokers who reduce the number of cigarettes they smoke typically compensate for the change by increasing\n","the intensity of smoking such that smoke exposure remains unchanged . An exception is when they use another nicotine product at the same time, such as\n","a nicotine patch or gum (see Chapter 7) . It also appears that if cigarette consumption drops below a threshold (perhaps around 5 cigarettes per day),\n","or if the cigarettes are designed to limit the potential for compensation (exempli gratia novel cigarettes in which the tobacco actually contains less\n","nicotine), compensation is very limited . Nicotine and its elimination from the body . Nicotine is an alkaloid obtained from tobacco plants and has\n","wide-ranging effects on the central nervous system (CNS) (see pages 37-8) .\n","\n","Bullets:\n","Smokers' intake of tar and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes.\n","\n","Predicted Summary:\n","Cigarettes are very flexible because smokers can control the intensity and frequency of puffing. This 'fingertip control' of the nicotine dose allows\n","smokers to meet their current need while avoiding the acute adverse effects of too much nicotine. Each smoker appears to have a preferred level of\n","nicotine intake and will adjust the way he or she smokes to achieve that level.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 5\n","\n","Text:\n","Its structure (Figure 1.2) resembles that of the major neurotransmitter acetylcholine, and it activates cholinergic receptors in the brain, which\n","accounts for many of the psychoactive effects . Once in the bloodstream, nicotine is distributed around the body, readily crossing cell membranes and\n","entering every tissue . It is eliminated quite rapidly, mainly through metabolism, but partly by excretion in urine . It is metabolized mostly to the\n","oxides cotinine and nicotine-1'-N-oxide . These appear to be largely inactive and are further metabolized and excreted in urine . The plasma\n","concentration of nicotine reduces by half every 90-120 minutes (its half-life; see Figure 1.1) . Duration of withdrawal symptoms . All nicotine is\n","cleared from the body within a day or two of abstinence . Some people think that this must therefore be the period when smokers experience withdrawal\n","symptoms (see Chapter 5) . However, the duration of withdrawal symptoms has nothing to do with this; it is related to how long it takes the body to\n","get used to not having nicotine in the system . The duration for most symptoms is 2-4 weeks . Estimating nicotine intake . Nicotine concentrations in\n","the blood could conceptually be a useful index of dependence, but its short half-life means that a single measure does not give a particularly\n","accurate picture of total intake over a day . Measurement of its metabolite, cotinine, is used instead . Cotinine has a half-life of 14-20 hours, so\n","its concentration in the blood is more stable than that of nicotine and it can be easily measured in saliva, urine or even hair . Saliva samples are\n","simple to obtain by means of a dental swab and are the method of choice for accurate estimation of daily nicotine intake . A daily nicotine intake of\n","16 mg (approximately 16 cigarettes/day, or one every hour) corresponds on average to a saliva cotinine concentration of 200 ng/mL; a daily nicotine\n","intake of 10 mg generates a saliva cotinine concentration of about 125 ng/mL . These estimations are not the same for urine or blood measurements .\n","Monoamine oxidase inhibitors in cigarette smoke . There is evidence that cigarette smoke contains other psychoactive compounds which some now believe\n","may contribute to its addictive properties . Most notably, there is at least one monoamine oxidase inhibitor (MAOI) . MAOIs reduce the rate at which\n","monoamine neurotransmitters such as dopamine are broken down and have been found to reduce depressive symptoms . In the case of smoking, they might\n","contribute to the rewarding effect of cigarette smoke or act synergistically with nicotine (which is primarily rewarding as it causes release of\n","dopamine in the nucleus accumbens - see Chapter 5) . This may help explain why people who suffer from depression are particularly likely to smoke .\n","Research is in its early days, but if MAOIs play a role in cigarette addiction, pure nicotine delivery systems may be less addictive, even if they\n","deliver nicotine as rapidly as cigarettes .\n","\n","Bullets:\n","Nicotine is rapidly metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a\n","day of abstinence.\n","\n","Predicted Summary:\n"," nicotine is distributed around the body, crossing cell membranes and entering every tissue. It is eliminated quite rapidly, mainly through\n","metabolism, but partly by excretion in urine. The plasma concentration of nicotine reduces by half every 90-120 minutes (its half-life; see Figure\n","1.1)\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 6\n","\n","Text:\n","Its structure (Figure 1.2) resembles that of the major neurotransmitter acetylcholine, and it activates cholinergic receptors in the brain, which\n","accounts for many of the psychoactive effects . Once in the bloodstream, nicotine is distributed around the body, readily crossing cell membranes and\n","entering every tissue . It is eliminated quite rapidly, mainly through metabolism, but partly by excretion in urine . It is metabolized mostly to the\n","oxides cotinine and nicotine-1'-N-oxide . These appear to be largely inactive and are further metabolized and excreted in urine . The plasma\n","concentration of nicotine reduces by half every 90-120 minutes (its half-life; see Figure 1.1) . Duration of withdrawal symptoms . All nicotine is\n","cleared from the body within a day or two of abstinence . Some people think that this must therefore be the period when smokers experience withdrawal\n","symptoms (see Chapter 5) . However, the duration of withdrawal symptoms has nothing to do with this; it is related to how long it takes the body to\n","get used to not having nicotine in the system . The duration for most symptoms is 2-4 weeks . Estimating nicotine intake . Nicotine concentrations in\n","the blood could conceptually be a useful index of dependence, but its short half-life means that a single measure does not give a particularly\n","accurate picture of total intake over a day . Measurement of its metabolite, cotinine, is used instead . Cotinine has a half-life of 14-20 hours, so\n","its concentration in the blood is more stable than that of nicotine and it can be easily measured in saliva, urine or even hair . Saliva samples are\n","simple to obtain by means of a dental swab and are the method of choice for accurate estimation of daily nicotine intake . A daily nicotine intake of\n","16 mg (approximately 16 cigarettes/day, or one every hour) corresponds on average to a saliva cotinine concentration of 200 ng/mL; a daily nicotine\n","intake of 10 mg generates a saliva cotinine concentration of about 125 ng/mL . These estimations are not the same for urine or blood measurements .\n","Monoamine oxidase inhibitors in cigarette smoke . There is evidence that cigarette smoke contains other psychoactive compounds which some now believe\n","may contribute to its addictive properties . Most notably, there is at least one monoamine oxidase inhibitor (MAOI) . MAOIs reduce the rate at which\n","monoamine neurotransmitters such as dopamine are broken down and have been found to reduce depressive symptoms . In the case of smoking, they might\n","contribute to the rewarding effect of cigarette smoke or act synergistically with nicotine (which is primarily rewarding as it causes release of\n","dopamine in the nucleus accumbens - see Chapter 5) . This may help explain why people who suffer from depression are particularly likely to smoke .\n","Research is in its early days, but if MAOIs play a role in cigarette addiction, pure nicotine delivery systems may be less addictive, even if they\n","deliver nicotine as rapidly as cigarettes .\n","\n","Bullets:\n","The nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva\n","or urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.\n","\n","Predicted Summary:\n"," nicotine is distributed around the body, crossing cell membranes and entering every tissue. It is eliminated quite rapidly, mainly through\n","metabolism, but partly by excretion in urine. The plasma concentration of nicotine reduces by half every 90-120 minutes (its half-life; see Figure\n","1.1)\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01')\n","\n","All Bullets:\n","Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff. Smokers absorb an average 1-2 mg of nicotine per cigarette (more\n","when cigarettes are smoked more intensively). Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide. Smokers' intake of tar\n","and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes. Nicotine is rapidly\n","metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a day of abstinence. The\n","nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva or\n","urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.\n","\n","All Predicted Summary:\n","Cigarettes are very flexible because smokers can control the intensity and frequency of puffing. This 'fingertip control' of the nicotine dose allows\n","smokers to meet their current need while avoiding the acute adverse effects of too much nicotine. Each smoker appears to have a preferred level of\n","nicotine intake and will adjust the way he or she smokes to achieve that level. Cigarettes are very flexible because smokers can control the intensity\n","and frequency of puffing. This 'fingertip control' of the nicotine dose allows smokers to meet their current need while avoiding the acute adverse\n","effects of too much nicotine. Each smoker appears to have a preferred level of nicotine intake and will adjust the way he or she smokes to achieve\n","that level. Cigarettes are very flexible because smokers can control the intensity and frequency of puffing. This 'fingertip control' of the nicotine\n","dose allows smokers to meet their current need while avoiding the acute adverse effects of too much nicotine. Each smoker appears to have a preferred\n","level of nicotine intake and will adjust the way he or she smokes to achieve that level. Cigarettes are very flexible because smokers can control the\n","intensity and frequency of puffing. This 'fingertip control' of the nicotine dose allows smokers to meet their current need while avoiding the acute\n","adverse effects of too much nicotine. Each smoker appears to have a preferred level of nicotine intake and will adjust the way he or she smokes to\n","achieve that level.  nicotine is distributed around the body, crossing cell membranes and entering every tissue. It is eliminated quite rapidly,\n","mainly through metabolism, but partly by excretion in urine. The plasma concentration of nicotine reduces by half every 90-120 minutes (its half-life;\n","see Figure 1.1)  nicotine is distributed around the body, crossing cell membranes and entering every tissue. It is eliminated quite rapidly, mainly\n","through metabolism, but partly by excretion in urine. The plasma concentration of nicotine reduces by half every 90-120 minutes (its half-life; see\n","Figure 1.1)\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n"],"name":"stdout"}]},{"cell_type":"markdown","metadata":{"id":"44GCdPTwQPlA"},"source":["There are some problems coming with the method of assigning bullets:\n","\n","* When the same chunk is assigned to multiple bullets, the same summary is generated, while the bullets change.\n","* Since one bullet is very short compared to one chunk, usually the generated summary is longer than the bullet.\n","* When the chunk assigned to a bullet does not contain the information present in the bullets, the summary cannot be correct.\n","\n","The first and second problems can be solved by merging together bullets which have the same chunk assigned, and generating a longer summary for the chunk. Can the model understand how long the generated summary should be based on the amount of information in the chunk also present in the bullets?\n","\n"]},{"cell_type":"markdown","metadata":{"id":"a12G34WCwY14"},"source":["### **Merge or Chunk**"]},{"cell_type":"markdown","metadata":{"id":"4gTs9EFbwY17"},"source":["#### Loading data"]},{"cell_type":"code","metadata":{"id":"xjXcnVU4wY19","executionInfo":{"status":"ok","timestamp":1608648638909,"user_tz":-60,"elapsed":14483,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["input_path = drive_dir+'summarization/moc_output/assign_bullets/'\n","df_moc_assign = pd.read_csv(input_path+'df_summ_'+MODEL+'.csv')\n","df_moc_assign = df_moc_assign.set_index(['book', 'chapter'])\n","\n","df_moc_assign.bullets = df_moc_assign.bullets.map(eval)\n","df_moc_assign.text = df_moc_assign.text.map(eval)\n","df_moc_assign.summary = df_moc_assign.summary.map(eval)\n","df_moc_assign['merge'] = df_moc_assign['merge'].map(eval)"],"execution_count":34,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"3ztqP179wY1_"},"source":["#### Rouge"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/","height":0},"id":"unGxTSeTwY2B","executionInfo":{"status":"ok","timestamp":1608648639637,"user_tz":-60,"elapsed":15202,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"1d856453-3bc3-40b9-d6ac-d5e58b3bf2ad"},"source":["plot_rouge(df_moc_assign, 'assign_bullets', 'rougeL', submethod='merge_or_chunk')"],"execution_count":35,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 720x432 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"markdown","metadata":{"id":"lpqFe6x6BFol"},"source":["#### Print Random Summaries"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"oGy-bldqBFor","executionInfo":{"status":"ok","timestamp":1608648639640,"user_tz":-60,"elapsed":15199,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"77880c5e-ac48-404f-bcd0-971c21bc96d7"},"source":["print_random_summaries(df_moc_assign, RANDOM_IDS)"],"execution_count":36,"outputs":[{"output_type":"stream","text":["(9781908541994, 'ch05') bullet 1\n","\n","Text:\n","Topical therapy. Topical therapy is useful in nearly all acne regimens. mild localized acne. moderate acne; in combination with, and following, oral\n","therapy. maintenance therapy; after stopping systemic agents for severe acne. Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics. The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance. Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose\n","combination product to enhance adherence. Topical agents differ in their efficacy against the various etiologic factors. Retinoids, azelaic acid and\n","BPO are effective for comedones and inflammatory acne. Topical antibiotics such as erythromycin and clindamycin are most effective for inflammatory\n","lesions. Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions. It is important to note that topical\n","antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P. acnes) strains. Patients often seek medical\n","attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels. Active ingredients\n","include BPO, salicylic acid and alpha-hydroxy acids. Topical therapy is generally applied after washing the face and allowing it to dry for 10-15\n","minutes. It is important to cover the entire affected area with a thin film of product, avoiding the eyes. Benzoyl peroxide. BPO is the most potent\n","agent against P. acnes, an obligate anaerobe that will not grow in the presence of oxygen. Unlike antibiotics, BPO is bactericidal against P. acnes\n","through its release of free oxygen radicals in sebaceous follicles. BPO therefore reduces bacterial colonization of the follicle and kills both\n","sensitive and resistant strains of P. acnes, which translates into a reduction in new inflammatory lesions. acnes does not develop resistance to BPO;\n","for this reason, the drug is a valuable component of any acne treatment regimen. BPO is mostly available in over-the-counter and prescription\n","formulations, including bar soaps, washes, gels and lotions. It is chiefly available in concentrations of 2.5%, 4%, 5% and 10%. However, there is no\n","evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the 2.5-5% concentrations. BPO\n","is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene (see page 52). Topical\n","retinoids and retinoid-like molecules. Topical retinoids are effective agents in the treatment of acne. Although dermatologists readily prescribe\n","them, topical retinoids are underutilized by pediatricians and general practitioners. Tretinoin, or all-trans-retinoic acid, is a vitamin A derivative\n","that reverses the altered keratinization in follicles affected by acne. By inhibiting the formation of the microcomedone, tretinoin prevents the\n","development of comedones and early inflammatory lesions.\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. BPO is the\n","most potent agent against P. acnes.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 2\n","\n","Text:\n","Topical therapy. Topical therapy is useful in nearly all acne regimens. mild localized acne. moderate acne; in combination with, and following, oral\n","therapy. maintenance therapy; after stopping systemic agents for severe acne. Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics. The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance. Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose\n","combination product to enhance adherence. Topical agents differ in their efficacy against the various etiologic factors. Retinoids, azelaic acid and\n","BPO are effective for comedones and inflammatory acne. Topical antibiotics such as erythromycin and clindamycin are most effective for inflammatory\n","lesions. Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions. It is important to note that topical\n","antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P. acnes) strains. Patients often seek medical\n","attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels. Active ingredients\n","include BPO, salicylic acid and alpha-hydroxy acids. Topical therapy is generally applied after washing the face and allowing it to dry for 10-15\n","minutes. It is important to cover the entire affected area with a thin film of product, avoiding the eyes. Benzoyl peroxide. BPO is the most potent\n","agent against P. acnes, an obligate anaerobe that will not grow in the presence of oxygen. Unlike antibiotics, BPO is bactericidal against P. acnes\n","through its release of free oxygen radicals in sebaceous follicles. BPO therefore reduces bacterial colonization of the follicle and kills both\n","sensitive and resistant strains of P. acnes, which translates into a reduction in new inflammatory lesions. acnes does not develop resistance to BPO;\n","for this reason, the drug is a valuable component of any acne treatment regimen. BPO is mostly available in over-the-counter and prescription\n","formulations, including bar soaps, washes, gels and lotions. It is chiefly available in concentrations of 2.5%, 4%, 5% and 10%. However, there is no\n","evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the 2.5-5% concentrations. BPO\n","is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene (see page 52). Topical\n","retinoids and retinoid-like molecules. Topical retinoids are effective agents in the treatment of acne. Although dermatologists readily prescribe\n","them, topical retinoids are underutilized by pediatricians and general practitioners. Tretinoin, or all-trans-retinoic acid, is a vitamin A derivative\n","that reverses the altered keratinization in follicles affected by acne. By inhibiting the formation of the microcomedone, tretinoin prevents the\n","development of comedones and early inflammatory lesions.\n","\n","Bullets:\n","Topical therapy should be selected to help achieve medical adherence. Realistic expectations of therapy should be explained.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. BPO is the\n","most potent agent against P. acnes.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 3\n","\n","Text:\n","Topical therapy. Topical therapy is useful in nearly all acne regimens. mild localized acne. moderate acne; in combination with, and following, oral\n","therapy. maintenance therapy; after stopping systemic agents for severe acne. Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics. The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance. Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose\n","combination product to enhance adherence. Topical agents differ in their efficacy against the various etiologic factors. Retinoids, azelaic acid and\n","BPO are effective for comedones and inflammatory acne. Topical antibiotics such as erythromycin and clindamycin are most effective for inflammatory\n","lesions. Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions. It is important to note that topical\n","antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P. acnes) strains. Patients often seek medical\n","attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels. Active ingredients\n","include BPO, salicylic acid and alpha-hydroxy acids. Topical therapy is generally applied after washing the face and allowing it to dry for 10-15\n","minutes. It is important to cover the entire affected area with a thin film of product, avoiding the eyes. Benzoyl peroxide. BPO is the most potent\n","agent against P. acnes, an obligate anaerobe that will not grow in the presence of oxygen. Unlike antibiotics, BPO is bactericidal against P. acnes\n","through its release of free oxygen radicals in sebaceous follicles. BPO therefore reduces bacterial colonization of the follicle and kills both\n","sensitive and resistant strains of P. acnes, which translates into a reduction in new inflammatory lesions. acnes does not develop resistance to BPO;\n","for this reason, the drug is a valuable component of any acne treatment regimen. BPO is mostly available in over-the-counter and prescription\n","formulations, including bar soaps, washes, gels and lotions. It is chiefly available in concentrations of 2.5%, 4%, 5% and 10%. However, there is no\n","evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the 2.5-5% concentrations. BPO\n","is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene (see page 52). Topical\n","retinoids and retinoid-like molecules. Topical retinoids are effective agents in the treatment of acne. Although dermatologists readily prescribe\n","them, topical retinoids are underutilized by pediatricians and general practitioners. Tretinoin, or all-trans-retinoic acid, is a vitamin A derivative\n","that reverses the altered keratinization in follicles affected by acne. By inhibiting the formation of the microcomedone, tretinoin prevents the\n","development of comedones and early inflammatory lesions.\n","\n","Bullets:\n","Topical antibiotics can lead to the development of antimicrobial resistance.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. BPO is the\n","most potent agent against P. acnes.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 4\n","\n","Text:\n","Topical therapy. Topical therapy is useful in nearly all acne regimens. mild localized acne. moderate acne; in combination with, and following, oral\n","therapy. maintenance therapy; after stopping systemic agents for severe acne. Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics. The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance. Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose\n","combination product to enhance adherence. Topical agents differ in their efficacy against the various etiologic factors. Retinoids, azelaic acid and\n","BPO are effective for comedones and inflammatory acne. Topical antibiotics such as erythromycin and clindamycin are most effective for inflammatory\n","lesions. Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions. It is important to note that topical\n","antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P. acnes) strains. Patients often seek medical\n","attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels. Active ingredients\n","include BPO, salicylic acid and alpha-hydroxy acids. Topical therapy is generally applied after washing the face and allowing it to dry for 10-15\n","minutes. It is important to cover the entire affected area with a thin film of product, avoiding the eyes. Benzoyl peroxide. BPO is the most potent\n","agent against P. acnes, an obligate anaerobe that will not grow in the presence of oxygen. Unlike antibiotics, BPO is bactericidal against P. acnes\n","through its release of free oxygen radicals in sebaceous follicles. BPO therefore reduces bacterial colonization of the follicle and kills both\n","sensitive and resistant strains of P. acnes, which translates into a reduction in new inflammatory lesions. acnes does not develop resistance to BPO;\n","for this reason, the drug is a valuable component of any acne treatment regimen. BPO is mostly available in over-the-counter and prescription\n","formulations, including bar soaps, washes, gels and lotions. It is chiefly available in concentrations of 2.5%, 4%, 5% and 10%. However, there is no\n","evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the 2.5-5% concentrations. BPO\n","is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene (see page 52). Topical\n","retinoids and retinoid-like molecules. Topical retinoids are effective agents in the treatment of acne. Although dermatologists readily prescribe\n","them, topical retinoids are underutilized by pediatricians and general practitioners. Tretinoin, or all-trans-retinoic acid, is a vitamin A derivative\n","that reverses the altered keratinization in follicles affected by acne. By inhibiting the formation of the microcomedone, tretinoin prevents the\n","development of comedones and early inflammatory lesions.\n","\n","Bullets:\n","Topical antibiotics should not be used as single agents for the treatment of acne.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. BPO is the\n","most potent agent against P. acnes.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 5\n","\n","Text:\n","Topical therapy. Topical therapy is useful in nearly all acne regimens. mild localized acne. moderate acne; in combination with, and following, oral\n","therapy. maintenance therapy; after stopping systemic agents for severe acne. Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics. The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance. Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose\n","combination product to enhance adherence. Topical agents differ in their efficacy against the various etiologic factors. Retinoids, azelaic acid and\n","BPO are effective for comedones and inflammatory acne. Topical antibiotics such as erythromycin and clindamycin are most effective for inflammatory\n","lesions. Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions. It is important to note that topical\n","antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P. acnes) strains. Patients often seek medical\n","attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels. Active ingredients\n","include BPO, salicylic acid and alpha-hydroxy acids. Topical therapy is generally applied after washing the face and allowing it to dry for 10-15\n","minutes. It is important to cover the entire affected area with a thin film of product, avoiding the eyes. Benzoyl peroxide. BPO is the most potent\n","agent against P. acnes, an obligate anaerobe that will not grow in the presence of oxygen. Unlike antibiotics, BPO is bactericidal against P. acnes\n","through its release of free oxygen radicals in sebaceous follicles. BPO therefore reduces bacterial colonization of the follicle and kills both\n","sensitive and resistant strains of P. acnes, which translates into a reduction in new inflammatory lesions. acnes does not develop resistance to BPO;\n","for this reason, the drug is a valuable component of any acne treatment regimen. BPO is mostly available in over-the-counter and prescription\n","formulations, including bar soaps, washes, gels and lotions. It is chiefly available in concentrations of 2.5%, 4%, 5% and 10%. However, there is no\n","evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the 2.5-5% concentrations. BPO\n","is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene (see page 52). Topical\n","retinoids and retinoid-like molecules. Topical retinoids are effective agents in the treatment of acne. Although dermatologists readily prescribe\n","them, topical retinoids are underutilized by pediatricians and general practitioners. Tretinoin, or all-trans-retinoic acid, is a vitamin A derivative\n","that reverses the altered keratinization in follicles affected by acne. By inhibiting the formation of the microcomedone, tretinoin prevents the\n","development of comedones and early inflammatory lesions.\n","\n","Bullets:\n","Topical retinoids are useful as first-line agents.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. BPO is the\n","most potent agent against P. acnes.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 6\n","\n","Text:\n","Topical therapy. Topical therapy is useful in nearly all acne regimens. mild localized acne. moderate acne; in combination with, and following, oral\n","therapy. maintenance therapy; after stopping systemic agents for severe acne. Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics. The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial\n","resistance. Topical retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose\n","combination product to enhance adherence. Topical agents differ in their efficacy against the various etiologic factors. Retinoids, azelaic acid and\n","BPO are effective for comedones and inflammatory acne. Topical antibiotics such as erythromycin and clindamycin are most effective for inflammatory\n","lesions. Retinoids and combination preparations can be used to treat non-inflammatory and inflammatory lesions. It is important to note that topical\n","antibiotics should be combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P. acnes) strains. Patients often seek medical\n","attention for their acne after trying a variety of over-the-counter products including soaps, scrubs, creams, lotions and gels. Active ingredients\n","include BPO, salicylic acid and alpha-hydroxy acids. Topical therapy is generally applied after washing the face and allowing it to dry for 10-15\n","minutes. It is important to cover the entire affected area with a thin film of product, avoiding the eyes. Benzoyl peroxide. BPO is the most potent\n","agent against P. acnes, an obligate anaerobe that will not grow in the presence of oxygen. Unlike antibiotics, BPO is bactericidal against P. acnes\n","through its release of free oxygen radicals in sebaceous follicles. BPO therefore reduces bacterial colonization of the follicle and kills both\n","sensitive and resistant strains of P. acnes, which translates into a reduction in new inflammatory lesions. acnes does not develop resistance to BPO;\n","for this reason, the drug is a valuable component of any acne treatment regimen. BPO is mostly available in over-the-counter and prescription\n","formulations, including bar soaps, washes, gels and lotions. It is chiefly available in concentrations of 2.5%, 4%, 5% and 10%. However, there is no\n","evidence that higher concentrations are more effective and they may be more irritating; the authors therefore recommend the 2.5-5% concentrations. BPO\n","is generally used as a single agent and in combination products with topical antibiotics or the topical retinoid adapalene (see page 52). Topical\n","retinoids and retinoid-like molecules. Topical retinoids are effective agents in the treatment of acne. Although dermatologists readily prescribe\n","them, topical retinoids are underutilized by pediatricians and general practitioners. Tretinoin, or all-trans-retinoic acid, is a vitamin A derivative\n","that reverses the altered keratinization in follicles affected by acne. By inhibiting the formation of the microcomedone, tretinoin prevents the\n","development of comedones and early inflammatory lesions.\n","\n","Bullets:\n","Any regimen containing an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide\n","to reduce and prevent the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. BPO is the\n","most potent agent against P. acnes.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 7\n","\n","Text:\n","Combination products. Recent advances in topical acne therapy include the development of fixed combination products that target more than one\n","pathogenic feature of the disease and may also increase treatment adherence among patients. Combination products that include BPO offer excellent\n","bactericidal effects and, when combined with erythromycin or clindamycin, offset the emergence of antibiotic-resistant P. acnes (see pages 51 and). A\n","fixed combination of BPO with adapalene targets three of the four pathogenic features of acne without the use of antibiotics. Other combinations\n","include topical tretinoin 0.025% with clindamycin 1%, tretinoin 0.025% with erythromycin 4% and topical isotretinoin 0.05% with erythromycin 2% (none\n","of these are available in the USA). Side effects. Local irritation. Most topical acne treatments, including salicylic acid, BPO and topical retinoids\n","will cause some degree of erythema, dryness and scaling of the skin. Contact dermatitis due to BPO has rarely been reported but should be considered\n","if treated areas develop an eczematous dermatitis. Use of topical antibiotics may also be associated with local irritation, but this tends to occur\n","less often than with other topical agents. The local side effects of topical retinoids include erythema, scaling, desquamation, burning or stinging,\n","pruritus and increased susceptibility to sunburn. Most patients will develop tolerance to the local side effects of topical retinoids within 3-4\n","weeks. If patients are unable to tolerate daily application of a topical retinoid, an alternate-day or every-third-day regimen can be followed until\n","tolerance develops. Topical retinoids are not recommended in pregnancy because of the theoretical risk of teratogenicity. Fortunately, studies have\n","shown that the risk of birth defects from topical tretinoin is unlikely. Pharmacokinetic studies have shown that serum retinoid levels may be\n","influenced more by diet than by facial application of topical tretinoin for acne. Epidemiological studies have failed to demonstrate an increased risk\n","of birth defects in infants whose mothers used topical retinoids on the face during the first trimester of pregnancy. There have, however, been\n","isolated case reports of birth defects in infants whose mothers used topical tretinoin during pregnancy. For this reason, it is recommended that\n","pregnant women cease using topical retinoids. Bleaching and staining. BPO can bleach clothing or bedding, particularly when it is applied to the chest\n","or back. It is therefore best to advise use of this medication at bedtime and to recommend covering the treated areas with an old shirt. Management of\n","side effects. Excessive dryness of the skin is one of the main reasons why patients discontinue topical treatment. Thus, recommendations regarding\n","effective ways of managing facial dryness should be an integral part of any acne treatment plan. Regular use of moisturizers is especially important,\n","but the clinician should be aware of the reluctance of many patients to use them because of concerns that moisturizers might worsen their acne. These\n","patients need reassurance that this is not the case: most moisturizers from reputable companies are tested for comedogenicity in clinical trials and\n","are labeled 'non-comedogenic'. Studies show that moisturizers applied before or after topical retinoids do not alter efficacy. Moisturizers are\n","available as creams and lotions; most patients prefer to use lotions as they are easy to apply and do not feel greasy. Lotions containing sunscreens\n","should be recommended, particularly in patients using topical retinoids. For recalcitrant dry areas, a heavier cream may be needed. Sunscreens are\n","important, as the sun can exacerbate facial irritation caused by topical acne medications. Some topical preparations make patients more\n","photosensitive. Thus, regular use of a sunscreen or a moisturizer containing a sunscreen is recommended to avoid sunburn as a side effect from\n","thinning of the stratum corneum by topical retinoids or phototoxicity from oral doxycycline. Alternative regimens. If irritation remains a problem\n","despite adequate use of moisturizers, the treatment regimen can be temporarily altered. For example, topical retinoids could be used every other day\n","or every third day until they are tolerated, or the duration of application could be gradually increased. The goal is to gradually increase the\n","frequency of application until the patient can tolerate daily application.\n","\n","Bullets:\n","Combining therapies or using fixed combination topical products improves efficacy by targeting more than one pathogenic feature and enhancing\n","treatment adherence.\n","\n","Predicted Summary:\n","Most topical acne treatments will cause some degree of erythema, dryness and scaling. Contact dermatitis due to BPO has rarely been reported but\n","should be considered if treated areas develop eczematous dermatitis.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05')\n","\n","All Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical therapy should be selected to help achieve medical adherence. Realistic\n","expectations of therapy should be explained. Topical antibiotics can lead to the development of antimicrobial resistance. Topical antibiotics should\n","not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Any regimen containing an antibiotic\n","(topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent the development\n","of antibiotic-resistant strains of P. acnes. Combining therapies or using fixed combination topical products improves efficacy by targeting more than\n","one pathogenic feature and enhancing treatment adherence.\n","\n","All Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. BPO is the\n","most potent agent against P. acnes. Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones\n","and inflammatory acne. BPO is the most potent agent against P. acnes. Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid\n","and BPO are effective for comedones and inflammatory acne. BPO is the most potent agent against P. acnes. Topical therapy is useful in nearly all acne\n","regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. BPO is the most potent agent against P. acnes. Topical\n","therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and inflammatory acne. BPO is the most\n","potent agent against P. acnes. Topical therapy is useful in nearly all acne regimens. Retinoids, azelaic acid and BPO are effective for comedones and\n","inflammatory acne. BPO is the most potent agent against P. acnes. Most topical acne treatments will cause some degree of erythema, dryness and\n","scaling. Contact dermatitis due to BPO has rarely been reported but should be considered if treated areas develop eczematous dermatitis.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9') bullet 1\n","\n","Text:\n","Atrial flutter. Typical atrial flutter is a macro-entrant atrial rhythm, rotating counterclockwise, occasionally clockwise, within the right atrium\n","(see Figure 2.7). Most common is a circuit confined to the anterior portion of the right atrium with a 2:1 atrioventricular (AV) block - an atrial\n","rate of 300 bpm and a regular ventricular response of 150 bpm related directly to the atrial rate. A QRS rate of exactly 150 bpm should raise\n","suspicion of atrial flutter. Other than atrial fibrillation (AF), atrial flutter is the most common arrhythmia seen by cardiologists. Patients who\n","have had AF may present with atypical atrial flutter at a later stage; patients who have had congenital abnormalities corrected at an early age may\n","present with atypical atrial flutter up to 10-20 years later. In typical atrial flutter, the circuit is critically dependent on an area of slow\n","conduction known as the cavotricuspid isthmus (see Figure 2.7). Other rarer atypical forms occur, particularly in patients with scarring in the atrium\n","(exempli gratia after radiofrequency ablation [RFA] or previous heart surgery). Atrial flutter typically has a saw-tooth appearance of flutter waves\n","on the baseline in the 12-lead ECG (see Figure 2.7). Clinical presentation. Atrial flutter can be aysmptomatic or may present with breathlessness,\n","tiredness or frank heart failure. Persistent palpitations may be a feature. Anticoagulation therapy is based on the same risk factors as those for AF\n","(see Chapter 8). Pharmacological treatment. In acute cases, cardioversion can be performed with intravenous ibutilide, or, if there is no structural\n","heart disease, a class 1c antiarrhythmic agent, such as flecainide or propafenone, combined with a beta-blocker. Intravenous flecainide alone is\n","sometimes used in Europe (but not in the USA) to slow conduction in the flutter circuit more than in the AV node itself. However, in some cases this\n","may slow the atrial rate from 300 to 200 bpm and may allow the AV node to conduct in a 1:1 fashion, producing a paradoxical increase in the\n","ventricular rate to 200 bpm, which may be associated with hemodynamic compromise; flecainide is often combined with a beta-blocker to prevent the\n","flutter being conducted to the ventricle in this 1:1 manner. The same principle applies for both intravenous and oral flecainide. Oral sotalol is\n","often used in patients with atrial flutter, as it has the combined action of an antiarrhythmic and a beta-blocker, but QT considerations and renal\n","excretion limit its use in women and the elderly.\n","\n","Bullets:\n","The risk of systemic embolization in atrial flutter should be considered similar to that for atrial fibrillation (AF).\n","\n","Predicted Summary:\n","Atrial flutter is the most common arrhythmia seen by cardiologists. Patients who have had AF may present with atypical atrial flutter at a later\n","stage. Atrial flutter typically has a saw-tooth appearance of flutter waves on the baseline.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9') bullet 2\n","\n","Text:\n","In the chronic setting, atrial flutter often responds poorly to drug therapy. AV nodal-blocking drugs slow the ventricular response. Direct-current\n","(DC) cardioversion is highly effective for atrial flutter. However, persistent atrial flutter (lasting longer than 48 hours) is associated with\n","significant embolic risk, and management before cardioversion should be as for patients with AF - treatment with oral anticoagulant therapy (warfarin)\n","for 4 weeks before cardioversion and for at least 1 month afterwards (see Chapter 8). Alternatively, a transesophageal echocardiogram can be performed\n","in patients who are not taking warfarin, or in whom serial measurements of the international normalized ratio (INR) over a month have not been\n","documented, to exclude left atrial thrombus and enable immediate cardioversion. Patients are then started, or continued, on warfarin, while heparin or\n","low-molecular-weight heparin is given until the INR is greater than 2, continuing warfarin for 1 month or more. In the acute setting, flutter often\n","converts with a low-energy shock of about 50 J, sometimes as low as 25 J. Radiofrequency (catheter) ablation is recommended for long-term treatment.\n","RFA restores sinus rhythm by creating a linear destructive lesion, across which the circulating depolarizing wavefront cannot pass. This is known as a\n","line of block and is usually created at the inferior wall of the right atrium (Figure 7.1). This technique is in contrast to the ablation of accessory\n","or slow pathways, which require highly localized lesions. The procedure can be performed during constant atrial flutter or in sinus rhythm with pacing\n","from the atrium or coronary sinus. Success rates are greater than 90% in most centers. The cavotricuspid isthmus is not smooth throughout its length\n","and has regions of thick muscle bundles. Ablation of these areas is best achieved with technology capable of producing deep lesions, such as large-tip\n","or cooled radiofrequency energy. Newer techniques involving computerized mapping of the atria and catheter position are improving overall success.\n","Most centers are now performing ablation as first-line treatment. Apart from the usual complications associated with instrumentation of the venous\n","circulation, heart block or cardiac tamponade are rarely reported. After ablation, the prognosis for patients with typical atrial flutter is\n","excellent. In patients with atypical atrial flutter recurrences are more common because of scarring of the atria. Up to 30% of patients with either\n","type of atrial flutter develop AF late after a successful flutter ablation and may require further treatment; atrial flutter and AF often go together.\n","\n","Bullets:\n","Ablation for typical atrial flutter is highly successful and low risk, and should be considered first-line treatment.\n","\n","Predicted Summary:\n","Direct-current (DC) cardioversion is highly effective for atrial flutter. Radiofrequency (catheter) ablation is recommended for long-term treatment.\n","Success rates are greater than 90% in most centers.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9') bullet 3\n","\n","Text:\n","In the chronic setting, atrial flutter often responds poorly to drug therapy. AV nodal-blocking drugs slow the ventricular response. Direct-current\n","(DC) cardioversion is highly effective for atrial flutter. However, persistent atrial flutter (lasting longer than 48 hours) is associated with\n","significant embolic risk, and management before cardioversion should be as for patients with AF - treatment with oral anticoagulant therapy (warfarin)\n","for 4 weeks before cardioversion and for at least 1 month afterwards (see Chapter 8). Alternatively, a transesophageal echocardiogram can be performed\n","in patients who are not taking warfarin, or in whom serial measurements of the international normalized ratio (INR) over a month have not been\n","documented, to exclude left atrial thrombus and enable immediate cardioversion. Patients are then started, or continued, on warfarin, while heparin or\n","low-molecular-weight heparin is given until the INR is greater than 2, continuing warfarin for 1 month or more. In the acute setting, flutter often\n","converts with a low-energy shock of about 50 J, sometimes as low as 25 J. Radiofrequency (catheter) ablation is recommended for long-term treatment.\n","RFA restores sinus rhythm by creating a linear destructive lesion, across which the circulating depolarizing wavefront cannot pass. This is known as a\n","line of block and is usually created at the inferior wall of the right atrium (Figure 7.1). This technique is in contrast to the ablation of accessory\n","or slow pathways, which require highly localized lesions. The procedure can be performed during constant atrial flutter or in sinus rhythm with pacing\n","from the atrium or coronary sinus. Success rates are greater than 90% in most centers. The cavotricuspid isthmus is not smooth throughout its length\n","and has regions of thick muscle bundles. Ablation of these areas is best achieved with technology capable of producing deep lesions, such as large-tip\n","or cooled radiofrequency energy. Newer techniques involving computerized mapping of the atria and catheter position are improving overall success.\n","Most centers are now performing ablation as first-line treatment. Apart from the usual complications associated with instrumentation of the venous\n","circulation, heart block or cardiac tamponade are rarely reported. After ablation, the prognosis for patients with typical atrial flutter is\n","excellent. In patients with atypical atrial flutter recurrences are more common because of scarring of the atria. Up to 30% of patients with either\n","type of atrial flutter develop AF late after a successful flutter ablation and may require further treatment; atrial flutter and AF often go together.\n","\n","Bullets:\n","Atypical atrial flutter usually includes right atrial flutter circling around regions of scarring, or left atrial flutter following ablation of AF.\n","\n","Predicted Summary:\n","Direct-current (DC) cardioversion is highly effective for atrial flutter. Radiofrequency (catheter) ablation is recommended for long-term treatment.\n","Success rates are greater than 90% in most centers.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9')\n","\n","All Bullets:\n","The risk of systemic embolization in atrial flutter should be considered similar to that for atrial fibrillation (AF). Ablation for typical atrial\n","flutter is highly successful and low risk, and should be considered first-line treatment. Atypical atrial flutter usually includes right atrial\n","flutter circling around regions of scarring, or left atrial flutter following ablation of AF.\n","\n","All Predicted Summary:\n","Atrial flutter is the most common arrhythmia seen by cardiologists. Patients who have had AF may present with atypical atrial flutter at a later\n","stage. Atrial flutter typically has a saw-tooth appearance of flutter waves on the baseline. Direct-current (DC) cardioversion is highly effective for\n","atrial flutter. Radiofrequency (catheter) ablation is recommended for long-term treatment. Success rates are greater than 90% in most centers. Direct-\n","current (DC) cardioversion is highly effective for atrial flutter. Radiofrequency (catheter) ablation is recommended for long-term treatment. Success\n","rates are greater than 90% in most centers.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 1\n","\n","Text:\n","Cigarettes as a nicotine delivery system. The cigarette. There are many different varieties of cigarette tobacco, each with its own flavor and\n","characteristics, and tobacco can be prepared in different ways that affect its taste, smell and pharmacological properties. Additives are included in\n","cigarettes by the manufacturers to engineer an attractive and efficient nicotine delivery system. Table 1.1 lists some of the many thousands of\n","chemicals in tobacco smoke. One thing that all cigarettes have in common is that they deliver nicotine to the lungs. A puff on a cigarette results in\n","rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation\n","(Figure 1.1); this process is repeated with every puff. In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This\n","is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply. In societies in which\n","cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more nicotine\n","from each cigarette, confirming that nicotine is the sought-after substance in tobacco. Control of the nicotine dose. As a drug delivery system,\n","cigarettes are very flexible because smokers can control the intensity and frequency of puffing. This 'fingertip control' of the nicotine dose allows\n","smokers to meet their current need while avoiding the acute adverse effects of too much nicotine. Many smokers, particularly older smokers and women,\n","choose so-called 'light' or 'low-tar' brands, believing that these are safer. According to the reported analyses of their deliveries, these brands\n","deliver as little as one-tenth of the tar and carbon monoxide of other brands. In fact, such reports are misleading: the data are based on artificial\n","measurements by smoking machines and do not mirror the actual delivery to a smoker. It is possible to extract as much tar and nicotine from these\n","cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that would otherwise dilute the\n","smoke - and that is exactly what smokers usually do. Each smoker appears to have a preferred level of nicotine intake and will adjust the way he or\n","she smokes to achieve that level. Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette packaging and marketing in the USA\n","and EU. Smokers who reduce the number of cigarettes they smoke typically compensate for the change by increasing the intensity of smoking such that\n","smoke exposure remains unchanged. An exception is when they use another nicotine product at the same time, such as a nicotine patch or gum (see\n","Chapter 7). It also appears that if cigarette consumption drops below a threshold (perhaps around 5 cigarettes per day), or if the cigarettes are\n","designed to limit the potential for compensation (exempli gratia novel cigarettes in which the tobacco actually contains less nicotine), compensation\n","is very limited. Nicotine and its elimination from the body. Nicotine is an alkaloid obtained from tobacco plants and has wide-ranging effects on the\n","central nervous system (CNS) (see pages 37-8).\n","\n","Bullets:\n","Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff.\n","\n","Predicted Summary:\n","In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to one-third of what they could\n","obtain if they puffed more frequently and inhaled the smoke more deeply. Each smoker appears to have a preferred level of nicotine intake and will\n","adjust the way he or she smokes to achieve that level.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 2\n","\n","Text:\n","Cigarettes as a nicotine delivery system. The cigarette. There are many different varieties of cigarette tobacco, each with its own flavor and\n","characteristics, and tobacco can be prepared in different ways that affect its taste, smell and pharmacological properties. Additives are included in\n","cigarettes by the manufacturers to engineer an attractive and efficient nicotine delivery system. Table 1.1 lists some of the many thousands of\n","chemicals in tobacco smoke. One thing that all cigarettes have in common is that they deliver nicotine to the lungs. A puff on a cigarette results in\n","rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation\n","(Figure 1.1); this process is repeated with every puff. In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This\n","is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply. In societies in which\n","cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more nicotine\n","from each cigarette, confirming that nicotine is the sought-after substance in tobacco. Control of the nicotine dose. As a drug delivery system,\n","cigarettes are very flexible because smokers can control the intensity and frequency of puffing. This 'fingertip control' of the nicotine dose allows\n","smokers to meet their current need while avoiding the acute adverse effects of too much nicotine. Many smokers, particularly older smokers and women,\n","choose so-called 'light' or 'low-tar' brands, believing that these are safer. According to the reported analyses of their deliveries, these brands\n","deliver as little as one-tenth of the tar and carbon monoxide of other brands. In fact, such reports are misleading: the data are based on artificial\n","measurements by smoking machines and do not mirror the actual delivery to a smoker. It is possible to extract as much tar and nicotine from these\n","cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that would otherwise dilute the\n","smoke - and that is exactly what smokers usually do. Each smoker appears to have a preferred level of nicotine intake and will adjust the way he or\n","she smokes to achieve that level. Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette packaging and marketing in the USA\n","and EU. Smokers who reduce the number of cigarettes they smoke typically compensate for the change by increasing the intensity of smoking such that\n","smoke exposure remains unchanged. An exception is when they use another nicotine product at the same time, such as a nicotine patch or gum (see\n","Chapter 7). It also appears that if cigarette consumption drops below a threshold (perhaps around 5 cigarettes per day), or if the cigarettes are\n","designed to limit the potential for compensation (exempli gratia novel cigarettes in which the tobacco actually contains less nicotine), compensation\n","is very limited. Nicotine and its elimination from the body. Nicotine is an alkaloid obtained from tobacco plants and has wide-ranging effects on the\n","central nervous system (CNS) (see pages 37-8).\n","\n","Bullets:\n","Smokers absorb an average 1-2 mg of nicotine per cigarette (more when cigarettes are smoked more intensively).\n","\n","Predicted Summary:\n","In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to one-third of what they could\n","obtain if they puffed more frequently and inhaled the smoke more deeply. Each smoker appears to have a preferred level of nicotine intake and will\n","adjust the way he or she smokes to achieve that level.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 3\n","\n","Text:\n","Cigarettes as a nicotine delivery system. The cigarette. There are many different varieties of cigarette tobacco, each with its own flavor and\n","characteristics, and tobacco can be prepared in different ways that affect its taste, smell and pharmacological properties. Additives are included in\n","cigarettes by the manufacturers to engineer an attractive and efficient nicotine delivery system. Table 1.1 lists some of the many thousands of\n","chemicals in tobacco smoke. One thing that all cigarettes have in common is that they deliver nicotine to the lungs. A puff on a cigarette results in\n","rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation\n","(Figure 1.1); this process is repeated with every puff. In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This\n","is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply. In societies in which\n","cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more nicotine\n","from each cigarette, confirming that nicotine is the sought-after substance in tobacco. Control of the nicotine dose. As a drug delivery system,\n","cigarettes are very flexible because smokers can control the intensity and frequency of puffing. This 'fingertip control' of the nicotine dose allows\n","smokers to meet their current need while avoiding the acute adverse effects of too much nicotine. Many smokers, particularly older smokers and women,\n","choose so-called 'light' or 'low-tar' brands, believing that these are safer. According to the reported analyses of their deliveries, these brands\n","deliver as little as one-tenth of the tar and carbon monoxide of other brands. In fact, such reports are misleading: the data are based on artificial\n","measurements by smoking machines and do not mirror the actual delivery to a smoker. It is possible to extract as much tar and nicotine from these\n","cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that would otherwise dilute the\n","smoke - and that is exactly what smokers usually do. Each smoker appears to have a preferred level of nicotine intake and will adjust the way he or\n","she smokes to achieve that level. Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette packaging and marketing in the USA\n","and EU. Smokers who reduce the number of cigarettes they smoke typically compensate for the change by increasing the intensity of smoking such that\n","smoke exposure remains unchanged. An exception is when they use another nicotine product at the same time, such as a nicotine patch or gum (see\n","Chapter 7). It also appears that if cigarette consumption drops below a threshold (perhaps around 5 cigarettes per day), or if the cigarettes are\n","designed to limit the potential for compensation (exempli gratia novel cigarettes in which the tobacco actually contains less nicotine), compensation\n","is very limited. Nicotine and its elimination from the body. Nicotine is an alkaloid obtained from tobacco plants and has wide-ranging effects on the\n","central nervous system (CNS) (see pages 37-8).\n","\n","Bullets:\n","Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide.\n","\n","Predicted Summary:\n","In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to one-third of what they could\n","obtain if they puffed more frequently and inhaled the smoke more deeply. Each smoker appears to have a preferred level of nicotine intake and will\n","adjust the way he or she smokes to achieve that level.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 4\n","\n","Text:\n","Cigarettes as a nicotine delivery system. The cigarette. There are many different varieties of cigarette tobacco, each with its own flavor and\n","characteristics, and tobacco can be prepared in different ways that affect its taste, smell and pharmacological properties. Additives are included in\n","cigarettes by the manufacturers to engineer an attractive and efficient nicotine delivery system. Table 1.1 lists some of the many thousands of\n","chemicals in tobacco smoke. One thing that all cigarettes have in common is that they deliver nicotine to the lungs. A puff on a cigarette results in\n","rapid absorption of nicotine into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation\n","(Figure 1.1); this process is repeated with every puff. In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This\n","is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply. In societies in which\n","cigarettes are more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more nicotine\n","from each cigarette, confirming that nicotine is the sought-after substance in tobacco. Control of the nicotine dose. As a drug delivery system,\n","cigarettes are very flexible because smokers can control the intensity and frequency of puffing. This 'fingertip control' of the nicotine dose allows\n","smokers to meet their current need while avoiding the acute adverse effects of too much nicotine. Many smokers, particularly older smokers and women,\n","choose so-called 'light' or 'low-tar' brands, believing that these are safer. According to the reported analyses of their deliveries, these brands\n","deliver as little as one-tenth of the tar and carbon monoxide of other brands. In fact, such reports are misleading: the data are based on artificial\n","measurements by smoking machines and do not mirror the actual delivery to a smoker. It is possible to extract as much tar and nicotine from these\n","cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation holes in the filter that would otherwise dilute the\n","smoke - and that is exactly what smokers usually do. Each smoker appears to have a preferred level of nicotine intake and will adjust the way he or\n","she smokes to achieve that level. Recognizing this, the terms 'light' and 'low tar' have been banned from cigarette packaging and marketing in the USA\n","and EU. Smokers who reduce the number of cigarettes they smoke typically compensate for the change by increasing the intensity of smoking such that\n","smoke exposure remains unchanged. An exception is when they use another nicotine product at the same time, such as a nicotine patch or gum (see\n","Chapter 7). It also appears that if cigarette consumption drops below a threshold (perhaps around 5 cigarettes per day), or if the cigarettes are\n","designed to limit the potential for compensation (exempli gratia novel cigarettes in which the tobacco actually contains less nicotine), compensation\n","is very limited. Nicotine and its elimination from the body. Nicotine is an alkaloid obtained from tobacco plants and has wide-ranging effects on the\n","central nervous system (CNS) (see pages 37-8).\n","\n","Bullets:\n","Smokers' intake of tar and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes.\n","\n","Predicted Summary:\n","In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to one-third of what they could\n","obtain if they puffed more frequently and inhaled the smoke more deeply. Each smoker appears to have a preferred level of nicotine intake and will\n","adjust the way he or she smokes to achieve that level.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 5\n","\n","Text:\n","Its structure (Figure 1.2) resembles that of the major neurotransmitter acetylcholine, and it activates cholinergic receptors in the brain, which\n","accounts for many of the psychoactive effects. Once in the bloodstream, nicotine is distributed around the body, readily crossing cell membranes and\n","entering every tissue. It is eliminated quite rapidly, mainly through metabolism, but partly by excretion in urine. It is metabolized mostly to the\n","oxides cotinine and nicotine-1'-N-oxide. These appear to be largely inactive and are further metabolized and excreted in urine. The plasma\n","concentration of nicotine reduces by half every 90-120 minutes (its half-life; see Figure 1.1). Duration of withdrawal symptoms. All nicotine is\n","cleared from the body within a day or two of abstinence. Some people think that this must therefore be the period when smokers experience withdrawal\n","symptoms (see Chapter 5). However, the duration of withdrawal symptoms has nothing to do with this; it is related to how long it takes the body to get\n","used to not having nicotine in the system. The duration for most symptoms is 2-4 weeks. Estimating nicotine intake. Nicotine concentrations in the\n","blood could conceptually be a useful index of dependence, but its short half-life means that a single measure does not give a particularly accurate\n","picture of total intake over a day. Measurement of its metabolite, cotinine, is used instead. Cotinine has a half-life of 14-20 hours, so its\n","concentration in the blood is more stable than that of nicotine and it can be easily measured in saliva, urine or even hair. Saliva samples are simple\n","to obtain by means of a dental swab and are the method of choice for accurate estimation of daily nicotine intake. A daily nicotine intake of 16 mg\n","(approximately 16 cigarettes/day, or one every hour) corresponds on average to a saliva cotinine concentration of 200 ng/mL; a daily nicotine intake\n","of 10 mg generates a saliva cotinine concentration of about 125 ng/mL. These estimations are not the same for urine or blood measurements. Monoamine\n","oxidase inhibitors in cigarette smoke. There is evidence that cigarette smoke contains other psychoactive compounds which some now believe may\n","contribute to its addictive properties. Most notably, there is at least one monoamine oxidase inhibitor (MAOI). MAOIs reduce the rate at which\n","monoamine neurotransmitters such as dopamine are broken down and have been found to reduce depressive symptoms. In the case of smoking, they might\n","contribute to the rewarding effect of cigarette smoke or act synergistically with nicotine (which is primarily rewarding as it causes release of\n","dopamine in the nucleus accumbens - see Chapter 5). This may help explain why people who suffer from depression are particularly likely to smoke.\n","Research is in its early days, but if MAOIs play a role in cigarette addiction, pure nicotine delivery systems may be less addictive, even if they\n","deliver nicotine as rapidly as cigarettes.\n","\n","Bullets:\n","Nicotine is rapidly metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a\n","day of abstinence.\n","\n","Predicted Summary:\n"," nicotine is distributed around the body, readily crossing cell membranes and entering every tissue. It is eliminated quite rapidly, mainly through\n","metabolism, but partly by excretion in urine. The plasma concentration of nicotine reduces by half every 90-120 minutes.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 6\n","\n","Text:\n","Its structure (Figure 1.2) resembles that of the major neurotransmitter acetylcholine, and it activates cholinergic receptors in the brain, which\n","accounts for many of the psychoactive effects. Once in the bloodstream, nicotine is distributed around the body, readily crossing cell membranes and\n","entering every tissue. It is eliminated quite rapidly, mainly through metabolism, but partly by excretion in urine. It is metabolized mostly to the\n","oxides cotinine and nicotine-1'-N-oxide. These appear to be largely inactive and are further metabolized and excreted in urine. The plasma\n","concentration of nicotine reduces by half every 90-120 minutes (its half-life; see Figure 1.1). Duration of withdrawal symptoms. All nicotine is\n","cleared from the body within a day or two of abstinence. Some people think that this must therefore be the period when smokers experience withdrawal\n","symptoms (see Chapter 5). However, the duration of withdrawal symptoms has nothing to do with this; it is related to how long it takes the body to get\n","used to not having nicotine in the system. The duration for most symptoms is 2-4 weeks. Estimating nicotine intake. Nicotine concentrations in the\n","blood could conceptually be a useful index of dependence, but its short half-life means that a single measure does not give a particularly accurate\n","picture of total intake over a day. Measurement of its metabolite, cotinine, is used instead. Cotinine has a half-life of 14-20 hours, so its\n","concentration in the blood is more stable than that of nicotine and it can be easily measured in saliva, urine or even hair. Saliva samples are simple\n","to obtain by means of a dental swab and are the method of choice for accurate estimation of daily nicotine intake. A daily nicotine intake of 16 mg\n","(approximately 16 cigarettes/day, or one every hour) corresponds on average to a saliva cotinine concentration of 200 ng/mL; a daily nicotine intake\n","of 10 mg generates a saliva cotinine concentration of about 125 ng/mL. These estimations are not the same for urine or blood measurements. Monoamine\n","oxidase inhibitors in cigarette smoke. There is evidence that cigarette smoke contains other psychoactive compounds which some now believe may\n","contribute to its addictive properties. Most notably, there is at least one monoamine oxidase inhibitor (MAOI). MAOIs reduce the rate at which\n","monoamine neurotransmitters such as dopamine are broken down and have been found to reduce depressive symptoms. In the case of smoking, they might\n","contribute to the rewarding effect of cigarette smoke or act synergistically with nicotine (which is primarily rewarding as it causes release of\n","dopamine in the nucleus accumbens - see Chapter 5). This may help explain why people who suffer from depression are particularly likely to smoke.\n","Research is in its early days, but if MAOIs play a role in cigarette addiction, pure nicotine delivery systems may be less addictive, even if they\n","deliver nicotine as rapidly as cigarettes.\n","\n","Bullets:\n","The nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva\n","or urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.\n","\n","Predicted Summary:\n"," nicotine is distributed around the body, readily crossing cell membranes and entering every tissue. It is eliminated quite rapidly, mainly through\n","metabolism, but partly by excretion in urine. The plasma concentration of nicotine reduces by half every 90-120 minutes.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01')\n","\n","All Bullets:\n","Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff. Smokers absorb an average 1-2 mg of nicotine per cigarette (more\n","when cigarettes are smoked more intensively). Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide. Smokers' intake of tar\n","and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes. Nicotine is rapidly\n","metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a day of abstinence. The\n","nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva or\n","urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.\n","\n","All Predicted Summary:\n","In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to one-third of what they could\n","obtain if they puffed more frequently and inhaled the smoke more deeply. Each smoker appears to have a preferred level of nicotine intake and will\n","adjust the way he or she smokes to achieve that level. In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This\n","is only about one-sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply. Each smoker appears\n","to have a preferred level of nicotine intake and will adjust the way he or she smokes to achieve that level. In the UK and the USA, smokers absorb an\n","average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to one-third of what they could obtain if they puffed more frequently and\n","inhaled the smoke more deeply. Each smoker appears to have a preferred level of nicotine intake and will adjust the way he or she smokes to achieve\n","that level. In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to one-third of what\n","they could obtain if they puffed more frequently and inhaled the smoke more deeply. Each smoker appears to have a preferred level of nicotine intake\n","and will adjust the way he or she smokes to achieve that level.  nicotine is distributed around the body, readily crossing cell membranes and entering\n","every tissue. It is eliminated quite rapidly, mainly through metabolism, but partly by excretion in urine. The plasma concentration of nicotine\n","reduces by half every 90-120 minutes.  nicotine is distributed around the body, readily crossing cell membranes and entering every tissue. It is\n","eliminated quite rapidly, mainly through metabolism, but partly by excretion in urine. The plasma concentration of nicotine reduces by half every\n","90-120 minutes.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n"],"name":"stdout"}]},{"cell_type":"markdown","metadata":{"id":"XRibhE4QRza9"},"source":["Same as with Chunk Chapter."]},{"cell_type":"markdown","metadata":{"id":"IZVlKDyZxNSl"},"source":["### **Paragraph**"]},{"cell_type":"markdown","metadata":{"id":"2zQEYGZlxNSn"},"source":["#### Loading data"]},{"cell_type":"code","metadata":{"id":"Vyw9TPsyxNSo","executionInfo":{"status":"ok","timestamp":1608648640126,"user_tz":-60,"elapsed":15683,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}}},"source":["input_path = drive_dir+'summarization/para_output/'\n","df_para = pd.read_csv(input_path+'df_summ_'+MODEL+'.csv')\n","df_para = df_para.set_index(['book', 'chapter'])\n","\n","df_para.bullets = df_para.bullets.map(eval)\n","df_para.text = df_para.text.map(eval)\n","df_para.summary = df_para.summary.map(eval)"],"execution_count":37,"outputs":[]},{"cell_type":"markdown","metadata":{"id":"SEh3RzxwxNSp"},"source":["#### Rouge"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/","height":0},"id":"XI7BTEcPxNSq","executionInfo":{"status":"ok","timestamp":1608648641049,"user_tz":-60,"elapsed":16600,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"a9d6f3bb-fa95-45db-efd3-9827c54afb08"},"source":["plot_rouge(df_para, 'assign_bullets', 'rougeL', submethod='paragraph')"],"execution_count":38,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 720x432 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"markdown","metadata":{"id":"98BwPF2dBJLv"},"source":["#### Print Random Summaries"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"MsZLT6_hBJL0","executionInfo":{"status":"ok","timestamp":1608648641054,"user_tz":-60,"elapsed":16594,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"1b28ea0a-3787-4bd0-84ef-dd6da622ba2a"},"source":["print_random_summaries(df_para, RANDOM_IDS)"],"execution_count":39,"outputs":[{"output_type":"stream","text":["(9781908541994, 'ch05') bullet 1\n","\n","Text:\n","Topical therapy. Topical therapy is useful in nearly all acne regimens. mild localized acne. moderate acne; in combination with, and following, oral\n","therapy. maintenance therapy; after stopping systemic agents for severe acne. Mild acne that consists of open and closed comedones and/or few\n","inflammatory lesions is amenable to topical therapy using agents such as salicylic acid, retinoids, azelaic acid, benzoyl peroxide (BPO) and topical\n","antibiotics.\n","\n","Bullets:\n","Topical therapy is a key component of nearly all acne regimens.\n","\n","Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Mild acne that consists of open and closed comedones and/or few inflammatory lesions is\n","amenable to topical therapy using agents such as salicylic acid, retinoids and topical antibiotics.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 2\n","\n","Text:\n","The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial resistance. Topical\n","retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose combination product\n","to enhance adherence.\n","\n","Bullets:\n","Topical antibiotics can lead to the development of antimicrobial resistance.\n","\n","Predicted Summary:\n","The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial resistance. Topical\n","retinoids are useful as first-line agents.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 3\n","\n","Text:\n","The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial resistance. Topical\n","retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose combination product\n","to enhance adherence. Topical agents differ in their efficacy against the various etiologic factors. Retinoids, azelaic acid and BPO are effective for\n","comedones and inflammatory acne. Topical antibiotics such as erythromycin and clindamycin are most effective for inflammatory lesions. Retinoids and\n","combination preparations can be used to treat non-inflammatory and inflammatory lesions. It is important to note that topical antibiotics should be\n","combined with BPO to reduce the emergence of resistant Propionibacterium acnes (P. acnes) strains.\n","\n","Bullets:\n","Topical antibiotics should not be used as single agents for the treatment of acne.\n","\n","Predicted Summary:\n","The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial resistance. Topical\n","retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose combination\n","product.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 4\n","\n","Text:\n","The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial resistance. Topical\n","retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose combination product\n","to enhance adherence.\n","\n","Bullets:\n","Topical retinoids are useful as first-line agents.\n","\n","Predicted Summary:\n","The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial resistance. Topical\n","retinoids are useful as first-line agents.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 5\n","\n","Text:\n","Sodium sulfacetamide is a sulfonamide, which is thought to inhibit the growth of P. acnes through competitive antagonism of para-aminobenzoic acid, an\n","essential requirement for bacterial growth. Sodium sulfacetamide (10%) is available in combination with sulfur (5%) in a prescription lotion, either\n","with or without tint. Topical tetracycline is available in Italy, but not the UK or USA. Antibiotic resistance. Since the 1970s, P. acnes has\n","developed resistance to both topical and oral antibiotics. It is important to bear this in mind when prescribing antibiotics. P. acnes resistance has\n","been shown to affect clinical outcomes of acne treatment. In addition, overuse of antibiotics can drive resistance in other commensal bacteria. For\n","these reasons, the use of topical antibiotics as single agents for acne is to be discouraged. Topical retinoids and BPO are useful as first-line\n","agents. Any regimen containing an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with BPO.\n","\n","Bullets:\n","Any regimen containing an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide\n","to reduce and prevent the development of antibiotic-resistant strains of P. acnes.\n","\n","Predicted Summary:\n","Sodium sulfacetamide is a sulfonamide, which is thought to inhibit the growth of P. acnes through competitive antagonism of para-aminobenzoic acid.\n","Topical tetracycline is available in Italy, but not the UK or USA.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 6\n","\n","Text:\n","Recent advances in topical acne therapy include the development of fixed combination products that target more than one pathogenic feature of the\n","disease and may also increase treatment adherence among patients. Combination products that include BPO offer excellent bactericidal effects and, when\n","combined with erythromycin or clindamycin, offset the emergence of antibiotic-resistant P. acnes (see pages 51 and). A fixed combination of BPO with\n","adapalene targets three of the four pathogenic features of acne without the use of antibiotics. Other combinations include topical tretinoin 0.025%\n","with clindamycin 1%, tretinoin 0.025% with erythromycin 4% and topical isotretinoin 0.05% with erythromycin 2% (none of these are available in the\n","USA).\n","\n","Bullets:\n","Combining therapies or using fixed combination topical products improves efficacy by targeting more than one pathogenic feature and enhancing\n","treatment adherence.\n","\n","Predicted Summary:\n","Recent advances in topical acne therapy include the development of fixed combination products. Combination products that include BPO offer excellent\n","bactericidal effects. When combined with erythromycin or clindamycin, offset the emergence of antibiotic-resistant P. acnes.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05') bullet 7\n","\n","Text:\n","Moisturizers. Excessive dryness of the skin is one of the main reasons why patients discontinue topical treatment. Thus, recommendations regarding\n","effective ways of managing facial dryness should be an integral part of any acne treatment plan. Regular use of moisturizers is especially important,\n","but the clinician should be aware of the reluctance of many patients to use them because of concerns that moisturizers might worsen their acne. These\n","patients need reassurance that this is not the case: most moisturizers from reputable companies are tested for comedogenicity in clinical trials and\n","are labeled 'non-comedogenic'. Studies show that moisturizers applied before or after topical retinoids do not alter efficacy.\n","\n","Bullets:\n","Topical therapy should be selected to help achieve medical adherence. Realistic expectations of therapy should be explained.\n","\n","Predicted Summary:\n","Moisturizers. Excessive dryness of the skin is one of the main reasons why patients discontinue topical treatment. Most moisturizers from reputable\n","companies are tested for comedogenicity in clinical trials. Studies show that moisturizers applied before or after topical retinoids do not alter\n","efficacy.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541994, 'ch05')\n","\n","All Bullets:\n","Topical therapy is a key component of nearly all acne regimens. Topical antibiotics can lead to the development of antimicrobial resistance. Topical\n","antibiotics should not be used as single agents for the treatment of acne. Topical retinoids are useful as first-line agents. Any regimen containing\n","an antibiotic (topical or oral), including a topical antibiotic/retinoid combination should be combined with benzoyl peroxide to reduce and prevent\n","the development of antibiotic-resistant strains of P. acnes. Combining therapies or using fixed combination topical products improves efficacy by\n","targeting more than one pathogenic feature and enhancing treatment adherence. Topical therapy should be selected to help achieve medical adherence.\n","Realistic expectations of therapy should be explained.\n","\n","All Predicted Summary:\n","Topical therapy is useful in nearly all acne regimens. Mild acne that consists of open and closed comedones and/or few inflammatory lesions is\n","amenable to topical therapy using agents such as salicylic acid, retinoids and topical antibiotics. The use of topical antibiotics as single agents\n","for acne is discouraged because of the potential for the development of bacterial resistance. Topical retinoids are useful as first-line agents. The\n","use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial resistance. Topical\n","retinoids are useful as first-line agents and topical antibiotics, when used, should be combined with BPO, ideally as a fixed-dose combination\n","product. The use of topical antibiotics as single agents for acne is discouraged because of the potential for the development of bacterial resistance.\n","Topical retinoids are useful as first-line agents. Sodium sulfacetamide is a sulfonamide, which is thought to inhibit the growth of P. acnes through\n","competitive antagonism of para-aminobenzoic acid. Topical tetracycline is available in Italy, but not the UK or USA. Recent advances in topical acne\n","therapy include the development of fixed combination products. Combination products that include BPO offer excellent bactericidal effects. When\n","combined with erythromycin or clindamycin, offset the emergence of antibiotic-resistant P. acnes. Moisturizers. Excessive dryness of the skin is one\n","of the main reasons why patients discontinue topical treatment. Most moisturizers from reputable companies are tested for comedogenicity in clinical\n","trials. Studies show that moisturizers applied before or after topical retinoids do not alter efficacy.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9') bullet 1\n","\n","Text:\n","Direct-current (DC) cardioversion is highly effective for atrial flutter. However, persistent atrial flutter (lasting longer than 48 hours) is\n","associated with significant embolic risk, and management before cardioversion should be as for patients with AF - treatment with oral anticoagulant\n","therapy (warfarin) for 4 weeks before cardioversion and for at least 1 month afterwards (see Chapter 8). Alternatively, a transesophageal\n","echocardiogram can be performed in patients who are not taking warfarin, or in whom serial measurements of the international normalized ratio (INR)\n","over a month have not been documented, to exclude left atrial thrombus and enable immediate cardioversion. Patients are then started, or continued, on\n","warfarin, while heparin or low-molecular-weight heparin is given until the INR is greater than 2, continuing warfarin for 1 month or more.\n","\n","Bullets:\n","Ablation for typical atrial flutter is highly successful and low risk, and should be considered first-line treatment.\n","\n","Predicted Summary:\n"," persistent atrial flutter (lasting longer than 48 hours) is associated with significant embolic risk. Management before cardioversion should be as\n","for patients with AF - treatment with oral anticoagulant therapy (warfarin)\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9') bullet 2\n","\n","Text:\n","The cavotricuspid isthmus is not smooth throughout its length and has regions of thick muscle bundles. Ablation of these areas is best achieved with\n","technology capable of producing deep lesions, such as large-tip or cooled radiofrequency energy. Newer techniques involving computerized mapping of\n","the atria and catheter position are improving overall success. Indications. Most centers are now performing ablation as first-line treatment.\n","Complications. Apart from the usual complications associated with instrumentation of the venous circulation, heart block or cardiac tamponade are\n","rarely reported. After ablation, the prognosis for patients with typical atrial flutter is excellent. In patients with atypical atrial flutter\n","recurrences are more common because of scarring of the atria. Up to 30% of patients with either type of atrial flutter develop AF late after a\n","successful flutter ablation and may require further treatment; atrial flutter and AF often go together.\n","\n","Bullets:\n","Atypical atrial flutter usually includes right atrial flutter circling around regions of scarring, or left atrial flutter following ablation of AF.\n","\n","Predicted Summary:\n","The cavotricuspid isthmus is not smooth throughout its length and has regions of thick muscle bundles. Ablation of these areas is best achieved with\n","technology capable of producing deep lesions, such as large-tip or cooled radiofrequency energy.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9') bullet 3\n","\n","Text:\n","Complications. Apart from the usual complications associated with instrumentation of the venous circulation, heart block or cardiac tamponade are\n","rarely reported. After ablation, the prognosis for patients with typical atrial flutter is excellent. In patients with atypical atrial flutter\n","recurrences are more common because of scarring of the atria. Up to 30% of patients with either type of atrial flutter develop AF late after a\n","successful flutter ablation and may require further treatment; atrial flutter and AF often go together.\n","\n","Bullets:\n","The risk of systemic embolization in atrial flutter should be considered similar to that for atrial fibrillation (AF).\n","\n","Predicted Summary:\n","Complications. Apart from the usual complications associated with instrumentation of the venous circulation, heart block or cardiac tamponade are\n","rarely reported. After ablation, the prognosis for patients with typical atrial flutter is excellent. In patients with atypical atrial flutter\n","recurrences are more common because of scarring of the atria.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781908541437, 'ch_9')\n","\n","All Bullets:\n","Ablation for typical atrial flutter is highly successful and low risk, and should be considered first-line treatment. Atypical atrial flutter usually\n","includes right atrial flutter circling around regions of scarring, or left atrial flutter following ablation of AF. The risk of systemic embolization\n","in atrial flutter should be considered similar to that for atrial fibrillation (AF).\n","\n","All Predicted Summary:\n"," persistent atrial flutter (lasting longer than 48 hours) is associated with significant embolic risk. Management before cardioversion should be as\n","for patients with AF - treatment with oral anticoagulant therapy (warfarin) The cavotricuspid isthmus is not smooth throughout its length and has\n","regions of thick muscle bundles. Ablation of these areas is best achieved with technology capable of producing deep lesions, such as large-tip or\n","cooled radiofrequency energy. Complications. Apart from the usual complications associated with instrumentation of the venous circulation, heart block\n","or cardiac tamponade are rarely reported. After ablation, the prognosis for patients with typical atrial flutter is excellent. In patients with\n","atypical atrial flutter recurrences are more common because of scarring of the atria.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 1\n","\n","Text:\n","One thing that all cigarettes have in common is that they deliver nicotine to the lungs. A puff on a cigarette results in rapid absorption of nicotine\n","into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation (Figure 1.1); this process is\n","repeated with every puff. In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to\n","one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply. In societies in which cigarettes are more\n","expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more nicotine from each cigarette,\n","confirming that nicotine is the sought-after substance in tobacco.\n","\n","Bullets:\n","Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff.\n","\n","Predicted Summary:\n","In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to one-third of what they could\n","obtain if they puffed more frequently and inhaled the smoke more deeply. In societies in which cigarettes are more expensive relative to earnings or\n","in situations where cigarettes are otherwise not freely available, smokers take more nicotine from each cigarette, confirming that nicotine is the\n","sought-after substance in tobacco.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 2\n","\n","Text:\n","One thing that all cigarettes have in common is that they deliver nicotine to the lungs. A puff on a cigarette results in rapid absorption of nicotine\n","into the bloodstream and delivery of a high-concentration 'bolus' of nicotine to the brain by the arterial circulation (Figure 1.1); this process is\n","repeated with every puff. In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to\n","one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply. In societies in which cigarettes are more\n","expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more nicotine from each cigarette,\n","confirming that nicotine is the sought-after substance in tobacco.\n","\n","Bullets:\n","Smokers absorb an average 1-2 mg of nicotine per cigarette (more when cigarettes are smoked more intensively).\n","\n","Predicted Summary:\n","In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to one-third of what they could\n","obtain if they puffed more frequently and inhaled the smoke more deeply. In societies in which cigarettes are more expensive relative to earnings or\n","in situations where cigarettes are otherwise not freely available, smokers take more nicotine from each cigarette, confirming that nicotine is the\n","sought-after substance in tobacco.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 3\n","\n","Text:\n","Many smokers, particularly older smokers and women, choose so-called 'light' or 'low-tar' brands, believing that these are safer. According to the\n","reported analyses of their deliveries, these brands deliver as little as one-tenth of the tar and carbon monoxide of other brands. In fact, such\n","reports are misleading: the data are based on artificial measurements by smoking machines and do not mirror the actual delivery to a smoker. It is\n","possible to extract as much tar and nicotine from these cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation\n","holes in the filter that would otherwise dilute the smoke - and that is exactly what smokers usually do. Each smoker appears to have a preferred level\n","of nicotine intake and will adjust the way he or she smokes to achieve that level. Recognizing this, the terms 'light' and 'low tar' have been banned\n","from cigarette packaging and marketing in the USA and EU.\n","\n","Bullets:\n","Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide.\n","\n","Predicted Summary:\n","Many smokers choose so-called 'light' or 'low-tar' brands, believing that these are safer. These brands deliver as little as one-tenth of the tar and\n","carbon monoxide of other brands. It is possible to extract as much tar and nicotine from these cigarettes as from higher-tar brands.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 4\n","\n","Text:\n","Many smokers, particularly older smokers and women, choose so-called 'light' or 'low-tar' brands, believing that these are safer. According to the\n","reported analyses of their deliveries, these brands deliver as little as one-tenth of the tar and carbon monoxide of other brands. In fact, such\n","reports are misleading: the data are based on artificial measurements by smoking machines and do not mirror the actual delivery to a smoker. It is\n","possible to extract as much tar and nicotine from these cigarettes as from higher-tar brands by more intensive puffing and by blocking the ventilation\n","holes in the filter that would otherwise dilute the smoke - and that is exactly what smokers usually do. Each smoker appears to have a preferred level\n","of nicotine intake and will adjust the way he or she smokes to achieve that level. Recognizing this, the terms 'light' and 'low tar' have been banned\n","from cigarette packaging and marketing in the USA and EU.\n","\n","Bullets:\n","Smokers' intake of tar and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes.\n","\n","Predicted Summary:\n","Many smokers choose so-called 'light' or 'low-tar' brands, believing that these are safer. These brands deliver as little as one-tenth of the tar and\n","carbon monoxide of other brands. It is possible to extract as much tar and nicotine from these cigarettes as from higher-tar brands.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 5\n","\n","Text:\n","Once in the bloodstream, nicotine is distributed around the body, readily crossing cell membranes and entering every tissue. It is eliminated quite\n","rapidly, mainly through metabolism, but partly by excretion in urine. It is metabolized mostly to the oxides cotinine and nicotine-1'-N-oxide. These\n","appear to be largely inactive and are further metabolized and excreted in urine. The plasma concentration of nicotine reduces by half every 90-120\n","minutes (its half-life; see Figure 1.1). Duration of withdrawal symptoms. All nicotine is cleared from the body within a day or two of abstinence.\n","Some people think that this must therefore be the period when smokers experience withdrawal symptoms (see Chapter 5). However, the duration of\n","withdrawal symptoms has nothing to do with this; it is related to how long it takes the body to get used to not having nicotine in the system. The\n","duration for most symptoms is 2-4 weeks.\n","\n","Bullets:\n","Nicotine is rapidly metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a\n","day of abstinence.\n","\n","Predicted Summary:\n","Once in the bloodstream, nicotine is distributed around the body, readily crossing cell membranes and entering every tissue. It is eliminated quite\n","rapidly, mainly through metabolism, but partly by excretion in urine. The plasma concentration of nicotine reduces by half every 90-120 minutes.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01') bullet 6\n","\n","Text:\n","Duration of withdrawal symptoms. All nicotine is cleared from the body within a day or two of abstinence. Some people think that this must therefore\n","be the period when smokers experience withdrawal symptoms (see Chapter 5). However, the duration of withdrawal symptoms has nothing to do with this;\n","it is related to how long it takes the body to get used to not having nicotine in the system. The duration for most symptoms is 2-4 weeks. Estimating\n","nicotine intake. Nicotine concentrations in the blood could conceptually be a useful index of dependence, but its short half-life means that a single\n","measure does not give a particularly accurate picture of total intake over a day. Measurement of its metabolite, cotinine, is used instead. Cotinine\n","has a half-life of 14-20 hours, so its concentration in the blood is more stable than that of nicotine and it can be easily measured in saliva, urine\n","or even hair. Saliva samples are simple to obtain by means of a dental swab and are the method of choice for accurate estimation of daily nicotine\n","intake.\n","\n","Bullets:\n","The nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva\n","or urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.\n","\n","Predicted Summary:\n"," duration of withdrawal symptoms is related to how long it takes the body to get used to not having nicotine in the system. The duration for most\n","symptoms is 2-4 weeks. Estimating nicotine intake.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n","(9781910797181, 'ch01')\n","\n","All Bullets:\n","Cigarettes deliver a 'bolus' of nicotine to the brain within seconds of each puff. Smokers absorb an average 1-2 mg of nicotine per cigarette (more\n","when cigarettes are smoked more intensively). Cigarettes also deliver tar, containing potent carcinogens, and carbon monoxide. Smokers' intake of tar\n","and nicotine from so-called 'low-tar' cigarettes is not substantially lower than the intake from higher-tar cigarettes. Nicotine is rapidly\n","metabolized and excreted; its concentration in the blood halves every 90-120 minutes. Almost all the nicotine is cleared over a day of abstinence. The\n","nicotine metabolite cotinine is eliminated much more slowly and is present in all body fluids, including saliva and urine; measurement of saliva or\n","urine cotinine content is therefore a useful means of assessing total nicotine intake over the past few days.\n","\n","All Predicted Summary:\n","In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-sixth to one-third of what they could\n","obtain if they puffed more frequently and inhaled the smoke more deeply. In societies in which cigarettes are more expensive relative to earnings or\n","in situations where cigarettes are otherwise not freely available, smokers take more nicotine from each cigarette, confirming that nicotine is the\n","sought-after substance in tobacco. In the UK and the USA, smokers absorb an average 1-2 mg of nicotine from each cigarette. This is only about one-\n","sixth to one-third of what they could obtain if they puffed more frequently and inhaled the smoke more deeply. In societies in which cigarettes are\n","more expensive relative to earnings or in situations where cigarettes are otherwise not freely available, smokers take more nicotine from each\n","cigarette, confirming that nicotine is the sought-after substance in tobacco. Many smokers choose so-called 'light' or 'low-tar' brands, believing\n","that these are safer. These brands deliver as little as one-tenth of the tar and carbon monoxide of other brands. It is possible to extract as much\n","tar and nicotine from these cigarettes as from higher-tar brands. Many smokers choose so-called 'light' or 'low-tar' brands, believing that these are\n","safer. These brands deliver as little as one-tenth of the tar and carbon monoxide of other brands. It is possible to extract as much tar and nicotine\n","from these cigarettes as from higher-tar brands. Once in the bloodstream, nicotine is distributed around the body, readily crossing cell membranes and\n","entering every tissue. It is eliminated quite rapidly, mainly through metabolism, but partly by excretion in urine. The plasma concentration of\n","nicotine reduces by half every 90-120 minutes.  duration of withdrawal symptoms is related to how long it takes the body to get used to not having\n","nicotine in the system. The duration for most symptoms is 2-4 weeks. Estimating nicotine intake.\n","\n","######################################################################################################################################################\n","######################################################################################################################################################\n","\n","\n"],"name":"stdout"}]},{"cell_type":"markdown","metadata":{"id":"QtJA4pJwUQ3H"},"source":["In most cases the paragraphs assigned to the bullet are very accurate and the generated summary coincide perfectly with the bullet.\n","\n","However, there are some problems arising:\n","\n","* Sometimes the paragraphs assigned to the bullet contain the information present in the bullet, but it is not extracted by the model. This can probably be solved with fine-tuning.\n","* Sometimes the paragraphs assigned to the bullet do NOT contain the information present in the bullet, this cannot be solved, as before with the chunks.\n","* The generated summary is less abstractive probably due to the fact that the input text is too short and does not let the model abstract key concepts.\n","* Using the assigned paragraphs as is can be a good enough summary of the bullet. However, in production we would not have the bullets."]},{"cell_type":"markdown","metadata":{"id":"P1SBWq0cmuuv"},"source":["## **Compare All Results**"]},{"cell_type":"markdown","metadata":{"id":"YLhN6dB4x477"},"source":["#### Compare All Bullets Methods"]},{"cell_type":"code","metadata":{"id":"9ia8WYqhrkaL","colab":{"base_uri":"https://localhost:8080/","height":507},"executionInfo":{"status":"ok","timestamp":1608545786454,"user_tz":-60,"elapsed":2314,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"a1cb75e3-d8a4-45a9-a6c0-b0dd67942352"},"source":["plot_compare_rouge(\n","    [chapter_best(df_base), chapter_best(df_moc), df_tr, df_lda_summ],\n","    ['baseline', 'merge_or_chunk', 'textrank', 'topic_modeling_lda'],\n","    'rougeL')"],"execution_count":null,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 864x576 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"markdown","metadata":{"id":"ktRVvfCiyFy0"},"source":["#### Compare All Bullets and Assign Bullets"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/","height":507},"id":"1s8fMTupyFy4","executionInfo":{"status":"ok","timestamp":1608545786920,"user_tz":-60,"elapsed":1945,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"73abe5e1-693e-4b2e-8c21-a0a4aa516d86"},"source":["plot_compare_rouge(\n","    [chapter_best(df_base), df_base_assign, chapter_best(df_moc), df_moc_assign],\n","    ['baseline', 'baseline_assign_bullets', 'merge_or_chunk', 'merge_or_chunk_assign_bullets'],\n","    'rougeL')"],"execution_count":null,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 864x576 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"markdown","metadata":{"id":"iy7CHqTRyu-D"},"source":["#### Compare Assign Bullets Methods"]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/","height":507},"id":"mAfefie5yu-I","executionInfo":{"status":"ok","timestamp":1608545808665,"user_tz":-60,"elapsed":1135,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"fc6732f3-83ae-4b64-b52f-20b45e17c818"},"source":["plot_compare_rouge(\n","    [df_base_assign, df_moc_assign, df_para],\n","    ['baseline_assign_bullets', 'merge_or_chunk_assign_bullets', 'paragraph_assign_bullets'],\n","    'rougeL')"],"execution_count":null,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 864x576 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"code","metadata":{"colab":{"base_uri":"https://localhost:8080/","height":507},"id":"2j1GKj9r7mIy","executionInfo":{"status":"ok","timestamp":1608649117813,"user_tz":-60,"elapsed":1016,"user":{"displayName":"Marco Pietro Abrate","photoUrl":"https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64","userId":"15422244832836998434"}},"outputId":"3b92853d-f1dd-48a0-bb40-b919c04537a9"},"source":["plot_compare_rouge(\n","    [chapter_avg(df_base), df_base_assign, df_para],\n","    ['baseline', 'baseline_assign_bullets', 'paragraph_assign_bullets'],\n","    'rougeL')"],"execution_count":42,"outputs":[{"output_type":"display_data","data":{"image/png":"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\n","text/plain":["<Figure size 864x576 with 1 Axes>"]},"metadata":{"tags":[],"needs_background":"light"}}]},{"cell_type":"code","metadata":{"id":"NSMXeLeCyu-O"},"source":[""],"execution_count":null,"outputs":[]}]}